Citation Report
List of articles citing

Integrated genomic characterization of endometrial carcinor

DOI: 10.1038/nature12113
Nature, 2013, 497, 67-73.

Source: https://exaly.com/paper-pdf/55857269/citation-report.pdf
Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2248	La formalisation de la GRH dans une PME comme enjeu d'une certification RSE. **2012**, 83, 20		6
2247	Large-scale integrative network-based analysis identifies common pathways disrupted by copy number alterations across cancers. **2013**, 14, 440		17
2246	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. **2013**, 14, 853-62		248
2245	Signatures of mutational processes in human cancer. *Nature*, **2013**, 500, 415-21	50.4	5895
2244	Inferring tumour purity and stromal and immune cell admixture from expression data. **2013**, 4, 2612		2572
2243	Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. **2013**, 155, 948-62		478
2242	OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. **2013**, 29, 2238-44		276
2241	Activating ESR1 mutations in hormone-resistant metastatic breast cancer. **2013**, 45, 1446-51		742
2240	MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis. **2013** , 4, 419-26		70
2239	The landscape of microsatellite instability in colorectal and endometrial cancer genomes. **2013**, 155, 858-68		247
2238	Network-based stratification of tumor mutations. **2013**, 10, 1108-15		546
2237	High-quality biobanking for personalized precision medicine: BioSpecimen Sciences at the helm. **2013**, 19, 447-456		7
2236	Mutational landscape and significance across 12 major cancer types. *Nature*, **2013**, 502, 333-339	50.4	2803
2235	Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. **2013**, 5, 197ra102		178
2234	The Cancer Genome Atlas Pan-Cancer analysis project. **2013**, 45, 1113-20		3933
2233	A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. **2013**, 12, 155		96
2232	Emerging patterns of somatic mutations in cancer. **2013**, 14, 703-18		366

2231	The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. **2013**, 39, 11-26		554
2230	Emerging landscape of oncogenic signatures across human cancers. **2013**, 45, 1127-33		889
2229	Clear cell carcinoma of ovary and uterus. **2013**, 15, 566-72		25
2228	Tumor subtype identification with weighted sparse non-negative matrix factorization for multiple heterogeneous data integration. **2013**,		0
2227	MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome. **2013**, 131, 309-14		41
2226	Tight junction proteins: from barrier to tumorigenesis. **2013**, 337, 41-8		136
2225	Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting. **2013**, 130, 6-8		
2224	Genetics: new classification for endometrial cancer puts genes in POLE position. **2013**, 10, 304		4
2223	Image-guided thermal ablation of tumor increases the plasma level of interleukin-6 and interleukin-10: is plasma level of interleukin-6 a surrogate for immunogenic cell death?. **2013**, 24, 1112-3		1
2222	Post treatment surveillance of type II endometrial cancer patients. **2013**, 131, 609-12		6
2221	Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy. **2013**, 131, 604-8		22
2220	From human genome to cancer genome: the first decade. **2013**, 23, 1054-62		103
2219	Erratum: Integrated genomic characterization of endometrial carcinoma. *Nature*, **2013**, 500, 242-242	50.4	32
2218	Means, motive, and opportunity: SDH mutations are suspects in pituitary tumors. **2013**, 98, 2274-6		7
2217	G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth. **2013**, 2013, 472720		106
2216	Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53. **2013**, 2013, 828165		20
2215	Multi-layered cancer chromosomal instability phenotype. **2013**, 3, 302		23
2214	The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies. **2013**, 3, 237		45

2213	JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. **2013**, 3, 3042	40
2212	Dominant mutations in S. cerevisiae PMS1 identify the Mlh1-Pms1 endonuclease active site and an exonuclease 1-independent mismatch repair pathway. **2013**, 9, e1003869	40
2211	Tumor heterogeneity and response to chemotherapy. **2013**, 14, 1949	
2210	Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment. **2013**, 23, 1620-8	18
2209	Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer. **2013**, 19, 6272-85	29
2208	MYC phosphorylation at novel regulatory regions suppresses transforming activity. **2013**, 73, 6504-15	22
2207	Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo. **2013**, 12, 2917-28	18
2206	Management of early stage, high-risk endometrial carcinoma: preoperative and surgical considerations. **2013**, 2013, 757249	1
2205	The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe. **2013**, 3, 304	18
2204	The estrogen receptor joins other cancer biomarkers as a predictor of outcome. **2013**, 2013, 479541	13
2203	Feasibility of RNA and DNA extraction from fresh pipelle and archival endometrial tissues for use in gene expression and SNP arrays. **2013**, 2013, 576842	19
2202	Review of biological network data and its applications. **2013**, 11, 200-10	57
2201	Treatment of uterine papillary serous carcinoma. **2013**, 1, 819-827	
2200	New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details. **2013**, 19, 5264-74	44
2199	Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology. **2013**, 19, 4315-25	27
2198	Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines. **2013**, 8, 1355-72	40
2197	The mutational landscape of phosphorylation signaling in cancer. **2013**, 3, 2651	116
2196	Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. **2013**, 45, 1121-6	82

2195	CEBPE promoter SNPs, caught red handed? A commentary on identification of functional nucleotide and haplotype variants in the promoter of the CEBPE gene. **2013**, 58, 571-2	
2194	Comprehensive analysis of long non-coding RNAs in ovarian cancer reveals global patterns and targeted DNA amplification. **2013**, 8, e80306	63
2193	Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer. **2013**, 8, e82770	31
2192	A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. **2014**, 9, e87361	112
2191	The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905. **2014**, 9, e94167	14
2190	Fusion transcript discovery in formalin-fixed paraffin-embedded human breast cancer tissues reveals a link to tumor progression. **2014**, 9, e94202	14
2189	Crystal structure of yeast DNA polymerase catalytic domain. **2014**, 9, e94835	30
2188	Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. **2014**, 9, e100041	53
2187	MUC1 positive, Kras and Pten driven mouse gynecologic tumors replicate human tumors and vary in survival and nuclear grade based on anatomical location. **2014**, 9, e102409	12
2186	RADIA: RNA and DNA integrated analysis for somatic mutation detection. **2014**, 9, e111516	59
2185	Biomarkers in women's cancers, gynecology, and obstetrics. **2014**, 2014, 602340	1
2184	Major clinical research advances in gynecologic cancer in 2013. **2014**, 25, 236-48	25
2183	Toward a systematic understanding of cancers: a survey of the pan-cancer study. **2014**, 5, 194	19
2182	Mechanisms of base substitution mutagenesis in cancer genomes. **2014**, 5, 108-46	32
2181	Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors. **2014**, 8, 1745-51	40
2180	Adjuvant therapy for endometrial cancer. **2014**, 25, 136-47	21
2179	Past, present, and future of hormonal therapy in recurrent endometrial cancer. **2014**, 6, 429-35	48
2178	Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer. **2014**, 5, 9783-97	25

2177	SWI/SNF chromatin remodeling enzymes in melanocyte differentiation and melanoma. **2014**, 24, 151-61	17
2176	Patient-derived xenograft models in gynecologic malignancies. **2014**, e258-66	31
2175	Mispair-specific recruitment of the Mlh1-Pms1 complex identifies repair substrates of the Saccharomyces cerevisiae Msh2-Msh3 complex. **2014**, 289, 9352-64	31
2174	Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. **2014**, 25, 552-563	242
2173	Prediction of individualized therapeutic vulnerabilities in cancer from genomic profiles. **2014**, 30, 2051-9	28
2172	Insights into cancer biology through next-generation sequencing. **2014**, 14 Suppl 6, s71-7	2
2171	The emerging roles of ARID1A in tumor suppression. **2014**, 15, 655-64	148
2170	Gene signature profiling of gynaecological malignancies. **2014**, 7, 252-255	
2169	Entwicklungen der gynäkologischen Onkologie – Verbesserung der Versorgung auf vielen Ebenen. **2014**, 47, 638-647	1
2168	L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor. **2014**, 14, 958	22
2167	Empirical prediction of genomic susceptibilities for multiple cancer classes. **2014**, 111, 1921-6	5
2166	HotSpotter: efficient visualization of driver mutations. **2014**, 15, 1044	7
2165	Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1. **2014**, 14, 884	12
2164	Comparative DNA methylome analysis of endometrial carcinoma reveals complex and distinct deregulation of cancer promoters and enhancers. **2014**, 15, 868	45
2163	Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. **2014**, 27, 1014-9	46
2162	Molecular Basis for Targeted Therapy in Gynecologic Cancer. **2014**, 1375-1383	
2161	SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. **2014**, 10, e1003665	301
2160	Abnormal dosage of ultraconserved elements is highly disfavored in healthy cells but not cancer cells. **2014**, 10, e1004646	15

2159	Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53. **2014**, 120, 3457-68	15
2158	Increased and imbalanced dNTP pools symmetrically promote both leading and lagging strand replication infidelity. **2014**, 10, e1004846	44
2157	Emerging drugs for endometrial cancer. **2014**, 19, 497-509	3
2156	Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. **2014**, 5, 252	31
2155	The long non-coding RNA HOTAIR is upregulated in endometrial carcinoma and correlates with poor prognosis. **2014**, 33, 325-32	89
2154	Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. **2014**, 5, 4988	182
2153	Ranking of cancer genes in Markov chain model through integration of heterogeneous sources of data. **2014**,	
2152	Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma. **2014**, 135, 49-53	20
2151	Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. **2014**, 26, 479-94	61
2150	Immunohistochemical characterization of endometrial carcinomas: endometrioid, serous and clear cell adenocarcinomas in association with genetic analysis. **2014**, 40, 2167-76	13
2149	High frequency strand slippage mutations in CTCF in MSI-positive endometrial cancers. **2014**, 35, 63-5	20
2148	Core and specific network markers of carcinogenesis from multiple cancer samples. **2014**, 362, 17-34	16
2147	The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. **2014**, 26, 923-937	562
2146	Cancer beyond organ and tissue specificity: next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers. **2014**, 135, 2362-9	30
2145	Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor. **2014**, 64, 585-96	59
2144	Oncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K). **2014**, 111, 16826-9	27
2143	Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. **2014**, 103, 29-52	334
2142	Insights into wild-type and mutant p53 functions provided by genetically engineered mice. **2014**, 35, 715-27	25

2141	Hypermutation in human cancer genomes: footprints and mechanisms. **2014**, 14, 786-800	274
2140	A novel reannotation strategy for dissecting DNA methylation patterns of human long intergenic non-coding RNAs in cancers. **2014**, 42, 8258-70	34
2139	Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights. **2014**, 20, 21-7	120
2138	Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration. **2014**, 6, 239-53	25
2137	Evidence of androgen action in endometrial and ovarian cancers. **2014**, 21, T203-18	43
2136	Estrogen receptor mutations and their role in breast cancer progression. **2014**, 16, 494	69
2135	Diagnostic utility of targeted next-generation sequencing in problematic cases. **2014**, 38, 534-41	15
2134	Grading uterine endometrioid carcinoma: a proposal that binary is best. **2014**, 38, 1583-7	19
2133	DJ-1 in endometrial cancer: a possible biomarker to improve differential diagnosis between subtypes. **2014**, 24, 649-58	28
2132	The immunohistochemistry signature of mismatch repair (MMR) proteins in a multiethnic Asian cohort with endometrial carcinoma. **2014**, 33, 554-9	9
2131	Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility. **2014**, 38, 189-96	77
2130	Approaches to uncovering cancer diagnostic and prognostic molecular signatures. **2014**, 1, e957981	1
2129	Adjuvant chemotherapy with external beamradiation therapy for high-grade, node-positive endometrial cancer. **2014**, 24, 1441-8	17
2128	Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma. **2014**, 38, 660-5	50
2127	Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors. **2014**, 24, 1262-7	26
2126	A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. **2014**, 74, 15-23	47
2125	Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. **2014**, 106,	83
2124	DNA replication error-induced extinction of diploid yeast. **2014**, 196, 677-91	36

2123	Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. **2014**, 20, 1846-55	20
2122	Influence of AKT on progesterone action in endometrial diseases. **2014**, 91, 63	25
2121	Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas. **2014**, 170, 385-91	26
2120	Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers. **2014**, 42, 12973-83	3
2119	Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma. **2014**, 24, S83-9	39
2118	Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. **2014**, 24, S90-5	43
2117	CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity. **2014**, 133, 83-9	9
2116	Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism. **2014**, 79, 49-63	117
2115	CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. **2014**, 7, 1020-9	113
2114	PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma. **2014**, 132, 188-93	21
2113	Frequent POLE1 p.S297F mutation in Chinese patients with ovarian endometrioid carcinoma. **2014**, 761, 49-52	20
2112	Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review. **2014**, 13, 1-12	30
2111	Genome-wide association study of endometrial cancer in E2C2. **2014**, 133, 211-24	33
2110	Genetic alterations and personalized medicine in melanoma: progress and future prospects. **2014**, 106, djt435	57
2109	Replicative DNA polymerase mutations in cancer. **2014**, 24, 107-13	78
2108	Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. **2014**, 24, 52-60	299
2107	Cancer Systems Biology: a peek into the future of patient care?. **2014**, 11, 167-76	120
2106	Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. **2014**, 343, 1010-4	281

2105	NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. **2014**, 134, 2630-2638	214
2104	FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer. **2014**, 14, 78	44
2103	The Relationship Between Estrogen and Genes in the Molecular Pathogenesis of Endometrial Carcinoma. **2014**, 3, 9-17	6
2102	Molecular Pathogenesis of Uterine Serous Carcinoma. **2014**, 3, 33-39	
2101	Prognostic biomarkers in endometrial and ovarian carcinoma. **2014**, 464, 315-31	35
2100	Chemical warfare among invaders: a detoxification interaction facilitates an ant invasion. **2014**, 343, 1014-7	40
2099	Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. **2014**, 232, 473-81	68
2098	WW domain-containing oxidoreductase's role in myriad cancers: clinical significance and future implications. **2014**, 239, 253-63	49
2097	Epistatic interactions and drug response. **2014**, 232, 255-63	19
2096	Individualized medicine from prewomb to tomb. **2014**, 157, 241-53	194
2095	Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. **2014**, 46, 613-7	165
2094	Discovery and validation of methylation markers for endometrial cancer. **2014**, 135, 1860-8	43
2093	Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. **2014**, 46, 573-82	695
2092	Clinical utility of immunohistochemistry and other ancillary techniques in assessment of uterine tumors. **2014**, 31, 193-4	
2091	Identification of ZDHHC14 as a novel human tumour suppressor gene. **2014**, 232, 566-77	36
2090	A common cancer-associated DNA polymerase ε mutation causes an exceptionally strong mutator phenotype, indicating fidelity defects distinct from loss of proofreading. **2014**, 74, 1895-901	88
2089	DNA sequencing of cancer: what have we learned?. **2014**, 65, 63-79	37
2088	Systems genetics approaches to understand complex traits. **2014**, 15, 34-48	407

2087	Cellular, histologic, and molecular changes associated with endometriosis and ovarian cancer. **2014**, 21, 55-63		43
2086	Integrated analysis of germline and somatic variants in ovarian cancer. **2014**, 5, 3156		199
2085	Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway. **2014**, 40, 507-12		16
2084	CTCF and BORIS in genome regulation and cancer. **2014**, 24, 8-15		35
2083	Genomic sequencing for cancer diagnosis and therapy. **2014**, 65, 33-48		30
2082	The evolution of the unstable cancer genome. **2014**, 24, 61-7		52
2081	MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. **2014**, 30, 1015-6		341
2080	Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature*, **2014**, 505, 495-501	50.4	1990
2079	Structural basis for processive DNA synthesis by yeast DNA polymerase e. **2014**, 21, 49-55		118
2078	A genome-wide view of microsatellite instability: old stories of cancer mutations revisited with new sequencing technologies. **2014**, 74, 6377-82		15
2077	Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. **2014**, 106,		124
2076	High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. **2014**, 111, 78-84		39
2075	Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. **2014**, 46, 1258-63		215
2074	Targeting HER2 in ovarian and uterine cancers: challenges and future directions. **2014**, 135, 364-70		44
2073	Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. **2014**, 135, 312-7		29
2072	High frequency of RPL22 mutations in microsatellite-unstable colorectal and endometrial tumors. **2014**, 35, 1442-5		34
2071	Classifying squamous cell carcinoma of the head and neck: prognosis, prediction and implications for therapy. **2014**, 14, 229-36		10
2070	Pan-cancer patterns of DNA methylation. **2014**, 6, 66		107

2069	Heterogeneous polymerase fidelity and mismatch repair bias genome variation and composition. **2014**, 24, 1751-64	111
2068	Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. **2014**, 24, 1740-50	187
2067	Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. **2014**, 26, 455-64	247
2066	Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. **2014**, 6, 5	127
2065	Advancing clinical oncology through genome biology and technology. **2014**, 15, 427	5
2064	STAT1 drives tumor progression in serous papillary endometrial cancer. **2014**, 74, 6519-30	51
2063	Vangl1 and Vangl2: planar cell polarity components with a developing role in cancer. **2014**, 21, R345-56	40
2062	RNF43 is frequently mutated in colorectal and endometrial cancers. **2014**, 46, 1264-6	287
2061	High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing. **2014**, 20, 2080-91	56
2060	miR-21-3p is a positive regulator of L1CAM in several human carcinomas. **2014**, 354, 455-66	33
2059	A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. **2014**, 45, 2394-403	13
2058	The emerging genomic landscape of endometrial cancer. **2014**, 60, 98-110	74
2057	Molecular heterogeneity of glioblastoma and its clinical relevance. **2014**, 20, 777-87	54
2056	Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. **2014**, 5, 5006	120
2055	Current status of molecular biomarkers in endometrial cancer. **2014**, 16, 403	45
2054	Lean Big Data integration in systems biology and systems pharmacology. **2014**, 35, 450-60	67
2053	Mutations in POLE and survival of colorectal cancer patients--link to disease stage and treatment. **2014**, 3, 1527-38	45
2052	Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. **2014**, 346, 85-89	157

2051	Oncology scan--the role of personalized medicine in gynecologic cancers. **2014**, 89, 947-9		4
2050	Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*, **2014**, 513, 202-9	50.4	3659
2049	Proteogenomic characterization of human colon and rectal cancer. *Nature*, **2014**, 513, 382-7	50.4	900
2048	Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. **2014**, 30, 326-39		179
2047	A novel wnt regulatory axis in endometrioid endometrial cancer. **2014**, 74, 5103-17		99
2046	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. **2014**, 13, 1690-704		239
2045	Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers. **2014**, 134, 426-7		29
2044	WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies. **2014**, 1846, 188-200		57
2043	Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. **2014**, 158, 929-944		935
2042	Novel genetic targets in endometrial cancer. **2014**, 18, 725-30		13
2041	Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling. **2014**, 15, 419		204
2040	Integrating biological pathways and genomic profiles with ChiBE 2. **2014**, 15, 642		21
2039	Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. **2014**, 15, 429		157
2038	The 'dnet' approach promotes emerging research on cancer patient survival. **2014**, 6, 64		38
2037	Genome-wide analysis of noncoding regulatory mutations in cancer. **2014**, 46, 1160-5		367
2036	Metabolic vulnerabilities in endometrial cancer. **2014**, 74, 5832-45		62
2035	A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer. **2014**, 92, 969-81		12
2034	Genetics of endometrial cancer. **2014**, 13, 499-505		11

2033	Biological significance of the CpG island methylator phenotype. **2014**, 455, 35-42	73
2032	Where cancer genomics should go next: a clinician's perspective. **2014**, 23, R69-75	12
2031	Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. **2014**, 65, 149-54	52
2030	Assessing the clinical utility of cancer genomic and proteomic data across tumor types. **2014**, 32, 644-52	205
2029	The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. **2014**, 5, 3963	99
2028	Systemic treatment of endometrial cancer: what is doxorubicin's role?. **2014**, 32, 2181-2	10
2027	Combining calls from multiple somatic mutation-callers. **2014**, 15, 154	14
2026	Data integration in the era of omics: current and future challenges. **2014**, 8 Suppl 2, I1	230
2025	Patterns and processes of somatic mutations in nine major cancers. **2014**, 7, 11	47
2024	Whole-exome sequencing of endometriosis identifies frequent alterations in genes involved in cell adhesion and chromatin-remodeling complexes. **2014**, 23, 6008-21	41
2023	Mechanisms underlying mutational signatures in human cancers. **2014**, 15, 585-98	514
2022	Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer. **2014**, 7, 613-9	17
2021	Cancer Bioinformatics. **2014**,	4
2020	Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. **2014**, 134, 599-606	8
2019	A pan-cancer proteomic perspective on The Cancer Genome Atlas. **2014**, 5, 3887	324
2018	Updates in diagnostic immunohistochemistry in endometrial carcinoma. **2014**, 31, 205-15	26
2017	Stratification and delineation of gastric cancer signaling by in vitro transcription factor activity profiling and integrative genomics. **2014**, 26, 880-94	10
2016	A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. **2014**, 133, 537-41	22

2015	ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. **2014**, 50, 1740-1746	65
2014	Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. **2014**, 133, 346-52	29
2013	Differential drug responses of circulating tumor cells within patient blood. **2014**, 352, 28-35	18
2012	Incorporating inter-relationships between different levels of genomic data into cancer clinical outcome prediction. **2014**, 67, 344-53	23
2011	Collection, integration and analysis of cancer genomic profiles: from data to insight. **2014**, 24, 92-8	17
2010	Update on prognostic markers for endometrial cancer. **2014**, 10, 277-88	27
2009	Recent and current Phase II clinical trials in endometrial cancer: review of the state of art. **2014**, 23, 773-92	13
2008	Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. **2014** , 111, 3110-5	537
2007	A systems-level integrative framework for genome-wide DNA methylation and gene expression data identifies differential gene expression modules under epigenetic control. **2014**, 30, 2360-6	109
2006	DNA polymerase and its roles in genome stability. **2014**, 66, 339-51	49
2005	Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. **2014**, 32, 129-60	65
2004	Quantifying the risk of recurrence and death in stage III (FIGO 2009) endometrial cancer. **2014**, 134, 297-301	10
2003	Classification of endometrial carcinoma: more than two types. **2014**, 15, e268-78	338
2002	POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. **2014**, 134, 15-9	129
2001	BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. **2014**, 8, 1429-40	26
2000	Trends in corpus uteri cancer mortality in member states of the European Union. **2014**, 50, 1675-84	34
1999	Mutational context and diverse clonal development in early and late bladder cancer. **2014**, 7, 1649-1663	94
1998	Characterizing DNA methylation alterations from The Cancer Genome Atlas. **2014**, 124, 17-23	128

1997	TCGA divides gastric cancer into four molecular subtypes: implications for individualized therapeutics. **2014**, 33, 469-70	26
1996	Molecular Targets in Gynecologic Cancers. **2014**, 1-17	
1995	Updates on the Management of Uterine Serous Carcinoma. **2014**, 195-204	
1994	Graded Inhibition of Oncogenic Ras-Signaling by Multivalent Ras-Binding Domains. **2014**, 59-86	
1993	The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma. **2014**, 24, 534-40	28
1992	Clinically aggressive "low-grade" uterine carcinosarcoma: A case report. **2015**, 14, 9-11	
1991	[FGF/FGFR blockade: New insights in endometrial cancer]. **2015**, 102, 964-5	0
1990	Molecular Pathology and Cytogenetics of Endometrial Carcinoma, Carcinosarcoma, and Uterine Sarcomas. **2015**, 85-103	
1989	MEK and PI3K inhibition in solid tumors: rationale and evidence to date. **2015**, 7, 170-80	84
1988	Cancer Pharmacogenomics. **2015**, 1, 164-191	
1987	Prognostic Factors in Uterine Cancer. **2015**, 107-146	
1986	Improved survival associated with somatic mutations in copy-number low endometrioid endometrial adenocarcinoma. **2015**, 10, 2743-2748	6
1985	MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations. **2015**, 5, 13321	79
1984	Cancer type-dependent genetic interactions between cancer driver alterations indicate plasticity of epistasis across cell types. **2015**, 11, 824	47
1983	A Latent Variable Approach for Integrative Clustering of Multiple Genomic Data Types. 155-173	
1982	Analyzing Combinations of Somatic Mutations in Cancer Genomes. 337-361	
1981	An unsupervised learning approach to find ovarian cancer genes through integration of biological data. **2015**, 16 Suppl 9, S3	6
1980	Atypical Polypoid Adenomyoma of the Uterus: An Immunohistochemical and Molecular Study of 21 Cases. **2015**, 39, 1148-55	29

1979	Endometriumkarzinom und Vorstufen. **2015**, 48, 422-430	1
1978	Failure to recognize preoperatively high-risk endometrial carcinoma is associated with a poor outcome. **2015**, 194, 153-60	12
1977	A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles. **2015**, 16 Suppl 7, S6	10
1976	Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer. **2015**, 16 Suppl 8, S5	22
1975	Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis. **2015**, 67, 3016-26	87
1974	Immunohistochemical study of endometrial high-grade endometrioid carcinoma with or without a concurrent low-grade component: implications for pathogenetic and survival differences. **2015**, 67, 474-82	3
1973	Cancer endocrinology: noticeable developments in the last decade. **2015**, 11, 2617-2620	1
1972	Network-based stratification analysis of 13 major cancer types using mutations in panels of cancer genes. **2015**, 16 Suppl 7, S7	21
1971	The kinase inhibitor D11 induces caspase-mediated cell death in cancer cells resistant to chemotherapeutic treatment. **2015**, 34, 125	13
1970	Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer. **2015**, 75, 1586-600	45
1969	Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma. **2015**, 112, 188-94	11
1968	Features of endometrial cancer in patients with 'metabolically healthy' versus 'standard' obesity: the decreasing frequency of metabolically healthy obesity. **2015**, 1, FSO68	5
1967	Microsatellite instability use in mismatch repair gene sequence variant classification. **2015**, 6, 150-62	7
1966	Genomic-Wide Analysis with Microarrays in Human Oncology. **2015**, 4, 454-73	9
1965	Reverse phase protein arrays in signaling pathways: a data integration perspective. **2015**, 9, 3519-27	32
1964	Possible therapeutic implication of PD-L1/PD-1 axis in endometrial cancer. **2015**, 5,	
1963	Activin B induces human endometrial cancer cell adhesion, migration and invasion by up-regulating integrin β1 via SMAD2/3 signaling. **2015**, 6, 31659-73	18
1962	Barriers prevent patient access to personalized therapies identified by molecular tumor profiling of gynecologic malignancies. **2015**, 5, 165-73	6

1961	The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. **2015**, 19, A68-77	1337
1960	Genome Modeling System: A Knowledge Management Platform for Genomics. **2015**, 11, e1004274	59
1959	ARID1A Is Essential for Endometrial Function during Early Pregnancy. **2015**, 11, e1005537	49
1958	Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC. **2015**, 10, e0129280	31
1957	Molecular Analysis of Mixed Endometrioid and Serous Adenocarcinoma of the Endometrium. **2015**, 10, e0130909	20
1956	Cancer-Testis Antigen Expression in Serous Endometrial Cancer with Loss of X Chromosome Inactivation. **2015**, 10, e0137476	9
1955	Profiling of Discrete Gynecological Cancers Reveals Novel Transcriptional Modules and Common Features Shared by Other Cancer Types and Embryonic Stem Cells. **2015**, 10, e0142229	38
1954	Small non-coding RNA deregulation in endometrial carcinogenesis. **2015**, 6, 4677-91	42
1953	Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?. **2015**, 2015, 219012	16
1952	Identification of Gene Expression Pattern Related to Breast Cancer Survival Using Integrated TCGA Datasets and Genomic Tools. **2015**, 2015, 878546	18
1951	ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. **2015**, 6, 28440-52	29
1950	Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. **2015**, 6, 17764-76	104
1949	Identifying core gene modules in glioblastoma based on multilayer factor-mediated dysfunctional regulatory networks through integrating multi-dimensional genomic data. **2015**, 43, 1997-2007	26
1948	Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas. **2015**, 39, 357-64	88
1947	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. **2015**, 372, 2509-20	5560
1946	Yeast DNA polymerase ? catalytic core and holoenzyme have comparable catalytic rates. **2015**, 290, 3825-35	15
1945	Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression. **2015**, 66, 517-28	24
1944	Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. **2015**, 12, 623-30	201

1943	Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. **2015**, 15, 334-46	307
1942	The emerging complexity of gene fusions in cancer. **2015**, 15, 371-81	382
1941	Endometrial cancer: redefining the molecular-targeted approach. **2015**, 76, 1-11	21
1940	Frequency and distribution of Notch mutations in tumor cell lines. **2015**, 15, 311	14
1939	Polymerase (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. **2015**, 138, 11-7	53
1938	POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. **2015**, 21, 3347-3355	184
1937	Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. **2015**, 16, 686-94	64
1936	Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies. **2015**, 128, 153-80	11
1935	Molecular cues on obesity signals, tumor markers and endometrial cancer. **2015**, 21, 89-106	21
1934	Identifying aggressive forms of endometrioid-type endometrial cancer: new insights into molecular subtyping. **2015**, 15, 1-3	16
1933	Computational and Statistical Epigenomics. **2015**,	2
1932	Future Directions and New Targets in Endometrial Cancer. **2015**, 259-271	
1931	Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. **2015**, 6, 6744	666
1930	Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. **2015**, 25, 1187-93	26
1929	Progress of cancer genomics. **2015**, 6, 557-60	
1928	In-depth molecular profiling of the biphasic components of uterine carcinosarcomas. **2015**, 1, 173-85	51
1927	Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors. **2015**, 1, 186-93	23
1926	Translational progress on tumor biomarkers. **2015**, 6, 665-71	9

1925	ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. **2015**, 117, 559-81	131
1924	Collateral Lethality: A new therapeutic strategy in oncology. **2015**, 1, 161-173	68
1923	Putative tumor suppression function of SIRT6 in endometrial cancer. **2015**, 589, 2274-81	23
1922	Activation of Saccharomyces cerevisiae Mlh1-Pms1 Endonuclease in a Reconstituted Mismatch Repair System. **2015**, 290, 21580-90	20
1921	Differences in genome-wide repeat sequence instability conferred by proofreading and mismatch repair defects. **2015**, 43, 4067-74	21
1920	A generative Bayesian model to identify cancer driver genes. **2015**,	
1919	Integrating omics data for identifying disease subtypes: A multiplex network-based approach. **2015** ,	
1918	Thyroid genomics: refining diagnosis, prognosis and treatment. **2015**, 2, 105-107	
1917	Uterine Cancer: Pathology. **2015**, 47-81	
1916	Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. **2016**, 108, djv427	111
1915	Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. **2016**, 108, djv428	81
1914	The future role of molecular staging in gynecologic cancer. **2015**, 131 Suppl 2, S127-31	3
1913	Upregulated Annexin A1 promotes cellular invasion in triple-negative breast cancer. **2015**, 33, 1064-70	28
1912	Oncostatin M activates STAT3 to promote endometrial cancer invasion and angiogenesis. **2015**, 34, 129-38	24
1911	Microarray expression profile of lncRNAs and the upregulated ASLNC04080 lncRNA in human endometrial carcinoma. **2015**, 46, 2125-37	48
1910	Measures for the degree of overlap of gene signatures and applications to TCGA. **2015**, 16, 735-44	10
1909	Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: endometrial cancer as a model. **2015**, 77-78, 31-40	6
1908	The mutational landscape of endometrial cancer. **2015**, 30, 25-31	30

1907	Improved survival of patients with hypermutation in uterine serous carcinoma. **2015**, 12, 3-4		11
1906	Somatic Diseases (Cancer): Whole Exome and Whole Genome Sequencing. **2015**, 343-360		
1905	mTOR Signaling in Endometrial Cancer: From a Molecular and Therapeutic Point of View. **2015**, 4, 1-10		10
1904	Statin use and survival in elderly patients with endometrial cancer. **2015**, 137, 252-7		24
1903	Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. **2015**, 137, 306-10		112
1902	Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. **2015**, 136, 246-53		85
1901	Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas. **2015**, 212, 188.e1-6		17
1900	"Omics" in pharmaceutical research: overview, applications, challenges, and future perspectives. **2015**, 13, 3-21		43
1899	Evaluation of melanoma antigen (MAGE) gene expression in human cancers using The Cancer Genome Atlas. **2015**, 208, 25-34		14
1898	The expression pattern of 19 genes predicts the histology of endometrial carcinoma. **2014**, 4, 5174		7
1897	Emerging critical roles of Fe-S clusters in DNA replication and repair. **2015**, 1853, 1253-71		137
1896	Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. **2015**, 91, 530-9		38
1895	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. **2015**, 47, 257-62		253
1894	Homologous-recombination-deficient tumours are dependent on Pol‡-mediated repair. *Nature*, **2015**, 518, 258-62	50.4	451
1893	Prognostic significance of POLE proofreading mutations in endometrial cancer. **2015**, 107, 402		169
1892	Coupling enrichment methods with proteomics for understanding and treating disease. **2015**, 9, 33-47		17
1891	Targeted mutation analysis of endometrial clear cell carcinoma. **2015**, 66, 664-74		63
1890	Novel genotype-phenotype associations in human cancers enabled by advanced molecular platforms and computational analysis of whole slide images. **2015**, 95, 366-76		39

1889	Microsatellite instability: an update. **2015**, 89, 899-921		118
1888	Big Bang and context-driven collapse. **2015**, 47, 196-7		17
1887	Avalanching mutations in biallelic mismatch repair deficiency syndrome. **2015**, 47, 194-6		3
1886	Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles. **2015**, 43, e44		72
1885	Cross-laboratory validation of the OncoScan FFPE Assay, a multiplex tool for whole genome tumour profiling. **2015**, 8, 5		66
1884	Molecular characteristics of endometrial cancer coexisting with peritoneal malignant mesothelioma in Li-Fraumeni-like syndrome. **2015**, 15, 8		9
1883	Differential DNA mismatch repair underlies mutation rate variation across the human genome. *Nature*, **2015**, 521, 81-4	50.4	224
1882	Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro. **2015**, 36, 5505-13		4
1881	Targeting the glucose-regulated protein-78 abrogates Pten-null driven AKT activation and endometrioid tumorigenesis. **2015**, 34, 5418-26		29
1880	Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. **2015**, 35 Suppl, S55-S77		67
1879	PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. **2015**, 137, 321-8		14
1878	Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers. **2015**, 5, 25		14
1877	Mutational Similarities Across Cancers: Implications for Research, Diagnostics, and Personalized Therapy Design. **2015**, 57-65		
1876	Role of Numb expression and nuclear translocation in endometrial cancer. **2015**, 9, 1531-1536		11
1875	The more tumors change, the more they stay tame: do T cells keep POLE ultramutated endometrial carcinomas in check?. **2015**, 138, 1-2		11
1874	Radiotherapy in the Era of Precision Medicine. **2015**, 25, 227-36		23
1873	NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activates IGF-1R/PI3K/Akt signaling. **2015**, 139, 127-33		19
1872	Cross-cancer profiling of molecular alterations within the human autophagy interaction network. **2015**, 11, 1668-87		89

1871	TANRIC: An Interactive Open Platform to Explore the Function of lncRNAs in Cancer. **2015**, 75, 3728-37	354
1870	TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. **2015**, 43, 6945-58	37
1869	Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. **2015**, 34, 479-96	74
1868	A clinically applicable molecular-based classification for endometrial cancers. **2015**, 113, 299-310	322
1867	Clinical translation for endometrial cancer stem cells hypothesis. **2015**, 34, 401-16	24
1866	Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. **2015**, 138, 323-31	16
1865	Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. **2015**, 1, e1500447	428
1864	Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. **2015**, 139, 118-26	41
1863	HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant. **2015**, 137, 160-6	24
1862	Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma. **2015**, 138, 620-6	22
1861	Volatility of Mutator Phenotypes at Single Cell Resolution. **2015**, 11, e1005151	11
1860	Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. **2015**, 1, 1319-23	378
1859	Integrative Epigenomics. **2015**, 127-139	
1858	Systems Epigenomics and Applications to Ageing and Cancer. **2015**, 161-185	
1857	Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. **2015**, 1, 486-94	27
1856	The cancer COMPASS: navigating the functions of MLL complexes in cancer. **2015**, 208, 178-91	91
1855	Publisher Note:Abstraction for data integration:Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction. **2015**, 58, 104-19	2
1854	Human ortholog of Drosophila Melted impedes SMAD2 release from TGF-β receptor I to inhibit TGF-β signaling. **2015**, 112, E3000-9	15

1853	Targeting FGFR Signaling in Cancer. **2015**, 21, 2684-94	301
1852	PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. **2015**, 9, 1694-703	40
1851	Protein domain-level landscape of cancer-type-specific somatic mutations. **2015**, 11, e1004147	46
1850	The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. **2015**, 20, 1058-68	36
1849	Absence of and hotspot mutations in patients with various subtypes of ovarian carcinomas. **2015**, 3, 33-37	11
1848	Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. **2015**, 137, 14-22	52
1847	Colon cancer-associated mutator DNA polymerase δ variant causes expansion of dNTP pools increasing its own infidelity. **2015**, 112, E2467-76	45
1846	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. **2015**, 28, 836-44	222
1845	Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium. **2015**, 137, 245-51	10
1844	Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function. **2015**, 12, 628-42	65
1843	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. **2015**, 21, 449-56	1031
1842	Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas. **2015**, 466, 415-22	27
1841	Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. **2015**, 134, 231-45	30
1840	Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover. **2015**, 6, e1687	39
1839	Pancancer analysis of DNA methylation-driven genes using MethylMix. **2015**, 16, 17	86
1838	Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. **2015**, 16, 45	101
1837	Molecular Pathology Informatics. **2015**, 8, 187-94	3
1836	PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer. **2015**, 138, 174-80	43

1835	Correlation of Smoking-Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer. **2015**, 1, 476-85	136
1834	Clinical and pathological characterization of endometrial cancer in young women: identification of a cohort without classical risk factors. **2015**, 138, 141-6	23
1833	Annotation of Sequence Variants in Cancer Samples: Processes and Pitfalls for Routine Assays in the Clinical Laboratory. **2015**, 17, 339-51	7
1832	dNTP pool levels modulate mutator phenotypes of error-prone DNA polymerase ζ variants. **2015**, 112, E2457-66	36
1831	9H-purine scaffold reveals induced-fit pocket plasticity of the BRD9 bromodomain. **2015**, 58, 2718-36	50
1830	Molecular staging of gynecological cancer: What is the future?. **2015**, 29, 776-89	9
1829	p53 at the Crossroads Between Stress Response Signaling and Tumorigenesis: From Molecular Mechanisms to Therapeutic Opportunities. **2015**, 51-73	
1828	Applications of NGS to Screen FFPE Tumours for Detecting Fusion Transcripts. **2015**, 155-177	
1827	Molecular pathogenesis of ovarian clear cell carcinoma. **2015**, 11, 1389-405	17
1826	Next Generation Sequencing in Cancer Research, Volume 2. **2015**,	4
1825	Inherited predisposition to endometrial cancer: moving beyond Lynch syndrome. **2015**, 121, 644-7	5
1824	The phosphoinositide 3-kinase pathway and therapy resistance in cancer. **2015**, 7, 13	75
1823	Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: association between tumor characteristics and survival outcome. **2015**, 125, 424-433	48
1822	Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma. **2015**, 25, 63-8	18
1821	Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. **2015**, 136, 554-61	66
1820	Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. **2015**, 17, 1356-64	76
1819	Microsatellite instable and microsatellite stable primary endometrial carcinoma cells and their subcutaneous and orthotopic xenografts recapitulate the characteristics of the corresponding primary tumor. **2015**, 25, 363-71	6
1818	Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression. **2015**, 112, 4737-42	50

1817	Novel molecular targets for urothelial carcinoma. **2015**, 19, 515-25	6
1816	Optimal drug prediction from personal genomics profiles. **2015**, 19, 1264-70	23
1815	The management of secondary lower limb lymphoedema in cancer patients: a systematic review. **2015**, 29, 112-9	24
1814	PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. **2015**, 14, 1466-1475	11
1813	Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. **2015**, 112, E1624-31	59
1812	Das Endometriumkarzinom. **2015**, 9, 19-34	
1811	New WHO Classification of Endometrial Hyperplasias. **2015**, 75, 135-136	82
1810	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. **2015**, 28, 515-528	278
1809	Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. **2015**, 42, 801-19	64
1808	Intron retention is a widespread mechanism of tumor-suppressor inactivation. **2015**, 47, 1242-8	217
1807	MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation. **2015**, 6, 7953	34
1806	Second-Line Therapy for Endometrial Cancer: The Need for Better Options. **2015**, 33, 3535-40	28
1805	Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo. **2015**, 14, 2519-26	24
1804	PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study, pre-operative recognition of high risk endometrial carcinoma: a multicentre prospective cohort study. **2015**, 15, 487	13
1803	PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. **2015**, 113, 1020-6	27
1802	Pathology of cancers of the female genital tract. **2015**, 131 Suppl 2, S132-45	26
1801	Tumor characterization and stratification by integrated molecular profiles reveals essential pan-cancer features. **2015**, 16, 503	26
1800	Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. **2015**, 1, 197-209	72

1799	Comparative analysis of oncogenes identified by microarray and RNA-sequencing as biomarkers for clinical prognosis. **2015**, 9, 1067-78	9
1798	CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. **2015**, 21, 2753-62	38
1797	Critical limitations of consensus clustering in class discovery. **2014**, 4, 6207	120
1796	Pan-cancer stratification of solid human epithelial tumors and cancer cell lines reveals commonalities and tissue-specific features of the CpG island methylator phenotype. **2015**, 8, 14	27
1795	Molecular analysis of isolated tumor glands from endometrial endometrioid adenocarcinomas. **2015**, 65, 240-9	5
1794	The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo. **2015**, 138, 378-82	4
1793	Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in S□ary syndrome. **2015**, 6, 8470	133
1792	Comprehensive assessment of cancer missense mutation clustering in protein structures. **2015**, 112, E5486-95	142
1791	Limited evidence that cancer susceptibility regions are preferential targets for somatic mutation. **2015**, 16, 193	17
1790	Dysregulation of ubiquitin ligases in cancer. **2015**, 23, 1-11	25
1789	Genetic Testing and Tissue Banking for Personalized Oncology: Analytical and Institutional Factors. **2015**, 42, 713-23	10
1788	Inferring pathway dysregulation in cancers from multiple types of omic data. **2015**, 7, 61	10
1787	Systematic analysis of somatic mutations impacting gene expression in 12 tumour types. **2015**, 6, 8554	71
1786	The mini-driver model of polygenic cancer evolution. **2015**, 15, 680-5	66
1785	Patterns of Chromosomal Aberrations in Solid Tumors. **2015**, 200, 115-42	33
1784	[Quinze questions importantes □se poser en oncologie en 2015]. **2015**, 102, S22-6	1
1783	Reprint of "Abstraction for data integration: Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction". **2015**, 59 Pt B, 123-38	9
1782	Gynecologic Tumors. **2015**, 507-535	

1781	The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women. **2015**, 24, 1407-15	114
1780	Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract. **2015**, 28, 1504-14	73
1779	Symposium on advances in endometrial cancer epidemiology and biology. **2015**, 138, 497-500	7
1778	Knowledge boosting: a graph-based integration approach with multi-omics data and genomic knowledge for cancer clinical outcome prediction. **2015**, 22, 109-20	58
1777	An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer. **2015**, 16, 140	51
1776	Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. **2015**, 22, 851-61	19
1775	Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer. **2015**, 107,	28
1774	Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo. **2015**, 29, 1707-20	18
1773	A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumors. **2015**, 28, 1603-12	71
1772	Update on pathology, staging and molecular pathology of endometrial (uterine corpus) adenocarcinoma. **2015**, 11, 3207-18	24
1771	Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. **2015**, 138, 614-9	7
1770	Effects of surgical volumes on the survival of endometrial carcinoma. **2015**, 139, 306-11	9
1769	The Cancer Genome Atlas Clinical Explorer: a web and mobile interface for identifying clinical-genomic driver associations. **2015**, 7, 112	58
1768	The role of functional data in interpreting the effects of genetic variation. **2015**, 26, 3904-8	10
1767	Laminin C1 expression by uterine carcinoma cells is associated with tumor progression. **2015**, 139, 338-44	30
1766	Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. **2015**, 47, 106-14	547
1765	Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. **2015**, 21, 448-59	43
1764	Development of a robust classifier for quality control of reverse-phase protein arrays. **2015**, 31, 912-8	33

1763	Regulatory MiR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma. **2015**, 61, 574-84	69
1762	SWI/SNF chromatin remodeling and human malignancies. **2015**, 10, 145-71	186
1761	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. **2015**, 24, 1478-92	46
1760	Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. **2015**, 28, 505-14	136
1759	Cancer stem cell division: when the rules of asymmetry are broken. **2015**, 24, 405-16	46
1758	Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. **2015**, 34, 3215-25	94
1757	POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: implications for Lynch syndrome testing. **2015**, 121, 331-4	13
1756	Comparison of gene expression patterns across 12 tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects. **2015**, 34, 2732-40	39
1755	Polymerase e (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. **2015**, 121, 386-94	111
1754	Genomic Applications in Pathology. **2015**,	
1753	Loss of Adherens Junction Protein E-Cadherin is a Biomarker of High- Grade Histology and Poor Prognosis in Endometrial Cancer. **2016**, 4,	5
1752	Meta-dimensional data integration identifies critical pathways for susceptibility, tumorigenesis and progression of endometrial cancer. **2016**, 7, 55249-55263	12
1751	Microsatellite Instability and its Significance to Hereditary and Sporadic Cancer. **2016**,	2
1750	NMU signaling promotes endometrial cancer cell progression by modulating adhesion signaling. **2016**, 7, 10228-42	13
1749	The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy. **2016**, 7, 68638-68649	48
1748	Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer. **2016**, 7, 39885-39893	21
1747	Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency. **2016**, 35, e259-68	10
1746	Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity. **2016**, 16, 252-65	6

1745	Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1. **2016**, 7, 46127-46141	30
1744	Mutations of Chromatin Structure Regulating Genes in Human Malignancies. **2016**, 17, 411-37	14
1743	High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer. **2016**, 2016, 5845061	19
1742	Networks and Consortia for Epigenetic Drug Discovery. **2016**, 143-166	1
1741	Mitochondrial DNA copy number variation across human cancers. **2016**, 5,	255
1740	Serous versus high-grade endometrioid endometrial carcinoma: immunohistochemistry of RFP is not useful for differentiation. **2016**, 67, 221-227	1
1739	LH/hCG-Receptor Expression May Have a Negative Prognostic Value in Low-Risk Endometrial Cancer. **2016**, 6, 190	3
1738	The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation. **2016**, 6,	16
1737	Identifying Cancer Subtypes from miRNA-TF-mRNA Regulatory Networks and Expression Data. **2016**, 11, e0152792	36
1736	Whole Genome Pathway Analysis Identifies an Association of Cadmium Response Gene Loss with Copy Number Variation in Mutant p53 Bearing Uterine Endometrial Carcinomas. **2016**, 11, e0159114	4
1735	TCGA Expedition: A Data Acquisition and Management System for TCGA Data. **2016**, 11, e0165395	38
1734	Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. **2016**, 7, 395	88
1733	Understanding Molecular Landscape of Endometrial Cancer through Next Generation Sequencing: What We Have Learned so Far?. **2016**, 7, 409	9
1732	An update of the classical Bokhman's dualistic model of endometrial cancer. **2016**, 15, 63-8	9
1731	Auf dem Weg zur Pr□isionsmedizin in der Gyn□ologischen Onkologie. **2016**, 37, 327-331	
1730	Mixed and Ambiguous Endometrial Carcinomas: A Heterogenous Group of Tumors With Different Clinicopathologic and Molecular Genetic Features. **2016**, 40, 972-81	25
1729	The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility. **2016**, 35, 16-24	28
1728	AKT in cancer: new molecular insights and advances in drug development. **2016**, 82, 943-56	148

1727	An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma. **2016**, 26, 497-504	12
1726	LncRNA-MEG3 inhibits cell proliferation of endometrial carcinoma by repressing Notch signaling. **2016**, 82, 589-94	78
1725	Endometrial cancer: Not your grandmother's cancer. **2016**, 122, 2787-98	90
1724	SLUG expression is an indicator of tumour recurrence in high-grade endometrial carcinomas. **2016**, 69, 374-82	10
1723	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. **2016**, 22, 4309-21	127
1722	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. **2016**, 2, 1434-1440	151
1721	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. **2016**, 26, 2-30	358
1720	Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. **2016**, 48, 61-8	77
1719	A high-resolution transcriptome map of cell cycle reveals novel connections between periodic genes and cancer. **2016**, 26, 946-62	52
1718	Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas. **2016**, 69, 288-97	57
1717	Genetic and epigenetic alterations of microRNAs and implications for human cancers and other diseases. **2016**, 55, 193-214	50
1716	Across-Platform Imputation of DNA Methylation Levels Incorporating Nonlocal Information Using Penalized Functional Regression. **2016**, 40, 333-40	8
1715	Interobserver Variability in the Diagnosis of Uterine High-Grade Endometrioid Carcinoma. **2016**, 140, 836-43	31
1714	Community detection from genomic datasets across human cancers. **2016**,	1
1713	New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. **2016**, 3, 14	86
1712	Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia. **2016**, 17, 140	46
1711	Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival. **2016**, 114, 688-96	48
1710	Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway. **2016**, 6, 27391	19

1709	Targeting mTOR pathway in gynecological malignancies: Biological rationale and systematic review of published data. **2016**, 108, 1-12	18
1708	Pan-cancer subtyping in a 2D-map shows substructures that are driven by specific combinations of molecular characteristics. **2016**, 6, 24949	14
1707	A missense methionine mutation augments catalytic activity but reduces thermal stability in two protein tyrosine phosphatases. **2016**, 481, 153-158	
1706	New concepts for an old problem: the diagnosis of endometrial hyperplasia. **2017**, 23, 232-254	120
1705	A weighted exact test for mutually exclusive mutations in cancer. **2016**, 32, i736-i745	37
1704	DNA damage response as a therapeutic target in gynecological cancers. **2016**, 28, 404-11	5
1703	Somatic PIK3CA mutations as a driver of sporadic venous malformations. **2016**, 8, 332ra42	98
1702	CD73s protection of epithelial integrity: Thinking beyond the barrier. **2016**, 4, e1224963	13
1701	Loss of the cell polarity determinant human Discs-large is a novel molecular marker of nodal involvement and poor prognosis in endometrial cancer. **2016**, 114, 1012-8	6
1700	A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. **2016**, 23, 681-91	40
1699	Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type. **2016**, 29, 60-6	49
1698	Current Issues in the Diagnosis and Treatment of Endometrial Carcinoma. **2016**, 76, 170-175	10
1697	ECGene: A Literature-Based Knowledgebase of Endometrial Cancer Genes. **2016**, 37, 337-43	12
1696	Dysregulated FGF signalling in neoplastic disorders. **2016**, 53, 126-35	54
1695	Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer. **2016**, 141, 564-569	24
1694	Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation. **2016**, 141, 570-579	2
1693	Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes. **2016**, 9, 189-99	19
1692	Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations. **2016**, 142, 150-157	4

1691	Kernelized Information-Theoretic Metric Learning for Cancer Diagnosis Using High-Dimensional Molecular Profiling Data. **2016**, 10, 1-23	5
1690	Genomics of SCC: Tumor Formation, Progression, and Future Therapeutic Implications for High-Risk Cutaneous Squamous Cell Carcinoma. **2016**, 67-102	0
1689	Cohesin mutations in human cancer. **2016**, 1866, 1-11	66
1688	Tumor grade and chemotherapy response in endometrioid endometrial cancer. **2016**, 17, 3-6	11
1687	Understanding mutagenesis through delineation of mutational signatures in human cancer. **2016**, 37, 531-40	66
1686	Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. **2016**, 22, 4215-24	286
1685	Nestin: A biomarker of aggressive uterine cancers. **2016**, 140, 503-11	4
1684	The tandem duplicator phenotype as a distinct genomic configuration in cancer. **2016**, 113, E2373-82	71
1683	Deletion of Arid1a in Reproductive Tract Mesenchymal Cells Reduces Fertility in Female Mice. **2016**, 94, 93	8
1682	Expression of tumor suppressor genes related to the cell cycle in endometrial cancer patients. **2016** , 61, 317-324	17
1681	Protocadherin 10 inhibits cell proliferation and induces apoptosis via regulation of DEP domain containing 1 in endometrial endometrioid carcinoma. **2016**, 100, 344-52	18
1680	Processing ribonucleotides incorporated during eukaryotic DNA replication. **2016**, 17, 350-63	110
1679	WeSME: uncovering mutual exclusivity of cancer drivers and beyond. **2017**, 33, 814-821	41
1678	Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. **2016**, 6, 714-26	100
1677	S100A4 promotes endometrial cancer progress through epithelial-mesenchymal transition regulation. **2016**, 35, 3419-26	5
1676	High-Risk Cutaneous Squamous Cell Carcinoma. **2016**,	4
1675	Five endometrial cancer risk loci identified through genome-wide association analysis. **2016**, 48, 667-674	56
1674	Integrating Omic Data with a Multiplex Network-based Approach for the Identification of Cancer Subtypes. **2016**, 15, 335-342	27

1673	Auf dem Weg zur Pr□isionsmedizin in der Gyn□ologischen Onkologie. **2016**, 10, 4-8	
1672	Perspectives on targeting the phosphatidylinositol 3-kinase pathway for personalized medicine in endometrial and ovarian cancers. **2016**, 5, 3-7	
1671	Phosphatidylinositol-3 kinase-dependent translational regulation of Id1 involves the PPM1G phosphatase. **2016**, 35, 5807-5816	12
1670	In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis. **2016**, 35, 5446-5455	39
1669	Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. **2016**, 141, 559-563	19
1668	Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. **2016**, 22, 5238-5248	30
1667	A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). **2016**, 122, 3519-3528	50
1666	Targeted therapy in endometrial cancer: Making progress. **2016**, 122, 3428-3429	1
1665	Epigenomic Consequences of Coding and Noncoding Driver Mutations. **2016**, 2, 585-605	7
1664	Immune signaling-based Cascade Propagation approach re-stratifies HNSCC patients. **2016**, 111, 72-79	4
1663	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. **2016**, 113, 12238-12243	123
1662	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. **2016**, 1, 207-216	160
1661	Conserved and Divergent Features of DNA Repair. **2016**, 651-666	
1660	The genomic landscape of schwannoma. **2016**, 48, 1339-1348	74
1659	Trends in the utilization of adjuvant vaginal brachytherapy in women with early-stage endometrial carcinoma: Results of an updated period analysis of SEER data. **2016**, 15, 554-61	18
1658	PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials. **2016**, 142, 588-96	17
1657	Progress in Vulvar and Endometrial Cancers: Exploiting Anatomy and Biology and Improving Systemic Therapy. **2016**, 96, 1-5	3
1656	Molecular genetic heterogeneity in undifferentiated endometrial carcinomas. **2016**, 29, 1390-1398	52

1655	LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma. **2016**, 139, 2529-39	28
1654	Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer. **2016**, 16, 2032-46	30
1653	Regression of Chemotherapy-Resistant Polymerase (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. **2016**, 22, 5682-5687	109
1652	Promotion of epithelial-mesenchymal transition by Frizzled2 is involved in the metastasis of endometrial cancer. **2016**, 36, 803-10	19
1651	The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. **2016**, 6,	204
1650	Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth. **2016**, 76, 5719-5731	55
1649	L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. **2016**, 115, 716-24	61
1648	Nurses' Health Study Contributions on the Epidemiology of Less Common Cancers: Endometrial, Ovarian, Pancreatic, and Hematologic. **2016**, 106, 1608-15	11
1647	A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment. **2016**, 56, 316-23	4
1646	Immunohistochemistry as a Practical Tool in Molecular Pathology. **2016**, 140, 766-9	12
1645	Association between differential gene expression and body mass index among endometrial cancers from The Cancer Genome Atlas Project. **2016**, 142, 317-22	18
1644	The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role. **2016**, 143, 398-405	9
1643	Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Uterine Tumors. **2016**, 9, 405-26	11
1642	Cyclin E as a potential therapeutic target in high grade serous ovarian cancer. **2016**, 143, 152-158	51
1641	Dysregulated Wnt signalling and recurrent mutations of the tumour suppressor RNF43 in early gastric carcinogenesis. **2016**, 240, 304-314	35
1640	Applications of integrative OMICs approaches to gene regulation studies. **2016**, 4, 283-301	4
1639	Therapeutic Modalities in Early-Stage Uterine Papillary Serous Carcinomas, Carcinosarcomas, Clear-Cell and Mixed Histology Carcinomas: Treatment of Choice Is Combined Chemotherapy and Radiation. **2016**, 201-221	
1638	Implication of genomic characterization in synchronous endometrial and ovarian cancers of endometrioid histology. **2016**, 143, 60-67	34

1637	Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. **2016**, 21, 1200-1211	164
1636	The future therapy of endometrial cancer: microRNA's functionality, capability, and putative clinical application. **2016**, 294, 889-895	11
1635	MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. **2016**, 37, 1004-12	5
1634	The clinical significance of K-ras mutation in endometrial "surface epithelial changes" and their associated endometrial adenocarcinoma. **2016**, 142, 163-168	7
1633	Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. **2016**, 143, 46-53	94
1632	RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers. **2016**, 64, 149-58	4
1631	[Grading of gynecological tumors : Current aspects]. **2016**, 37, 337-51	1
1630	The emerging role of long non-coding RNAs in endometrial cancer. **2016**, 209, 445-455	33
1629	Optimized p53 immunohistochemistry is an accurate predictor of mutation in ovarian carcinoma. **2016**, 2, 247-258	192
1628	Features of omental adipose tissue in endometrial cancer patients with 'standard' or 'metabolically healthy' obesity: associations with tumor process characteristics. **2016**, 5, 1900	3
1627	Discovery of biomarkers for endometrial cancer: current status and prospects. **2016**, 16, 1315-1336	37
1626	Methylation status of homeobox genes in common human cancers. **2016**, 108, 185-193	24
1625	Systematic analysis of mutation distribution in three dimensional protein structures identifies cancer driver genes. **2016**, 6, 26483	15
1624	Novel kinase fusion transcripts found in endometrial cancer. **2015**, 5, 18657	11
1623	Immunotherapy in Endometrial Cancer: In the Nick of Time. **2016**, 22, 5623-5625	18
1622	Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. **2016**, 21, 1250-1259	56
1621	CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas. **2016**, 48, 506-16	23
1620	A genetic basis for the variation in the vulnerability of cancer to DNA damage. **2016**, 7, 11428	95

1619	MiR-200a acts as an oncogene in colorectal carcinoma by targeting PTEN. **2016**, 101, 308-313	17
1618	[Metastatic mechanisms of uterine malignancies and therapeutic consequences]. **2016**, 37, 549-556	1
1617	Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. **2016**, 6, 25521	11
1616	Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. **2016**, 143, 460-465	53
1615	Characterization of cytokinome landscape for clinical responses in human cancers. **2016**, 5, e1214789	19
1614	Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung. **2016**, 113, 10672-7	31
1613	An empirical likelihood ratio test robust to individual heterogeneity for differential expression analysis of RNA-seq. **2018**, 19, 109-117	2
1612	Epigenetic Mechanisms in Lynch Syndrome. **2016**, 1-9	1
1611	Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis. **2016**, 23, 61-6	12
1610	Function of Deubiquitinating Enzyme USP14 as Oncogene in Different Types of Cancer. **2016**, 38, 993-1002	23
1609	Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. **2016**, 6, 19649	10
1608	Thyrostimulin-TSHR signaling promotes the proliferation of NIH:OVCAR-3 ovarian cancer cells via trans-regulation of the EGFR pathway. **2016**, 6, 27471	17
1607	Molecular determinants for lymph node metastasis in clinically early-stage endometrial cancer. **2016**, 11, 323-329	6
1606	Molecular profiles to biology and pathways: a systems biology approach. **2016**, 35, 53	5
1605	Integrating gene set analysis and nonlinear predictive modeling of disease phenotypes using a Bayesian multitask formulation. **2016**, 17, 0	5
1604	Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma: an observational ancillary analysis. **2016**, 3, 13	1
1603	Pr□anzerosen und Malignome des Endometriums. **2016**, 49, 754-761	
1602	Prediction of chemo-response in serous ovarian cancer. **2016**, 15, 66	20

1601	Molecular Analysis of Single Tumor Glands Using the Crypt Isolation Method in Endometrial Carcinomas. **2016**, 26, 1658-1666	
1600	Loss of Mismatch Repair Protein Expression in Unselected Endometrial Adenocarcinoma Precursor Lesions. **2016**, 26, 228-32	13
1599	Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies. **2016**, 42, 757-62	12
1598	Bioconductor's EnrichmentBrowser: seamless navigation through combined results of set- & network-based enrichment analysis. **2016**, 17, 45	36
1597	A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding. **2016**, 98, 1159-1169	17
1596	ICM: a web server for integrated clustering of multi-dimensional biomedical data. **2016**, 44, W154-9	13
1595	Investigating core genetic-and-epigenetic cell cycle networks for stemness and carcinogenic mechanisms, and cancer drug design using big database mining and genome-wide next-generation sequencing data. **2016**, 15, 2593-2607	20
1594	Role of Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: Is Observation a Valid Strategy?. **2016**, 26, 491-6	8
1593	Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. **2016**, 35, 48-55	110
1592	Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. **2016**, 34, 3062-8	90
1591	Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature. **2016**, 111, 290-302	93
1590	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. **2016**, 48, 848-55	135
1589	Immunotherapy for gynecologic cancers. **2016**, 142, 3-5	9
1588	Multiple Weak Linear Motifs Enhance Recruitment and Processivity in SPOP-Mediated Substrate Ubiquitination. **2016**, 428, 1256-1271	28
1587	Lynch Syndrome: Female Genital Tract Cancer Diagnosis and Screening. **2016**, 9, 201-14	24
1586	DNA Replication-A Matter of Fidelity. **2016**, 62, 745-55	75
1585	When Genome Maintenance Goes Badly Awry. **2016**, 62, 777-87	51
1584	Gynecologic Manifestations of Less Commonly Encountered Hereditary Syndromes. **2016**, 9, 269-87	2

1583	ELF5 isoform expression is tissue-specific and significantly altered in cancer. **2016**, 18, 4	23
1582	The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice. **2016**, 203, 1601-11	7
1581	Association between the CYP11 family and six cancer types. **2016**, 12, 35-40	12
1580	Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. **2016**, 151, 440-447.e1	29
1579	Paired boxed gene 1 expression: A single potential biomarker for differentiating endometrial lesions associated with favorable outcomes in patients with endometrial carcinoma. **2016**, 42, 1159-67	3
1578	Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. **2016**, 115, 303-11	23
1577	Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types. **2016**, 7, 10499	80
1576	Tumor progression, metastasis, and modulators of epithelial-mesenchymal transition in endometrioid endometrial carcinoma: an update. **2016**, 23, R85-R111	53
1575	Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas. **2016**, 141, 113-20	30
1574	A panoply of errors: polymerase proofreading domain mutations in cancer. **2016**, 16, 71-81	205
1573	The kinome 'at large' in cancer. **2016**, 16, 83-98	167
1572	Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment. **2016**, 17, 297-307	24
1571	Methylation-dependent regulation of HIF-1α stability restricts retinal and tumour angiogenesis. **2016**, 7, 10347	102
1570	Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas. **2016**, 145, 8-21	38
1569	Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis. **2016**, 22, 2865-73	93
1568	New era of integrated cancer biomarker discovery using reverse-phase protein arrays. **2016**, 31, 35-45	27
1567	Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices. **2016**, 140, 152-60	11
1566	BRCAness revisited. **2016**, 16, 110-20	678

1565	Neo-adjuvant chemotherapy for advanced stage endometrial carcinoma: a glimmer of hope in select patients. **2016**, 293, 47-53	18
1564	Large-scale profiling of microRNAs for The Cancer Genome Atlas. **2016**, 44, e3	85
1563	Systematic discovery of complex insertions and deletions in human cancers. **2016**, 22, 97-104	62
1562	Transcriptome Analysis of Recurrently Deregulated Genes across Multiple Cancers Identifies New Pan-Cancer Biomarkers. **2016**, 76, 216-26	56
1561	Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer. **2016**, 22, 513-23	19
1560	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. **2016**, 27, 16-41	497
1559	DNA Methylation Microarrays. **2016**, 19-46	2
1558	TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. **2016**, 35, 289-300	51
1557	Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. **2016**, 141, 86-94	21
1556	Germline mutations of the DNA repair pathways in uterine serous carcinoma. **2016**, 141, 101-7	8
1555	Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. **2016**, 141, 65-71	10
1554	Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers. **2016**, 141, 2-9	26
1553	Use of "big data" in drug discovery and clinical trials. **2016**, 141, 17-23	19
1552	Initiation of a formalized precision medicine program in gynecologic oncology. **2016**, 141, 24-8	12
1551	Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. **2016**, 141, 43-8	18
1550	The importance of p53 pathway genetics in inherited and somatic cancer genomes. **2016**, 16, 251-65	93
1549	Akt regulates progesterone receptor B-dependent transcription and angiogenesis in endometrial cancer cells. **2016**, 35, 5191-201	25
1548	GWAS meta-analysis of 16 852 women identifies new susceptibility locus for endometrial cancer. **2016**, 25, 2612-2620	15

1547	Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer. **2016**, 107, 452-60	30
1546	Thermodynamic measures of cancer: Gibbs free energy and entropy of protein-protein interactions. **2016**, 42, 339-50	26
1545	Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments. **2016**, 59, 99-108	28
1544	Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis. **2016**, 26, 933-8	26
1543	An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. **2016**, 35, 430-41	121
1542	Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond. **2016**, 140, 565-74	29
1541	Update on Lynch syndrome genomics. **2016**, 15, 385-93	90
1540	Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas. **2016**, 114, 554-61	13
1539	L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA). **2016**, 141, 336-340	53
1538	Molecular Pathology Informatics. **2016**, 36, 57-66	1
1537	Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma. **2016**, 18, 541-9	6
1536	Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies. **2016**, 11, 283-312	72
1535	Genomic testing and precision medicine--What does this mean for gynecologic oncology?. **2016**, 140, 3-5	4
1534	Rare cancers: a sea of opportunity. **2016**, 17, e52-e61	60
1533	Genetic alterations in endometrial cancer by targeted next-generation sequencing. **2016**, 100, 8-12	20
1532	Various ARID1A expression patterns and their clinical significance in gastric cancers. **2016**, 49, 61-70	20
1531	Molecular Pathology of Solid Tumors. **2016**, 557-594	
1530	Predictive Modeling: A New Paradigm for Managing Endometrial Cancer. **2016**, 23, 975-88	21

1529	Hormones and endometrial carcinogenesis. **2016**, 25, 129-48	26
1528	(Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes. **2016**, 22, 329-37	23
1527	New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?. **2016**, 18, 23	6
1526	Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer. **2016**, 94, 835-47	45
1525	Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia. **2016**, 22, 6217-6227	20
1524	An update on the current pharmacotherapy for endometrial cancer. **2016**, 17, 489-99	17
1523	Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis. **2016**, 25, 438-45	10
1522	Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterations. **2016**, 48, 117-25	60
1521	Molecular Characterization of an Endometrial Endometrioid Adenocarcinoma Metastatic to a Thyroid Hürthle Cell Adenoma Showing Cancerization of Follicles. **2016**, 27, 213-9	8
1520	Bromodomains: Structure, function and pharmacology of inhibition. **2016**, 106, 1-18	141
1519	Practical issues in the diagnosis of serous carcinoma of the endometrium. **2016**, 29 Suppl 1, S45-58	26
1518	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. **2016**, 29, 174-81	42
1517	Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. **2016**, 29, 302-14	85
1516	Identification of potential COPD genes based on multi-omics data at the functional level. **2016**, 12, 191-204	4
1515	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. **2016**, 34, 155-63	465
1514	Is the NCI MATCH trial a match for gynecologic oncology?. **2016**, 140, 161-6	17
1513	Developmental DNA methyltransferase inhibitors in the treatment of gynecologic cancers. **2016**, 17, 323-38	7
1512	Emerging strategies for targeting PI3K in gynecologic cancer. **2016**, 140, 333-44	16

1511	YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. **2016**, 35, 2247-65		46
1510	Endometrial Cancer. **2016**, 1203-1229.e7		4
1509	proofreading mutation, immune response and prognosis in endometrial cancer. **2016**, 5, e1072675		26
1508	ccmGDB: a database for cancer cell metabolism genes. **2016**, 44, D959-68		27
1507	MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy. **2016**, 6, 45-58		35
1506	Endometrial cancer. **2016**, 387, 1094-1108		797
1505	Wnt signalling in gynaecological cancers: A future target for personalised medicine?. **2016**, 140, 345-51		27
1504	Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy. **2016**, 68, 916-24		45
1503	Immunohistochemical Profiling of Endometrial Serous Carcinoma. **2017**, 36, 128-139		39
1502	Integrated genomic and molecular characterization of cervical cancer. *Nature*, **2017**, 543, 378-384	50.4	755
1501	Cholesterol Synthetase DHCR24 Induced by Insulin Aggravates Cancer Invasion and Progesterone Resistance in Endometrial Carcinoma. **2017**, 7, 41404		19
1500	The allosteric AKT inhibitor, MK2206, decreases tumor growth and invasion in patient derived xenografts of endometrial cancer. **2017**, 18, 958-964		16
1499	Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. **2017**, 123, 802-813		267
1498	The promise of molecular staging for the future. **2017**, 123, 728-730		2
1497	Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. **2017**, 13, 608-624		44
1496	Prediction of lymphatic dissemination in endometrioid endometrial cancer: Comparison of three risk-stratification models in a single-institution cohort. **2017**, 144, 510-514		11
1495	Immunotherapy and patients treated for cancer with microsatellite instability. **2017**, 104, 42-51		45
1494	Genomic insights in gynecologic cancer. **2017**, 41, 8-36		7

1493	Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations. **2017**, 19, 42-45	23
1492	The NF1 gene in tumor syndromes and melanoma. **2017**, 97, 146-157	92
1491	Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs. **2017**, 8, 14249	25
1490	Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens. **2017**, 23, 3802-3812	33
1489	Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. **2017**, 19, 100-111	18
1488	Transcriptional coregulator RIP140: an essential regulator of physiology. **2017**, 58, R147-R158	9
1487	PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2 Endometrial Cancers. **2017**, 16, 637-648	26
1486	Genetic Variants in Epigenetic Pathways and Risks of Multiple Cancers in the GAME-ON Consortium. **2017**, 26, 816-825	7
1485	Mining Cancer Transcriptomes: Bioinformatic Tools and the Remaining Challenges. **2017**, 21, 249-258	7
1484	Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers. **2017**, 22, 152-157	5
1483	Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. **2017**, 13, 914	44
1482	YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway. **2017**, 77, 1637-1648	32
1481	Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast. **2017**, 11, 913-926	6
1480	Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer. **2017**, 13, 1063-1070	10
1479	CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. **2017**, 30, 1032-1041	116
1478	SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation. **2017**, 7,	36
1477	The importance of regulatory ubiquitination in cancer and metastasis. **2017**, 16, 634-648	90
1476	Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report. **2017**, 17, 66	9

1475	miR-944 acts as a prognostic marker and promotes the tumor progression in endometrial cancer. **2017**, 88, 902-910	33
1474	Hypermutated Colorectal Cancer and Neoantigen Load. **2017**, 187-215	2
1473	Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer. **2017**, 7, 410-423	77
1472	The Relationship Between DOT1L, Histone H3 Methylation, and Genome Stability in Cancer. **2017**, 3, 18-27	3
1471	Synchronous endometrial and ovarian carcinomas: predictors of risk and associations with survival and tumor expression profiles. **2017**, 28, 447-457	16
1470	Cancer Genomics and Evolution. **2017**, 1-27	0
1469	Metabolomic characterisation of the effects of oncogenic PIK3CA transformation in a breast epithelial cell line. **2017**, 7, 46079	14
1468	RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro. **2017**, 28, 514-521	12
1467	Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer. **2017**, 470, 655-664	19
1466	Endometrial Cancer. **2017**, 1-15	
1465	Integrative epigenetic and genetic pan-cancer somatic alteration portraits. **2017**, 12, 561-574	15
1464	Intrinsic Molecular Processes: Impact on Mutagenesis. **2017**, 3, 357-371	4
1463	Uterine cancer, mutational phenotype, and the era of immune checkpoint blockade. **2017**, 13, 175-180	1
1462	Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification. **2017**, 78, 82-90	3
1461	Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary. **2017**, 41, 685-695	41
1460	Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer. **2017**, 37, 2603-2610	29
1459	Knowledge about the presence or absence of miRNA isoforms (isomiRs) can successfully discriminate amongst 32 TCGA cancer types. **2017**, 45, 2973-2985	115
1458	Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium. **2017**, 36, 555-561	25

1457	Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma. **2017**, 71, 480-487	2
1456	VprBP/DCAF1 Regulates the Degradation and Nonproteolytic Activation of the Cell Cycle Transcription Factor FoxM1. **2017**, 37,	22
1455	The role of pathology in the management of patients with endometrial carcinoma. **2017**, 13, 1003-1020	5
1454	Reliability of algorithmic somatic copy number alteration detection from targeted capture data. **2017**, 33, 2791-2798	9
1453	Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis. **2017**, 41, 1121-1128	54
1452	Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative. **2017**, 146, 327-333	16
1451	Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes Deficient Prostate Cancer to Radiation. **2017**, 16, 1279-1289	29
1450	[Hereditary colorectal cancer : An update on genetics and entities in terms of differential diagnosis]. **2017**, 38, 156-163	4
1449	Endometrium. **2017**, 557-575	
1448	Genetic landscape of clear cell endometrial cancer and the era of precision medicine. **2017**, 123, 3216-3218	2
1447	Epigenetics in endometrial carcinogenesis - part 1: DNA methylation. **2017**, 9, 737-755	15
1446	Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. **2017**, 123, 3261-3268	52
1445	Identification of critical base pairs required for CTCF binding in motif M1 and M2. **2017**, 8, 544-549	7
1444	Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition. **2017**, 40, 281-292	7
1443	DNA Polymerase e Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity. **2017**, 22, 497-502	17
1442	Development of organoids from mouse and human endometrium showing endometrial epithelium physiology and long-term expandability. **2017**, 144, 1775-1786	132
1441	Morphological Features and Prognostic Significance of ARID1A-Deficient Esophageal Adenocarcinomas. **2017**, 141, 970-977	11
1440	Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing. **2017**, 30, 1048-1068	20

1439	Molecular Genetics of Endometrial Carcinoma. **2017**,	1
1438	Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences. **2017**, 943, 3-46	48
1437	Traditional Approaches to Molecular Genetic Analysis. **2017**, 943, 99-118	2
1436	Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS. **2017**, 30, 140-148	3
1435	Clinical Behavior and Treatment of Endometrial Cancer. **2017**, 943, 47-74	14
1434	Pathology of Endometrial Carcinoma. **2017**, 943, 75-96	28
1433	LKB1 as a Tumor Suppressor in Uterine Cancer: Mouse Models and Translational Studies. **2017**, 943, 211-241	3
1432	Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. **2017**, 140, 1396-1404	39
1431	Endometrial Carcinoma: Specific Targeted Pathways. **2017**, 943, 149-207	37
1430	Next-Generation Sequencing. **2017**, 943, 119-148	31
1429	Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy. **2017**, 56, 16-25	51
1428	Molecular profiles of benign and (pre)malignant endometrial lesions. **2017**, 38, 329-335	17
1427	Adjuvante Strahlentherapie beim Endometriumkarzinom. **2017**, 23, 29-33	
1426	Structural insights into the function of ZRANB3 in replication stress response. **2017**, 8, 15847	34
1425	Genomic profiling of gynecologic cancers and implications for clinical practice. **2017**, 29, 18-25	3
1424	The Microcystic, Elongated, and Fragmented (MELF) Pattern of Invasion: A Single Institution Report of 464 Consecutive FIGO Grade 1 Endometrial Endometrioid Adenocarcinomas. **2017**, 41, 49-55	30
1423	Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. **2017**, 41, 245-252	56
1422	DJ-1 is a reliable serum biomarker for discriminating high-risk endometrial cancer. **2017**, 39, 1010428317705746	64

1421	miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. **2017**, 7, 3614	18
1420	Structural Basis for the Versatile and Methylation-Dependent Binding of CTCF to DNA. **2017**, 66, 711-720.e3	126
1419	KIF11 silencing and inhibition induces chromosome instability that may contribute to cancer. **2017**, 56, 668-680	26
1418	Molecular characterization of endometrial cancer and therapeutic implications. **2017**, 29, 35-39	8
1417	DNA Damage and Repair Biomarkers of Immunotherapy Response. **2017**, 7, 675-693	331
1416	A molecular portrait of microsatellite instability across multiple cancers. **2017**, 8, 15180	288
1415	L1CAM and HER2 Expression in Early Endometrioid Uterine Cancer. **2017**, 36, 356-363	6
1414	A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer. **2017**, 45, 8269-8281	25
1413	High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. **2017**, 146, 247-253	18
1412	Stratification of risk groups according to survival after recurrence in endometrial cancer patients. **2017**, 96, e6920	6
1411	Carcinogenicity, efficiency and biosafety analysis in xeno-free human amniotic stem cells for regenerative medical therapies. **2017**, 19, 990-1001	7
1410	Precision Medicine in Gynecology and Obstetrics. **2017**,	1
1409	Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. **2017**, 109,	7
1408	Frailty measure is more predictive of outcomes after curative therapy for endometrial cancer than traditional risk factors in women 60 and older. **2017**, 145, 526-530	22
1407	PathwayMapper: a collaborative visual web editor for cancer pathways and genomic data. **2017**, 33, 2238-2240	31
1406	Nucleotide selectivity defect and mutator phenotype conferred by a colon cancer-associated DNA polymerase δ mutation in human cells. **2017**, 36, 4427-4433	14
1405	A systematic review and pooled analysis of retrospective series of eribulin in metastatic breast cancer. **2017**, 28, 557-564	15
1404	Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors. **2017**, 145, 446-452	30

1403	STAR and AKR1B10 are down-regulated in high-grade endometrial cancer. **2017**, 171, 43-53	14
1402	TGF-β induces endometrial cancer cell adhesion and migration by up-regulating integrin β3 via SMAD-independent MEK-ERK1/2 signaling. **2017**, 34, 92-101	15
1401	Targeted radionuclide therapy for lung cancer with iodine-131-labeled peptide in a nude-mouse model. **2017**, 28, 480-488	1
1400	A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient. **2017**, 28, 551-556	8
1399	Protein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer. **2017**, 28, 569-580	22
1398	Adriamycin in combination with dexamethasone and octreotide lacks activity on the treatment of a 4T1 metastatic breast cancer model. **2017**, 28, 489-502	1
1397	Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN. **2017**, 92, 109-114	3
1396	Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. **2017**, 7, 738	7
1395	Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias. **2017**, 242, 152-164	22
1394	DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. **2017**, 12, 416-432	66
1393	Integrated Molecular Characterization of Uterine Carcinosarcoma. **2017**, 31, 411-423	210
1392	Targeted Therapy in Gynecological Malignancy. **2017**, 663-680	
1391	The enigmatic oncogene and tumor suppressor-like properties of RAD54B: Insights into genome instability and cancer. **2017**, 56, 513-523	10
1390	The role of interleukin-1b and its antagonist (diacerein) in estradiol benzoate-induced endometrial hyperplasia and atypia in female rats. **2017**, 31, 438-446	23
1389	FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. **2017**, 145, 366-373	26
1388	Pan-cancer analysis distinguishes transcriptional changes of aneuploidy from proliferation. **2017**, 27, 501-511	31
1387	CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic. **2017**, 36, 4100-4110	29
1386	Insights into the pathological mechanisms of p85α mutations using a yeast-based phosphatidylinositol 3-kinase model. **2017**, 37,	9

1385	PI3K/PTEN/AKT Genetic Mouse Models of Endometrial Carcinoma. **2017**, 943, 261-273		7
1384	Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. **2017**, 144, 146-152		38
1383	Genomic pathobiology of gastric carcinoma. **2017**, 67, 63-71		8
1382	Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?. **2017**, 123, 1545-1554		29
1381	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. **2017**, 19, 244-254		66
1380	Molecular approaches for classifying endometrial carcinoma. **2017**, 145, 200-207		88
1379	Patients with endometrial cancer at risk for lymphatic metastasis should undergo pelvic and periaortic lymphadenectomy as part of their initial surgery. **2017**, 123, 192-196		4
1378	Immunotherapy for Gastrointestinal Cancer. **2017**,		0
1377	Targeting fibroblast growth factor pathways in endometrial cancer. **2017**, 41, 37-47		19
1376	Honing the classification of high-risk endometrial cancer with inclusion of lymphovascular space invasion. **2017**, 26, 1-7		4
1375	Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report. **2017**, 72, 215-225		32
1374	Integrated genomic characterization of oesophageal carcinoma. *Nature*, **2017**, 541, 169-175	50.4	965
1373	Immunological profiling of molecularly classified high-risk endometrial cancers identifies -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. **2017**, 6, e1264565		79
1372	Bokhman Redux: Endometrial cancer "types" in the 21st century. **2017**, 144, 243-249		70
1371	Looking beyond drivers and passengers in cancer genome sequencing data. **2017**, 28, 938-945		22
1370	Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma. **2017**, 140, 1551-1563		21
1369	Immunohistochemistry to determine mismatch repair-deficiency in endometrial cancer: the appropriate standard. **2017**, 28, 9-10		1
1368	The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century. **2017**, 70, 56-69		18

1367	Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis. **2017**, 8, 1081	13
1366	POLE somatic mutations in advanced colorectal cancer. **2017**, 6, 2966-2971	31
1365	Targeted Therapy and Prevention of Endometrial Cancer. **2017**, 187-223	
1364	Primum non nocere: Are we ready for POLE testing in endometrial cancer?. **2017**, 147, 240-242	5
1363	Pan-cancer analysis reveals presence of pronounced DNA methylation drift in CpG island methylator phenotype clusters. **2017**, 9, 1341-1352	10
1362	Precision Molecular Pathology of Uterine Cancer. **2017**,	2
1361	[Endometrial cancer: Predictive models and clinical impact]. **2017**, 104, 1022-1031	11
1360	[Histological and molecular classification of endometrial carcinoma and therapeutical implications]. **2017**, 104, 1001-1012	7
1359	[Abnormalities of DNA repair and gynecological cancers]. **2017**, 104, 971-980	1
1358	Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. **2017**, 147, 648-653	19
1357	Molecular Testing of Colorectal Cancer in the Modern Era: What Are We Doing and Why?. **2017**, 10, 1009-1020	3
1356	Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma. **2017**, 23, 7232-7241	19
1355	[Radiochemotherapy improves failure-free survival in stage´III endometrial cancer : Final results of the PORTEC-3 trial]. **2017**, 193, 1070-1071	1
1354	Interethnic DNA methylation difference and its implications in pharmacoepigenetics. **2017**, 9, 1437-1454	13
1353	EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. **2017**, 19, 1371-1378	179
1352	Cancer Precision Medicine: Why More Is More and DNA Is Not Enough. **2017**, 20, 70-80	20
1351	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. **2017**, 3, e173290	152
1350	Comprehensive Analysis of Hypermutation in Human Cancer. **2017**, 171, 1042-1056.e10	417

1349	An enhanced deterministic K-Means clustering algorithm for cancer subtype prediction from gene expression data. **2017**, 91, 213-221	43
1348	Comprehensive analysis of normal adjacent to tumor transcriptomes. **2017**, 8, 1077	216
1347	A novel approach for data integration and disease subtyping. **2017**, 27, 2025-2039	78
1346	Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome. **2017**, 471, 521-530	8
1345	CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. **2017**, 214, 2715-2732	43
1344	Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. **2017** , 84, 290-303	89
1343	The roles of ubiquitin modifying enzymes in neoplastic disease. **2017**, 1868, 456-483	29
1342	Accuracy of Endometrial Sampling in Endometrial Carcinoma: A Systematic Review and Meta-analysis. **2017**, 130, 803-813	62
1341	Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. **2017**, 187, 2246-2258	66
1340	Variation in type II endometrial cancer risk by Hispanic subpopulation: An exploratory analysis. **2017**, 147, 329-333	11
1339	Analysis of somatic microsatellite indels identifies driver events in human tumors. **2017**, 35, 951-959	72
1338	Network-based machine learning and graph theory algorithms for precision oncology. **2017**, 1, 25	43
1337	Genomic Characterization of Vulvar (Pre)cancers Identifies Distinct Molecular Subtypes with Prognostic Significance. **2017**, 23, 6781-6789	63
1336	Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer. **2017**, 16, 2881-2891	24
1335	New use of microsatellite instability analysis in endometrial cancer. **2017**, 14, 3297-3301	26
1334	Techniques to Identify Novel Fusion Genes and to Detect Known Fusion Genes. **2017**, 59-79	
1333	PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. **2017**, 7, 10240	14
1332	Molecular Signatures for Tumor Classification: An Analysis of The Cancer Genome Atlas Data. **2017**, 19, 881-891	13

1331	geneSurv: An interactive web-based tool for survival analysis in genomics research. **2017**, 89, 487-496		2
1330	Mutational heterogeneity in non-serous ovarian cancers. **2017**, 7, 9728		29
1329	Misregulation of Histone Methylation Regulators in Cancer. **2017**, 221-248		2
1328	The genetic landscape of endometrial clear cell carcinomas. **2017**, 243, 230-241		116
1327	The whole-genome landscape of medulloblastoma subtypes. *Nature*, **2017**, 547, 311-317	50.4	472
1326	Downregulation of tyrosine threonine kinase inhibits tumor growth via G2/M arrest in human endometrioid endometrial adenocarcinoma. **2017**, 39, 1010428317712444		4
1325	UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. **2017**, 19, 649-658		2229
1324	Molecular genetics and targeted therapy of WNT-related human diseases (Review). **2017**, 40, 587-606		112
1323	Dedifferentiated carcinoma with clear cell carcinoma of the endometrium: A case report. **2017**, 67, 472-476		3
1322	Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma. **2017**, 67, 69-77		22
1321	Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer. **2017**, 146, 596-602		15
1320	Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma. **2017**, 147, 24-29		3
1319	Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. **2017**, 146, 588-595		52
1318	Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome. **2017**, 87, 557-565		6
1317	Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies. **2017**, 32, 155-168.e6		61
1316	Immunohistochemistry in Gynecologic Pathology: An Example-Based Practical Update. **2017**, 141, 1052-1071		15
1315	ASCT2 regulates glutamine uptake and cell growth in endometrial carcinoma. **2017**, 6, e367		40
1314	In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor. **2017**, 28, 503-513		16

1313	Novel approaches to early detection of endometrial cancer. **2017**, 29, 40-46	10
1312	Treatment strategies for endometrial cancer: current practice and perspective. **2017**, 29, 47-58	96
1311	A Selective Biomarker Panel Increases the Reproducibility and the Accuracy in Endometrial Biopsy Diagnosis. **2017**, 36, 339-347	6
1310	Amplification of the pathway in pelvic high-grade serous carcinomas of tubo-ovarian and endometrial origin. **2017**, 7, 301-307	15
1309	Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment. **2017**, 23, 6458-6467	31
1308	Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. **2017**, 23, 1046-1054	102
1307	Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups. **2017**, 30, 1748-1759	44
1306	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. **2017**, 24, 311-335	299
1305	Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes. **2017**, 4, 211-220	33
1304	Promoter-level transcriptome in primary lesions of endometrial cancer identified biomarkers associated with lymph node metastasis. **2017**, 7, 14160	7
1303	BAF53a is a potential prognostic biomarker and promotes invasion and epithelial-mesenchymal transition of glioma cells. **2017**, 38, 3327-3334	15
1302	Detection of Somatic Mutations in Exome Sequencing of Tumor-only Samples. **2017**, 7, 15959	6
1301	Transmembrane helix connectivity in Orai1 controls two gates for calcium-dependent transcription. **2017**, 10,	53
1300	Decreased SIRT4 protein levels in endometrioid adenocarcinoma tissues are associated with advanced AJCC stage. **2017**, 19, 419-424	11
1299	Characterization of ascites-derived tumor cells from an endometrial cancer patient. **2017**, 108, 2352-2357	11
1298	PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort. **2017**, 112, 96-101	12
1297	Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients. **2017**, 123, 4004-4012	14
1296	Conditional abrogation of transforming growth factor-β receptor 1 in PTEN-inactivated endometrium promotes endometrial cancer progression in mice. **2017**, 243, 89-99	17

1295	Endometriumkarzinom. **2017**, 23, 2-4	
1294	Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials. **2017**, 5, 71-83	6
1293	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Endometrium. **2017**, 141, 1508-1512	13
1292	Harmonisation of biobanking standards in endometrial cancer research. **2017**, 117, 485-493	4
1291	Normally lethal amino acid substitutions suppress an ultramutator DNA Polymerase ⍵variant. **2017**, 7, 46535	3
1290	Commonly used medications and endometrial cancer survival: a population-based cohort study. **2017**, 117, 432-438	24
1289	GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma. **2017**, 77, 4448-4459	16
1288	Multiple network algorithm for epigenetic modules via the integration of genome-wide DNA methylation and gene expression data. **2017**, 18, 72	39
1287	Revealing common disease mechanisms shared by tumors of different tissues of origin through semantic representation of genomic alterations and topic modeling. **2017**, 18, 105	1
1286	Intestinal differentiated mucinous adenocarcinoma of the endometrium with sporadic MSI high status: a case report. **2017**, 12, 39	5
1285	Cancer predisposition syndromes: lessons for truly precision medicine. **2017**, 241, 226-235	10
1284	High cardiovascular disease mortality after endometrial cancer diagnosis: Results from the Surveillance, Epidemiology, and End Results (SEER) Database. **2017**, 140, 555-564	51
1283	Pathology and Molecular Pathology of Uterine and Ovarian Cancers. **2017**, 247-278	
1282	Neomorphic mutations create therapeutic challenges in cancer. **2017**, 36, 1607-1618	19
1281	Practical guidance for mismatch repair-deficiency testing in endometrial cancer. **2017**, 28, 96-102	104
1280	Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. **2017**, 3, 774-783	157
1279	Renovated (nondual) approach to endometrial cancer typing: endocrine and inflammatory issues. **2017**, 13, 109-112	2
1278	Integrated Epigenomics Analysis Reveals a DNA Methylation Panel for Endometrial Cancer Detection Using Cervical Scrapings. **2017**, 23, 263-272	43

1277	Massive parallel sequencing of solid tumours - challenges and opportunities for pathologists. **2017**, 70, 123-133	9
1276	Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers. **2017**, 30, 134-145	21
1275	Can reduced field-of-view diffusion sequence help assess microsatellite instability in FIGO stage 1 endometrial cancer?. **2017**, 45, 1216-1224	8
1274	Landscape of Genomic Alterations in Pituitary Adenomas. **2017**, 23, 1841-1851	64
1273	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. **2017**, 26, 126-135	183
1272	Epigenetic changes as prognostic predictors in endometrial carcinomas. **2017**, 12, 19-26	12
1271	Genomic Amplification of (PD-L1) in Small-Cell Lung Cancer. **2017**, 23, 1220-1226	74
1270	Endometrial cancer evolution: new molecular-biologic types and hormonal-metabolic shifts. **2017**, 13, 2593-2605	9
1269	Epigenetic and genetic deregulation in cancer target distinct signaling pathway domains. **2017**, 45, 583-596	12
1268	Aktuelle Aspekte zur Diagnostik und Therapie des Endometriumkarzinoms. **2017**, 38, 111-117	
1267	A framework for analyzing DNA methylation data from Illumina Infinium HumanMethylation450 BeadChip. **2017**,	
1266	Tissue-Agnostic Drug Development. **2017**, 37, 222-230	12
1265	Transcriptional response profiles of paired tumor-normal samples offer novel perspectives in pan-cancer analysis. **2017**, 8, 41334-41347	19
1264	Microsatellite Instability Testing Using Next-Generation Sequencing Data and Therapy Implications.. **2017**, 1, 1-4	6
1263	Molecular Testing in Gynecologic Cancer. **2017**, 361-379	
1262	The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers. **2017**, 8, 346	22
1261	AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells. **2017**, 10, 4153-4159	30
1260	EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?. **2017**, 18,	52

1259	Risks at the DNA Replication Fork: Effects upon Carcinogenesis and Tumor Heterogeneity. **2017**, 8,	22
1258	Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. **2017**, 18,	234
1257	Pan-Cancer Mutational and Transcriptional Analysis of the Integrator Complex. **2017**, 18,	18
1256	Epithelial-to-Mesenchymal Transition in the Female Reproductive Tract: From Normal Functioning to Disease Pathology. **2017**, 7, 145	63
1255	New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway. **2017**, 7, 170	14
1254	Signal Transduction Networks Analysis: The Reverse Phase Protein Array. **2017**,	
1253	A Review of mTOR Pathway Inhibitors in Gynecologic Cancer. **2017**, 2017, 4809751	38
1252	Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers. **2017**, 9, 553-563	11
1251	Update on immune checkpoint inhibitors in gynecological cancers. **2017**, 28, e20	45
1250	Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. **2017**, 8, 7452-7463	132
1249	Endometrial Cancer Genomics. **2017**, 199-227	
1248	Identification of endometrial cancer methylation features using combined methylation analysis methods. **2017**, 12, e0173242	13
1247	Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients. **2017**, 12, e0176045	22
1246	Oncogenic HrasG12V expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma. **2017**, 12, e0186102	2
1245	A novel method of gene transduction to the murine endometrium using in vivo electroporation. **2017**, 79, 1573-1577	1
1244	Loss of polarity alters proliferation and differentiation in low-grade endometrial cancers by disrupting Notch signaling. **2017**, 12, e0189081	15
1243	Significant associations between driver gene mutations and DNA methylation alterations across many cancer types. **2017**, 13, e1005840	21
1242	Next-Generation Sequencing in Gynaecological Tumours: The Prognostic and Predictive Value of the Most Common Mutations Found in Ovarian, Endometrial, and Cervical Tumours: Literature Review and the University Medical Centre Utrecht Next-Generation Sequencing Data. **2017**, 84, 339-350	1

1241	Network dynamics-based cancer panel stratification for systemic prediction of anticancer drug response. **2017**, 8, 1940	24
1240	p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry. **2017**, 12, 81	2
1239	Predicting cancer type from tumour DNA signatures. **2017**, 9, 104	25
1238	EZH2 inhibition in mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers. **2017**, 4, 17	27
1237	New therapies for advanced, recurrent, and metastatic endometrial cancers. **2017**, 4, 19	58
1236	Mutation status coupled with RNA-sequencing data can efficiently identify important non-significantly mutated genes serving as diagnostic biomarkers of endometrial cancer. **2017**, 18, 472	3
1235	Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. **2017**, 8, 90532-90544	60
1234	Molecular Landscapes of Endometrial Cancer Is it Time to Change our Clinical Practice?. **2017**, 07,	
1233	Identification of lung adenocarcinoma specific dysregulated genes with diagnostic and prognostic value across 27 TCGA cancer types. **2017**, 8, 87292-87306	13
1232	Profiling cancer-associated genetic alterations and molecular classification of cancer in Korean gastric cancer patients. **2017**, 8, 69888-69905	14
1231	Identification of novel mutations in endometrial cancer patients by whole-exome sequencing. **2017** , 50, 1778-1784	28
1230	Sequencing of Lynch syndrome tumors reveals the importance of epigenetic alterations. **2017**, 8, 108020-108030	9
1229	Immunotherapy in Gynecologic Cancers. **2017**,	
1228	PD-1 inhibitors in endometrial cancer. **2017**, 8, 106169-106170	11
1227	Hypermutation and microsatellite instability in gastrointestinal cancers. **2017**, 8, 112103-112115	46
1226	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. **2017**, 35, 2535-2541	244
1225	Landscape of Microsatellite Instability Across 39 Cancer Types. **2017**, 2017,	332
1224	Epigenetic regulation of NOTCH1 and NOTCH3 by KMT2A inhibits glioma proliferation. **2017**, 8, 63110-63120	18

1223	Recent Advances in Endometrial Cancer. **2017**, 6, 81		37
1222	Big Drug Design Mechanisms via Systems Biology and Big Database Mining. **2017**, 737-845		1
1221	Impact of Hormone Receptor Status and Ki-67 Expression on Disease-Free Survival in Patients Affected by High-risk Endometrial Cancer. **2018**, 28, 505-513		17
1220	Insights from Large-Scale Cancer Genome Sequencing. **2018**, 2, 429-444		3
1219	Letter in response to: McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018; 244: 538-549. **2018**, 245, 249-250		10
1218	Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. **2018**, 42, 561-568		117
1217	Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline Mutation. **2018**, 23, 650-653		7
1216	Adjuvant chemoradiotherapy versus radiotherapy alone in high-risk endometrial cancer: A systematic review and meta-analysis. **2018**, 149, 612-619		11
1215	The landscape of genomic alterations across childhood cancers. *Nature*, **2018**, 555, 321-327	50.4	603
1214	The Yokohama system for reporting directly sampled endometrial cytology: The quest to develop a standardized terminology. **2018**, 46, 400-412		23
1213	MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. **2018**, 76, 133-140		6
1212	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report. **2018**,		11
1211	Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma. **2018**, 149, 173-180		10
1210	Prognostic Significance of Nodal Location and Ratio in Stage IIIC Endometrial Carcinoma Among a Multi-Institutional Academic Collaboration. **2018**, 41, 1220-1224		2
1209	DNA mismatch repair in cancer. **2018**, 189, 45-62		171
1208	Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. **2018**, 4, 154-166		28
1207	Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?. **2018**, 29, 1081-1082		2
1206	Establishment of a nine-gene prognostic model for predicting overall survival of patients with endometrial carcinoma. **2018**, 7, 2601-2611		12

1205	A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. **2018**, 19, 71-86	76
1204	BRAF papillary thyroid carcinoma has two distinct mRNA expression patterns with different clinical behaviors. **2018**, 40, 1707-1718	2
1203	Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. **2018**, 245, 283-296	43
1202	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. **2018**, 173, 400-416.e11	1072
1201	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. **2018**, 173, 291-304.e6	888
1200	Oncogenic Signaling Pathways in The Cancer Genome Atlas. **2018**, 173, 321-337.e10	1124
1199	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. **2018**, 23, 227-238.e3	235
1198	A novel unsupervised learning model for detecting driver genes from pan-cancer data through matrix tri-factorization framework with pairwise similarities constraints. **2018**, 296, 64-73	20
1197	Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer. **2018**, 149, 301-309	24
1196	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. **2018**, 23, 239-254.e6	405
1195	A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. **2018**, 24, 3253-3262	47
1194	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. **2018**, 11, 475-486	52
1193	Iron and Its Role in Cancer Defense: A Double-Edged Sword. **2018**, 18,	16
1192	The NCI-MATCH trial and precision medicine in gynecologic cancers. **2018**, 148, 585-590	33
1191	ROR1 and ROR2 play distinct and opposing roles in endometrial cancer. **2018**, 148, 576-584	17
1190	Tumor Mutational Burden Guides Therapy in a Treatment Refractory Mutant Uterine Carcinosarcoma. **2018**, 23, 518-523	30
1189	Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. **2018**, 24, 2182-2193	49
1188	Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer. **2018**, 16, 201-209	43

1187	Association of microRNA-200c expression levels with clinicopathological factors and prognosis in endometrioid endometrial cancer. **2018**, 97, 560-569	15
1186	Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder. **2018**, 472, 969-974	2
1185	Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA). **2018**, 35, 20	3
1184	Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. **2018**, 10, 1758834017746040	10
1183	The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. **2018**, 244, 538-549	86
1182	Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. **2018**, 28, 514-523	27
1181	Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. **2018**, 29, 1180-1188	179
1180	Pancancer analysis identifies prognostic high-APOBEC1 expression level implicated in cancer in-frame insertions and deletions. **2018**, 39, 327-335	12
1179	Functional Analysis of Cancer-Associated DNA Polymerase Variants in. **2018**, 8, 1019-1029	27
1178	Gynaecological pathology: problematic areas, new concepts and emerging developments. **2018**, 50, 119-121	1
1177	Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis. **2018**, 28, 385-393	44
1176	Network science in clinical trials: A patient-centered approach. **2018**, 52, 135-150	6
1175	The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future. **2018**, 472, 885-896	24
1174	Polymerase epsilon mutations and concomitant -microglobulin mutations in cancer. **2018**, 647, 31-38	9
1173	Contribution of cervical cytology in the diagnostic work-up of patients with endometrial cancer. **2018**, 29, 63-70	12
1172	Targeting DNA repair: the genome as a potential biomarker. **2018**, 244, 586-597	28
1171	Gynaecological neoplasms in common familial syndromes (Lynch and HBOC). **2018**, 50, 222-237	17
1170	Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma. **2018**, 472, 623-633	16

1169	Significance of venous thromboembolism in women with uterine carcinosarcoma. **2018**, 148, 267-274	11
1168	Characterizing genomic differences of human cancer stratified by the TP53 mutation status. **2018**, 293, 737-746	3
1167	Precision oncology in the age of integrative genomics. **2018**, 36, 46-60	65
1166	Discovering personalized driver mutation profiles of single samples in cancer by network control strategy. **2018**, 34, 1893-1903	44
1165	Adiponectin, Leptin, and Insulin-Pathway Receptors as Endometrial Cancer Subtyping Markers. **2018**, 9, 33-39	8
1164	Combining gene essentiality with feature selection method to explore multi-cancer biomarkers. **2018**, 172, 241-247	2
1163	MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization. **2018**, 110, 517-526	2
1162	Type I Versus Type II Endometrial Cancer: Differential Impact of Comorbidity. **2018**, 28, 586-593	10
1161	Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair. **2018**, 9, 1746	95
1160	A framework for analyzing DNA methylation data from Illumina Infinium HumanMethylation450 BeadChip. **2018**, 19, 115	18
1159	Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. **2018**, 17, 81	19
1158	Serum DNA integrity index as a potential molecular biomarker in endometrial cancer. **2018**, 37, 16	28
1157	Genomic profiling identifies amplification in association with sarcomatous transformation in a subset of uterine carcinosarcomas. **2018**, 4, 69-78	8
1156	Targeted therapy according to next generation sequencing-based panel sequencing. **2018**, 64, 9-14	10
1155	Validating the concept of mutational signatures with isogenic cell models. **2018**, 9, 1744	87
1154	Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. **2018**, 11, 477-490	18
1153	Expanding the pipeline. The 2018 Society of Gynecologic Oncology presidential address. **2018**, 149, 435-438	0
1152	Does ATRX germline variation predispose to osteosarcoma? Three additional cases of osteosarcoma in two ATR-X syndrome patients. **2018**, 26, 1217-1221	14

1151	Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer. **2018**, 4,	2
1150	Racial disparities in molecular subtypes of endometrial cancer. **2018**, 149, 106-116	25
1149	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. **2018**, 33, 676-689.e3	377
1148	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. **2018**, 33, 690-705.e9	277
1147	Molecular changes preceding endometrial and ovarian cancer: a study of consecutive endometrial specimens from Lynch syndrome surveillance. **2018**, 31, 1291-1301	17
1146	Adjuvant Treatment for Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues. **2018**, 24, 3197-3203	30
1145	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. **2018**, 10,	110
1144	The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis. **2018**, 149, 283-290	19
1143	Clinical and Genomic Crosstalk between Glucocorticoid Receptor and Estrogen Receptor in Endometrial Cancer. **2018**, 22, 2995-3005	38
1142	An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers. **2018**, 40, 372-388	12
1141	Biological function and histone recognition of family IV bromodomain-containing proteins. **2018**, 233, 1877-1886	31
1140	Adenocarcinoma of the Uterine Corpus. **2018**, 121-154.e8	1
1139	Androgen Receptor Expression in Endometrial Carcinoma. **2018**, 37, 167-173	12
1138	Human Hairless Protein Roles in Skin/Hair and Emerging Connections to Brain and Other Cancers. **2018**, 119, 69-80	9
1137	Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences. **2018**, 85, 35-40	10
1136	Targeted Therapy and Molecular Genetics. **2018**, 470-492.e10	2
1135	Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing. **2018**, 57, 51-60	52
1134	Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. **2018**, 117, 488-496	9

1133	Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency. **2018**, 28, 59-68	21
1132	Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. **2018**, 142, 1230-1243	34
1131	Focus on Gynecologic Malignancies. **2018**,	
1130	Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study. **2018**, 71, 65-73	5
1129	Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer. **2018**, 14, 94-101	66
1128	Gender proteomics II. Which proteins in sexual organs. **2018**, 178, 18-30	3
1127	Mechanisms of DNA damage repair in adult stem cells and implications for cancer formation. **2018**, 1864, 89-101	31
1126	Despite Diagnostic Morphology, Many Mixed Endometrial Carcinomas Show Unexpected Immunohistochemical Staining Patterns. **2018**, 37, 405-413	7
1125	Mutation analysis by whole exome sequencing of endometrial hyperplasia and carcinoma in one patient: Abnormalities of polymerase epsilon and the phosphatidylinositol-3 kinase pathway. **2018**, 44, 179-183	8
1124	A Practical Approach to Tumor Heterogeneity in Clinical Research and Diagnostics. **2018**, 85, 7-17	10
1123	Ultrasound characteristics of endometrial cancer as defined by International Endometrial Tumor Analysis (IETA) consensus nomenclature: prospective multicenter study. **2018**, 51, 818-828	40
1122	Does a p53 "Wild-type" Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma?. **2018**, 25, 61-70	7
1121	Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch/Sucrose Nonfermentable Complex Proteins. **2018**, 42, 76-83	50
1120	Sporadic endometrial adenocarcinoma with MMR deficiency due to biallelic MSH2 somatic mutations. **2018**, 17, 281-285	4
1119	The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. **2018**, 124, 65-73	18
1118	The roles of pathology in targeted therapy of women with gynecologic cancers. **2018**, 148, 213-221	17
1117	HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. **2018**, 118, 378-387	24
1116	Molecular insights into the classification of high-grade endometrial carcinoma. **2018**, 50, 151-161	26

1115	SEOM clinical guidelines for endometrial cancer (2017). **2018**, 20, 29-37	13
1114	PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. **2018**, 37, 341-351	63
1113	Advances in endometrial cancer protein biomarkers for use in the clinic. **2018**, 15, 81-99	12
1112	Synthetically lethal nanoparticles for treatment of endometrial cancer. **2018**, 13, 72-81	35
1111	Aberrant GATA2 epigenetic dysregulation induces a GATA2/GATA6 switch in human gastric cancer. **2018**, 37, 993-1004	15
1110	Estrogen and high-fat diet induced alterations in C57BL/6 mice endometrial transcriptome profile. **2018**, 7, 36-46	7
1109	Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study. **2018**, 72, 100-106	18
1108	Adipose-Derived VEGF-mTOR Signaling Promotes Endometrial Hyperplasia and Cancer: Implications for Obese Women. **2018**, 16, 309-321	19
1107	Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review. **2018**, 81, 111-117	8
1106	Aspirin use and endometrial cancer risk and survival. **2018**, 148, 222-232	27
1105	An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. **2018**, 148, 174-180	53
1104	Immunohistochemical Profiles of Endometrioid Endometrial Carcinomas With and Without Metastatic Disease. **2018**, 26, 173-179	3
1103	Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing. **2018**, 72, 248-258	17
1102	Impact of age at diagnosis on racial disparities in endometrial cancer patients. **2018**, 149, 12-21	17
1101	Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only. **2018**, 28, 1789-1795	7
1100	The Epigenetic Landscape in the Treatment of Gynecologic Malignancies. **2018**, 38, 480-487	7
1099	-Activating Mutations in Small Bowel Adenocarcinomas.. **2018**, 2, 1-9	1
1098	Phosphatidylinositol 3-Kinase Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. **2018**, 36, 1291-1299	190

1097	Moving From Mutation to Actionability. **2018**, 38, 495-503	4
1096	Endometrial Carcinoma. **2018**, 1-62	
1095	Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer. **2019**, 41, 1560-1574	9
1094	Endometrial CancerPathology and Genetics. **2018**,	0
1093	Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations. **2018**, 2018, 3810108	11
1092	The landscape of miRNA-related ceRNA networks for marking different renal cell carcinoma subtypes. **2018**,	5
1091	Novel CTCF mutations in Chinese patients with ovarian endometriosis. **2018**, 18, 1031-1036	4
1090	Sustainable Response of a Patient With Metastasized Pancreatic Cancer and a Hypermutational Phenotype to Immunotherapy. New Therapeutic Concept for a Rare Subtype?. **2018**, 2, 1-6	1
1089	Flow Simulation on Multilayer Networks: a New Approach to Community Detection in Complex Systems. **2018**,	
1088	Mutational analysis of selected high-grade malignancies in a premenopausal gynecologic cancer population: a potential for targeted therapies?. **2018**, 38,	1
1087	Tolerance of Chromosomal Instability in Cancer: Mechanisms and Therapeutic Opportunities. **2018**, 78, 6529-6535	19
1086	Brain metastases in patients with low-grade endometrial carcinoma. **2018**, 26, 87-90	7
1085	Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases. **2018**, 10, 4915-4928	13
1084	Knockdown of CCNO decreases the tumorigenicity of gastric cancer by inducing apoptosis. **2018**, 11, 7471-7481	7
1083	Uterine Cancer. **2018**,	1
1082	Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers. **2018**, 20, 94	24
1081	Solid Tumor Genomics. **2018**, 191-200	
1080	The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers. **2018**, 8, 1518-1528	51

1079	The miR-503 cluster is coordinately under-expressed in endometrial endometrioid adenocarcinoma and targets many oncogenes, cell cycle genes, DNA repair genes and chemotherapy response genes. **2018**, 11, 7205-7211	5
1078	The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies. **2018**, 19, 70	12
1077	Therapy Implications of DNA Mismatch Repair Deficiency, Microsatellite Instability, and Tumor Mutation Burden. **2018**, 1, 193-208	3
1076	New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. **2018**, 9, 10635-10649	32
1075	The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer. **2018**, 11, 139	35
1074	L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion. **2018**, 13, e0209294	8
1073	Identification of long non-coding RNA expression patterns useful for molecular-based classification of type 1 endometrial cancers. **2019**, 41, 1209-1217	3
1072	RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. **2018**, 10,	5
1071	Class I Phosphoinositide 3-Kinase /p110α and /p110β Isoforms in Endometrial Cancer. **2018**, 19,	10
1070	Crosstalk between SOX2 and cytokine signaling in endometrial carcinoma. **2018**, 8, 17550	15
1069	Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer. **2018**, 13, e0208221	10
1068	Efficacy of liquid-based genetic diagnosis of endometrial cancer. **2018**, 109, 4025-4032	5
1067	Identification of differentially methylated cell types in epigenome-wide association studies. **2018**, 15, 1059-1066	75
1066	MSIpred: a python package for tumor microsatellite instability classification from tumor mutation annotation data using a support vector machine. **2018**, 8, 17546	27
1065	Identification and Characterization of MicroRNAs Associated with Somatic Copy Number Alterations in Cancer. **2018**, 10,	4
1064	Profiling of Clinical Phenotypes for Human Targets Using Adverse Event Data. **2018**, 7,	8
1063	CTCF Expression is Essential for Somatic Cell Viability and Protection Against Cancer. **2018**, 19,	11
1062	Molecular Lesions of Insulator CTCF and Its Paralogue CTCFL (BORIS) in Cancer: An Analysis from Published Genomic Studies. **2018**, 7,	6

1061	Folate receptor-targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study. **2018**, 9, 791-801	23
1060	Targeted gene sequencing of Lynch syndrome-related and sporadic endometrial carcinomas. **2018**, 81, 235-244	4
1059	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. **2018**, 7, 422-437.e7	85
1058	Creative Writing - An Under-Utilized Cancer Therapy. **2018**, 03,	
1057	Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma. **2018**, 7, 5632-5642	31
1056	Detection of endometrial precancer by a targeted gynecologic cancer liquid biopsy. **2018**, 4,	7
1055	Cancer of the corpus uteri. **2018**, 143 Suppl 2, 37-50	166
1054	Pathology of cancers of the female genital tract including molecular pathology. **2018**, 143 Suppl 2, 93-108	14
1053	PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. **2018**, 231, 104-110	34
1052	Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors. **2018**, 151, 401-406	17
1051	Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. **2018**, 119, 1067-1074	90
1050	Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. **2018**, 13, e0206665	9
1049	The Emerging Role of the Microenvironment in Endometrial Cancer. **2018**, 10,	29
1048	Light absorption distribution of uterine tissue filled with strong scattering medium irradiated by diffused light source. **2018**, 14, 396-400	0
1047	Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors. **2018**, 25, 1066-1080.e8	104
1046	The DNA damage response in immunotherapy and radiation. **2018**, 3, 527-533	18
1045	Network integration of multi-tumour omics data suggests novel targeting strategies. **2018**, 9, 4514	21
1044	Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo. **2018**, 23,	13

1043	Mutational interactions define novel cancer subgroups. **2018**, 9, 4353	12
1042	Overexpression of the matrix metalloproteinase 11 gene is a potential biomarker for type 1 endometrial cancer. **2018**, 16, 1073-1078	5
1041	Inhibition of PI3K/AKT Signaling Pathway Radiosensitizes Pancreatic Cancer Cells with ARID1A Deficiency. **2018**, 9, 890-900	19
1040	A machine learning approach for somatic mutation discovery. **2018**, 10,	44
1039	A novel case of endometrial dedifferentiated adenocarcinoma associated with MLH1 promotor hypermethylation and microsatellite instability. **2018**, 214, 1904-1908	2
1038	Clinicopathologic Features and Treatment Outcomes in Patients with Stage I, High-Risk Histology or High-Grade Endometrial Cancer after Primary Staging Surgery: A Taiwanese Gynecologic Oncology Group Study. **2018**, 7,	4
1037	Cancer Progress and Priorities: Uterine Cancer. **2018**, 27, 985-994	22
1036	Pan-cancer inference of intra-tumor heterogeneity reveals associations with different forms of genomic instability. **2018**, 14, e1007669	43
1035	Genetic Alterations of TRAF Proteins in Human Cancers. **2018**, 9, 2111	37
1034	POLE gene hotspot mutations in advanced pancreatic cancer. **2018**, 144, 2161-2166	7
1033	Endometrial cancer-how many patients could benefit from sentinel lymph node dissection?. **2018**, 16, 95	11
1032	Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy. **2018**, 29, e34	14
1031	A distinct class of antioxidant response elements is consistently activated in tumors with NRF2 mutations. **2018**, 19, 235-249	26
1030	Identification of micro-RNA expression profile related to recurrence in women with ESMO low-risk endometrial cancer. **2018**, 16, 131	10
1029	A Comparison of GATA3, TTF1, CD10, and Calretinin in Identifying Mesonephric and Mesonephric-like Carcinomas of the Gynecologic Tract. **2018**, 42, 1596-1606	63
1028	Multidomain architecture of estrogen receptor reveals interfacial cross-talk between its DNA-binding and ligand-binding domains. **2018**, 9, 3520	30
1027	Endometrial cancer: Molecular markers and management of advanced stage disease. **2018**, 150, 569-580	82
1026	A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. **2018**, 150, 274-281	67

1025	Adenocarcinoma, Carcinosarcoma, and Other Epithelial Tumors of the Endometrium. **2018**, 582-651	
1024	PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF. **2018**, 16, 1241-1254	18
1023	Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors. **2018**, 29, 549-559	10
1022	Targeting BCL-2 regulated apoptosis in cancer. **2018**, 8,	234
1021	Endometrial Cancer. **2018**, 653-677	2
1020	Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. **2018**, 150, 127-135	33
1019	Gynecologic Cancers: Molecular Updates 2018. **2018**, 38, 421-438	7
1018	Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors. **2018**, 52, 253-258	5
1017	Tumour-associated missense mutations in the dMi-2 ATPase alters nucleosome remodelling properties in a mutation-specific manner. **2018**, 9, 2112	23
1016	Using gene expression in patients with endometrial intraepithelial neoplasia to assess the risk of cancer. **2018**, 24, 24-26	3
1015	Peritumoral granulomatous reaction in endometrial carcinoma: association with DNA mismatch repair protein deficiency, particularly loss of PMS2 expression. **2018**, 73, 428-437	
1014	Management Strategies for Recurrent Endometrial Cancer. **2018**, 18, 873-885	33
1013	In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib. **2018**, 57, 1445-1457	8
1012	Is ßCatenin a Druggable Target for Cancer Therapy?. **2018**, 43, 623-634	58
1011	PIK3CA and p53 Mutations by Next Generation Sequencing in Lymphoepithelioma-Like Carcinoma of the Endometrium. **2018**, 2018, 5894589	4
1010	Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. **2018**, 24, 4845-4853	10
1009	Disparate genomic characteristics of concurrent endometrial adenocarcinoma and ovarian granulosa cell tumor, revealed by targeted next-generation sequencing. **2018**, 214, 1231-1233	0
1008	Impact of lower uterine segment involvement in type II endometrial cancer and the unique mutational profile of serous tumors. **2018**, 24, 43-47	3

1007	Role of RNF20 in cancer development and progression - a comprehensive review. **2018**, 38,	19
1006	p190 RhoGAP promotes contact inhibition in epithelial cells by repressing YAP activity. **2018**, 217, 3183-3201	9
1005	RNA-seq Reveals the Overexpression of IGSF9 in Endometrial Cancer. **2018**, 2018, 2439527	8
1004	Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer. **2018**, 4, 9-18	11
1003	Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor. **2018**, 150, 219-226	10
1002	Hormonal strategies in gynecologic cancer: Bridging biology and therapy. **2018**, 150, 207-210	5
1001	Luteinizing Hormone/Human Chorionic Gonadotropin Receptor Immunohistochemical Score Associated with Poor Prognosis in Endometrial Cancer Patients. **2018**, 2018, 1618056	6
1000	miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation. **2018**, 98, 1397-1407	43
999	Two critical positions in zinc finger domains are heavily mutated in three human cancer types. **2018**, 14, e1006290	20
998	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. **2018**, 31, 1851-1861	24
997	Endometrial cancer risk and survival by tumor MMR status. **2018**, 29, e39	19
996	Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency. **2018**, 40, 479-487	19
995	Distribution-based measures of tumor heterogeneity are sensitive to mutation calling and lack strong clinical predictive power. **2018**, 8, 11445	10
994	Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer. **2018**, 18, 657	22
993	Massively parallel sequencing of cell-free DNA in plasma for detecting gynaecological tumour-associated copy number alteration. **2018**, 8, 11205	13
992	L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. **2018**, 119, 480-486	38
991	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. **2018**, 24, 5939-5947	60
990	MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT. **2018**, 18, 605	4

989	Targeted Next-Generation Sequencing Identifies Actionable Targets in Estrogen Receptor Positive and Estrogen Receptor Negative Endometriod Endometrial Cancer. **2018**, 9, 750	2
988	High expression of the p53 isoform Δ133p is associated with reduced progression-free survival in uterine serous carcinoma. **2018**, 18, 684	10
987	Combining Pathway Identification and Breast Cancer Survival Prediction via Screening-Network Methods. **2018**, 9, 206	5
986	Overview on Clinical Relevance of Intra-Tumor Heterogeneity. **2018**, 5, 85	109
985	Genetic Evidence for Early Peritoneal Spreading in Pelvic High-Grade Serous Cancer. **2018**, 8, 58	5
984	Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. **2018**, 10,	33
983	Understanding Intratumor Heterogeneity and Evolution in NSCLC and Potential New Therapeutic Approach. **2018**, 10,	13
982	Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas. **2018**, 13, e0199688	16
981	Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers. **2018**, 37, 139	18
980	The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations. **2018**, 34, 197-210.e5	82
979	Germline and somatic variations influence the somatic mutational signatures of esophageal squamous cell carcinomas in a Chinese population. **2018**, 19, 538	9
978	Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability. **2018**, 13, e0195655	19
977	Wnt5a signaling induced phosphorylation increases APT1 activity and promotes melanoma metastatic behavior. **2018**, 7,	13
976	A Pan-Cancer Compendium of Genes Deregulated by Somatic Genomic Rearrangement across More Than 1,400 Cases. **2018**, 24, 515-527	49
975	Crosstalk between PKCδ and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium. **2018**, 24, 655-669	22
974	AT-rich interactive domain 5B regulates androgen receptor transcription in human prostate cancer cells. **2018**, 78, 1238-1247	3
973	AKT isoform-specific expression and activation across cancer lineages. **2018**, 18, 742	18
972	Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. **2018**, 17, 2136-2143	7

971	Clustering multilayer omics data using MuNCut. **2018**, 19, 198	9
970	A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma. **2018**, 18, 39	44
969	LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data. **2018**, 18, 494	6
968	New insights from the widening homogeneity perspective to target intratumor heterogeneity. **2018**, 38, 17	6
967	RCT verbessert "failure-free survival" beim Endometriumkarzinom im Stadium III. **2018**, 21, 33-34	
966	Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice. **2018**, 50, 389-401	24
965	Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. **2018**, 24, 4225-4241	48
964	Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro. **2018**, 18, 168	12
963	Adenomatous Polyposis Syndromes: Polymerase Proofreading-Associated Polyposis. **2018**, 113-134	2
962	Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma. **2018**, 25, 3676-3684	10
961	Evolution of adjuvant treatment in endometrial cancer-no evidence and new questions?. **2018**, 194, 965-974	4
960	Family A and B DNA Polymerases in Cancer: Opportunities for Therapeutic Interventions. **2018**, 7,	2
959	Identification of nine new susceptibility loci for endometrial cancer. **2018**, 9, 3166	70
958	An update of Wnt signalling in endometrial cancer and its potential as a therapeutic target. **2018**,	24
957	Copy number signatures and mutational processes in ovarian carcinoma. **2018**, 50, 1262-1270	155
956	Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes. **2018**, 85, 44-51	8
955	Frequent Mutations in Natural Killer/T Cell Lymphoma. **2018**, 49, 1-16	21
954	DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer. **2018**, 10,	8

953	Patient-Derived Xenograft Models for Endometrial Cancer Research. **2018**, 19,	18
952	Hypoxia is involved in the reduction of HtrA3 in patients with endometrial hyperplasia and cancer. **2018**, 503, 2918-2923	8
951	mA mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. **2018**, 20, 1074-1083	358
950	Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late. **2018**, 19,	27
949	Modeling Endometrial Cancer: Past, Present, and Future. **2018**, 19,	49
948	Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors. **2018**, 473, 583-590	6
947	Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial. **2018**, 151, 69-75	89
946	The dawn of the liquid biopsy in the fight against cancer. **2018**, 9, 2912-2922	63
945	Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers. **2018**, 143, 2955-2961	2
944	Application of Systems Biology in the Research of TCM Formulae. **2018**, 31-67	3
943	Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology. **2018**, 19,	46
942	Miniseries of reviews: gynecological pathology. **2018**, 472, 883-884	
941	Molecular Basis of Gynecologic Diseases. **2018**, 507-529	
940	Potential candidate treatment agents for targeting of cholangiocarcinoma identified by gene expression profile analysis. **2018**, 9, 42-52	5
939	Tissue-specific DNA methylation loss during ageing and carcinogenesis is linked to chromosome structure, replication timing and cell division rates. **2018**, 46, 7022-7039	17
938	Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease. **2018**, 17, 1995-2003	8
937	Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing. **2018**, 39, 159-167	21
936	Molecular profiling and sequential somatic mutation shift in hypermutator tumours harbouring POLE mutations. **2018**, 8, 8700	13

935	Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. **2018**, 45, 738-752.e6	15
934	The Jumonji-C oxygenase JMJD7 catalyzes (3S)-lysyl hydroxylation of TRAFAC GTPases. **2018**, 14, 688-695	18
933	Exploration of DNA methylation markers for diagnosis and prognosis of patients with endometrial cancer. **2018**, 13, 490-504	11
932	Fibroblast Growth Factor Receptor Inhibitors: Enhancing Therapeutic Strategies for Solid Tumors. **2019**, 101-121	
931	Hormone-Responsive Cancers. **2019**, 717-741.e8	1
930	Comparison of clinicopathologic and survival characteristics of high grade endometrial cancers; single center experience. **2019**, 43, 160-166	2
929	Molecular basis of distinct oestrogen responses in endometrial and breast cancer. **2019**, 26, 31-46	8
928	A comparison of mechanistic signaling pathway activity analysis methods. **2019**, 20, 1655-1668	22
927	Epigenetic Dysregulation at the Crossroad of Women's Cancer. **2019**, 11,	6
926	Clinical actionability of molecular targets in endometrial cancer. **2019**, 19, 510-521	118
925	Establishment of patient-derived xenograft model in ovarian cancer and its influence factors analysis. **2019**, 45, 2062-2073	8
924	Impact of adjuvant treatment on outcome in high-risk early-stage endometrial cancer: a retrospective three-center study. **2019**, 29, 133-139	3
923	ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion. **2019**, 10, 3554	48
922	Identification of Coding and Long Noncoding RNAs Differentially Expressed in Tumors and Preferentially Expressed in Healthy Tissues. **2019**, 79, 5167-5180	19
921	Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. **2019**, 10, 3574	58
920	Changing Incidence of Uterine Cancer in Rural Egypt: Possible Impact of Nutritional and Epidemiologic Transitions. **2019**, 5, 1-7	1
919	Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A. **2019**, 79, 4009-4010	4
918	Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome. **2019**, 9, 11677	14

917	Molecular biomarkers predicting early development of endometrial carcinoma: A pilot study. **2019**, 28, e13137	5
916	Nuclear expression of β-catenin in endometrial hyperplasia as marker of premalignancy. **2019**, 127, 699-709	32
915	Meta-analysis of gene expression alterations and clinical significance of the HECT domain-containing ubiquitin ligase HUWE1 in cancer. **2019**, 18, 2292-2303	6
914	Cancer-associated mutations in DICER1 RNase IIIa and IIIb domains exert similar effects on miRNA biogenesis. **2019**, 10, 3682	23
913	Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease. **2019**, 37, 2490-2500	10
912	The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers. **2019**, 37, 2449-2459	11
911	Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies). **2019**, 20,	14
910	Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. **2019**, 21, 1041-1051	146
909	Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors. **2019**, 21, 83	13
908	Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing. **2019**, 32, 1823-1833	28
907	Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results. **2019**, 75, 813-824	9
906	Emergence of Mutation as a Biomarker and an Actionable Target in Solid Cancers. **2019**, 24, e1303-e1314	30
905	Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing. **2019**, 9, 10426	19
904	Identification of prognosis markers for endometrial cancer by integrated analysis of DNA methylation and RNA-Seq data. **2019**, 9, 9924	13
903	Identification of a novel lncRNA GABPB1-IT1 that is downregulated and predicts a poor prognosis in non-small cell lung cancer. **2019**, 18, 838-845	2
902	miRNAs as Candidate Biomarker for the Accurate Detection of Atypical Endometrial Hyperplasia/Endometrial Intraepithelial Neoplasia. **2019**, 9, 526	7
901	Integrative genomic analysis identifies associations of molecular alterations to APOBEC and BRCA1/2 mutational signatures in breast cancer. **2019**, 7, e810	5
900	YAP promotes the malignancy of endometrial cancer cells via regulation of IL-6 and IL-11. **2019**, 25, 32	17

899	Usefulness of immunohistochemistry for mismatch repair protein and microsatellite instability examination in adenocarcinoma and background endometrium of sporadic endometrial cancer cases. **2019**, 45, 2037-2042	5
898	Metformin Enhances Nomegestrol Acetate Suppressing Growth of Endometrial Cancer Cells and May Correlate to Downregulating mTOR Activity In Vitro and In Vivo. **2019**, 20,	6
897	Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. **2019**, 20, 1273-1285	160
896	Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: Outcomes from an institutional series. **2019**, 240, 220-225	13
895	Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme. **2019**, 118, 156-165	5
894	Molecular profiling and molecular classification of endometrioid ovarian carcinomas. **2019**, 154, 516-523	39
893	Multi-omics profiling reveals distinct microenvironment characterization of endometrial cancer. **2019**, 118, 109244	8
892	Systematic analysis of the intersection of disease mutations with protein modifications. **2019**, 12, 109	4
891	Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression. **2019**, 17, 85	15
890	Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer. **2019**, 29, 1429-1441	13
889	Pathway-level information extractor (PLIER) for gene expression data. **2019**, 16, 607-610	23
888	Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases. **2019**, 92, 10-17	17
887	Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management. **2019**, 154, 467-474	21
886	Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy. **2019**, 154, 461-466	19
885	Development and Maldevelopment of the Female Reproductive System. **2019**, 1-40	0
884	Endometrial Carcinogenesis. **2019**, 409-424	
883	Endometrial Carcinoma. **2019**, 455-513	1
882	Label propagation defines signaling networks associated with recurrently mutated cancer genes. **2019**, 9, 9401	0

881	Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy. **2019**, 110, 2620-2628	15
880	Predicting prognosis of endometrioid endometrial adenocarcinoma on the basis of gene expression and clinical features using Random Forest. **2019**, 18, 1597-1606	4
879	Epithelial and Mixed Epithelial/Mesenchymal Malignancies of the Uterine Corpus. **2019**, 79-121	
878	Endometrial Carcinoma. **2019**, 473-533	5
877	High-Grade Endometrial Carcinomas: Classification with Molecular Insights. **2019**, 12, 343-362	6
876	Proteomic Biomarkers for the Detection of Endometrial Cancer. **2019**, 11,	32
875	ALDH-Dependent Glycolytic Activation Mediates Stemness and Paclitaxel Resistance in Patient-Derived Spheroid Models of Uterine Endometrial Cancer. **2019**, 13, 730-746	32
874	Somatic substitution signature as an innovative tool in lung cancer diagnosis. **2019**, 9, 14561	2
873	Reflection on the current status of endometrial cancer in New Zealand. **2019**, 59, 874-876	
872	. **2019**,	1
871	Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. **2019**, 10, 4965	39
870	Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome. **2019**, 5,	12
869	Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma. **2019** , 10, 986	10
868	[MSI Metastatic solid tumors treatment and immunotherapies]. **2019**, 106, 143-150	2
867	Keratin 17 is a negative prognostic biomarker in high-grade endometrial carcinomas. **2019**, 94, 40-50	10
866	Enriching Personalized Endometrial Cancer Research with the Harmonization of Biobanking Standards. **2019**, 11,	5
865	The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy. **2019**, 20,	21
864	Unique Molecular Features in High-Risk Histology Endometrial Cancers. **2019**, 11,	7

863	PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. **2019**, 10, CD012160	25
862	Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation. **2019**, 155, 365-373	3
861	Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. **2019**, 155, 420-428	18
860	SOX17 Inhibits Tumor Metastasis Via Wnt Signaling In Endometrial Cancer. **2019**, 12, 8275-8286	18
859	Role of Molecular Markers in Endometrial Cancer: Review. **2019**, 17, 1	
858	Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations.. **2019**, 3, 1-13	4
857	Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. **2019**, 37, 2786-2794	85
856	Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers. **2019**, 20, 75	6
855	Research progress on the PI3K/AKT signaling pathway in gynecological cancer (Review). **2019**, 19, 4529-4535	63
854	GSVD- and tensor GSVD-uncovered patterns of DNA copy-number alterations predict adenocarcinomas survival in general and in response to platinum. **2019**, 3, 036104	8
853	Precision medicine in endometrial cancer. **2019**, 154, 451-453	7
852	Alteration of tumor associated neutrophils by PIK3CA expression in endometrial carcinoma from TCGA data. **2019**, 12, 81	7
851	TCGA molecular groups of endometrial cancer: Pooled data about prognosis. **2019**, 155, 374-383	70
850	WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling. **2019**, 17, 109	26
849	The molecular origin and taxonomy of mucinous ovarian carcinoma. **2019**, 10, 3935	59
848	Systemic therapy for the treatment of endometrial cancer. **2019**, 20, 2019-2032	12
847	Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. **2019**, 30, 1821-1830	52
846	The Drosophila Model in Cancer. **2019**,	1

845	Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors. **2019**, 28, 903-916	4
844	Analysis of Promoter-Associated Chromatin Interactions Reveals Biologically Relevant Candidate Target Genes at Endometrial Cancer Risk Loci. **2019**, 11,	18
843	PTEN and Gynecological Cancers. **2019**, 11,	16
842	Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. **2019**, 10, 4369	8
841	Detection of POLE Subtypes in High-Grade Endometrioid Carcinoma by BaseScope-ISH Assay. **2019**, 9, 831	8
840	Complete and Prolonged Response to Immune Checkpoint Blockade in -Mutated Colorectal Cancer.. **2019**, 3, 1-5	8
839	Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. **2019**, 3,	8
838	Redox inhibition of protein phosphatase PP2A: Potential implications in oncogenesis and its progression. **2019**, 27, 101105	14
837	Expression and potential role of SNF5 in endometrial carcinoma. **2019**, 19, 16	1
836	Endometrial Tumor Immune Response: Predictive Biomarker of Response to Immunotherapy. **2019**, 25, 2366-2368	8
835	Antitumor effect of XCT790, an ERR inverse agonist, on ER negative endometrial cancer cells. **2019**, 42, 223-235	4
834	Germline and Somatic Tumor Testing in Gynecologic Cancer Care. **2019**, 46, 37-53	7
833	Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis. **2019**, 14, 67-80	44
832	The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification. **2019**, 30, e13	25
831	Two-sided role of estrogen on endometrial carcinogenesis: stimulator or suppressor?. **2019**, 35, 370-375	0
830	Integrating clinical, molecular, proteomic and histopathological data within the tissue context: tissunomics. **2019**, 75, 4-19	5
829	Endometrial Cancer: Obesity, Genetics, and Targeted Agents. **2019**, 46, 89-105	33
828	Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer. **2019**, 38, 404-413	18

827	Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 as a molecular target in breast cancer: a therapeutic perspective of gynecological cancer. **2019**, 42, 128-139	3
826	Cancer Screening and Prevention Highlights in Gynecologic Cancer. **2019**, 46, 19-36	7
825	Personalized Medicine in Gynecologic Cancer: Fact or Fiction?. **2019**, 46, 155-163	6
824	Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma. **2019**, 474, 585-598	7
823	Structural consequence of the most frequently recurring cancer-associated substitution in DNA polymerase □**2019**, 10, 373	20
822	Immunohistochemical Nuclear Expression of ₿Catenin as a Surrogate of CTNNB1 Exon 3 Mutation in Endometrial Cancer. **2019**, 151, 529-538	53
821	Activin-like kinase 5 (ALK5) inactivation in the mouse uterus results in metastatic endometrial carcinoma. **2019**, 116, 3883-3892	21
820	Innovative strategies for annotating the "relationSNP" between variants and molecular phenotypes. **2019**, 12, 10	3
819	Advancing Drug Development in Gynecologic Malignancies. **2019**, 25, 4874-4880	10
818	Biomarkers of Gynecological Cancers. **2019**, 133-150	
817	Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status. **2019**, 475, 223-231	8
816	De Novo Hotspot Mutation in a Patient With Endometrial Cancer Treated With an Aromatase Inhibitor. **2019**, 3,	2
815	Atlas of Uterine Pathology. **2019**,	
814	Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC. **2019**, 11, 4931-4946	20
813	PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer. **2019**, 9, 462	19
812	The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis. **2019**, 11,	23
811	Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene. **2019**, 8, 4587-4597	18
810	From parts to mechanisms: research heuristics for addressing heterogeneity in cancer genetics. **2019**, 41, 27	1

809	Defining a mutational signature for endometrial cancer screening and early detection. **2019**, 61, 129-132	0
808	A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma. **2019**, 120, 18465-18477	24
807	High risk endometrial cancer: Clues towards a revision of the therapeutic paradigm. **2019**, 48, 863-871	4
806	Learning common and specific patterns from data of multiple interrelated biological scenarios with matrix factorization. **2019**, 47, 6606-6617	15
805	Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma. **2019**, 32, 1508-1520	8
804	Bird's eye view of modern cytopathology: Report from the seventh international Molecular Cytopathology Meeting in Naples, Italy, 2018. **2019**, 127, 350-357	2
803	A Novel Set of WNT Pathway Effectors as a Predictive Marker of Uterine Corpus Endometrial Carcinoma-Study Based on Weighted Co-expression Matrices. **2019**, 9, 360	2
802	ProMisE on the horizon: molecular classification of endometrial cancer in young women. **2019**, 153, 465-466	3
801	Biomarkers in Cancer Therapy. **2019**,	1
800	Identifying Epistasis in Cancer Genomes: A Delicate Affair. **2019**, 177, 1375-1383	47
799	The Highly Recurrent PP2A A Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis. **2019**, 79, 4242-4257	19
798	Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. **2019**, 25, 1054-1056	341
797	Solid Tumors Challenges and New Insights of CAR T Cell Engineering. **2019**, 15, 619-636	46
796	Endometrial cancer an update. **2019**, 29, 225-232	1
795	Factor analysis for survival time prediction with informative censoring and diverse covariates. **2019**, 38, 3719-3732	1
794	Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta-Analysis. **2019**, 24, e880-e890	20
793	Oncogenic mutations in histologically normal endometrium: the new normal?. **2019**, 249, 173-181	60
792	Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. **2019**, 25, 5584-5594	44

791	New perspectives on screening and early detection of endometrial cancer. **2019**, 145, 3194-3206	21
790	Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed. **2019**, 39, e126-e140	19
789	Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. **2019**, 154, 22-28	14
788	Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer. **2019**, 154, 218-227	10
787	Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors. **2019**, 154, 189-198	58
786	Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. **2019**, 154, 124-130	38
785	Systematic characterization of germline variants from the DiscovEHR study endometrial carcinoma population. **2019**, 12, 59	1
784	Dedifferentiated endometrial adenocarcinoma with neuroendocrine differentiation and ballooning-cell features: Report of a rare entity with an unusual histology. **2019**, 15, 92-94	
783	Molecular markers in uterine serous cancer: Correlation between endometrial biopsy and hysterectomy specimens. **2019**, 29, 98-101	6
782	Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. **2019**, 20,	17
781	Current recommendations and recent progress in endometrial cancer. **2019**, 69, 258-279	129
780	DNA ploidy status, S-phase fraction, and p53 are not independent prognostic factors for survival in endometrioid endometrial carcinoma FIGO stage I-III. **2019**, 29, 305-311	1
779	Genomic Profiling of the Steroidogenic Acute Regulatory Protein in Breast Cancer: In Silico Assessments and a Mechanistic Perspective. **2019**, 11,	5
778	Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma. **2019**, 145, 2781-2791	5
777	Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network. **2019**, 51, 362-368	5
776	Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience. **2019**, 28, 120-123	10
775	Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. **2019**, 25, 3962-3973	16
774	Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?. **2019** , 154, 236-245	27

773	Immune check-point in endometrial cancer. **2019**, 24, 910-916	8
772	Genome-Wide Association Studies of Endometrial Cancer: Latest Developments and Future Directions. **2019**, 28, 1095-1102	21
771	Mutation analysis of POLE gene in patients with early-onset colorectal cancer revealed a rare silent variant within the endonuclease domain with potential effect on splicing. **2019**, 19, 393-400	7
770	Clinicopathologic characteristics, tumor infiltrating lymphocytes and programed cell death ligand-1 expression in 162 endometrial carcinomas with deficient mismatch repair function. **2019**, 29, 113-118	5
769	The Role of ARID1A in Endometrial Cancer and the Molecular Pathways Associated With Pathogenesis and Cancer Progression. **2019**, 33, 659-667	12
768	A Novel Approach to Preoperative Risk Stratification in Endometrial Cancer: The Added Value of Immunohistochemical Markers. **2019**, 9, 265	11
767	Network Medicine in Pathobiology. **2019**, 189, 1311-1326	29
766	Emodin Promotes Apoptosis of Human Endometrial Cancer Through Regulating the MAPK and PI3K/ AKT Pathways. **2018**, 13, 489-496	7
765	Zone Formation of Lymphocyte Infiltration at the Invasive Front Results in the Prolonged Survival of Individuals With Endometrial Serous Carcinoma and Endometrioid Carcinoma With Serous Component. **2019**, 39, 2085-2089	
764	Genome-wide DNA methylation analysis in obese women predicts an epigenetic signature for future endometrial cancer. **2019**, 9, 6469	12
763	Lymph node dissection in endometrial cancer and clinical outcome: A population-based study in 5546 patients. **2019**, 154, 65-71	13
762	Endocrinology of obese and nonobese endometrial cancer patients: is there role of tumor molecular-biological type?. **2019**, 15, 1335-1346	2
761	Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing. **2019**, 9, 123	10
760	Anti-M□lerian Hormone Expression in Endometrial Cancer Tissue. **2019**, 20,	6
759	Clinical and molecular classification of vulvar squamous pre-cancers. **2019**, 29, 821-828	15
758	The BAF complex in development and disease. **2019**, 12, 19	72
757	Immunotherapy in endometrial cancer: new scenarios on the horizon. **2019**, 30, e46	49
756	Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. **2019**, 25, 403-418	173

755	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. **2019**, 8,	4
754	Autocrine motility factor promotes endometrial cancer progression by targeting GPER-1. **2019**, 17, 22	15
753	A Combined Morphologic and Molecular Approach to Retrospectively Identify KRAS-Mutated Mesonephric-like Adenocarcinomas of the Endometrium. **2019**, 43, 389-398	31
752	Microsatellite instability in endometrial cancer: New purpose for an old test. **2019**, 125, 2154-2163	7
751	Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers. **2019**, 153, 517-520	26
750	Patterns of Failures and Clinical Outcome of Patients with Early-Stage, High-Risk, Node-Negative Endometrial Cancer Treated with Surgery Followed by Adjuvant Platinum-Based Chemotherapy and Vaginal Brachytherapy. **2019**, 96, 235-241	4
749	Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation. **2019** , 41, 2667-2678	1
748	Expression of in endometrial carcinoma tissues and its effect on epithelial to mesenchymal transition.. **2020**, 9, 7248-7258	0
747	Whole-exome sequencing in cervical adenocarcinoma in mainland Chinese patients.. **2020**, 9, 6889-6899	
746	Oncobox molecular profiling for a patient with recurrent endometrial cancer. **2022**, 33-37	
745	New Trends in the Detection of Gynecological Precancerous Lesions and Early-Stage Cancers.. **2021** , 13,	1
744	Regulatory patterns analysis of transcription factor binding site clustered regions and identification of key genes in endometrial cancer.. **2022**, 20, 812-823	
743	Endometrial Cancer: Transitioning from Histology to Genomics.. **2022**, 29, 741-757	3
742	Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis.. **2022**, 1	1
741	Tumor board presentation of a woman with metastatic, hormone receptor-positive, mismatch repair-deficient endometrial cancer.. **2022**,	0
740	Clinicopathologic and protein markers distinguishing the "polymerase epsilon exonuclease" from the "copy number low" subtype of endometrial cancer.. **2022**,	1
739	Clinical evaluation of a droplet digital PCR assay for detecting mutations and molecular classification of endometrial cancer.. **2021**,	1
738	Telomere and Telomerase-Associated Proteins in Endometrial Carcinogenesis and Cancer-Associated Survival.. **2022**, 23,	0

737	Biomarkers in Gynecologic Carcinomas. **2022**, 275-307	
736	Molecular Pathology of Endometrial Carcinoma: A General Appraisal. **2022**, 209-216	
735	Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma.. **2021**, 11, 798173	0
734	Establishing a Prognostic Signature Based on Epithelial-Mesenchymal Transition-Related Genes for Endometrial Cancer Patients.. **2021**, 12, 805883	0
733	CpG Island Methylator Phenotype-A Hope for the Future or a Road to Nowhere?. **2022**, 23,	3
732	Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H).. **2022**, 28, e934493	
731	Clinicopathologic vs. Molecular Integrated Prognostication of Endometrial Carcinoma by European Guidelines.. **2022**, 14,	0
730	Hybrid PET/MRI in Staging Endometrial Cancer: Diagnostic and Predictive Value in a Prospective Cohort.. **2022**, 47,	0
729	Key changes to the world health organisation (who) classification of female genital tumours introduced in the 5 edition (2020).. **2022**,	1
728	Clear cell carcinoma of the endometrium.. **2022**,	4
727	Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma.. **2022**, 23, 51	0
726	Nueva clasificaci molecular del carcinoma de endometrio: impacto en el diagn tico histopatol gico, tratamiento y pron tico. **2022**, 24, 365-374	
725	Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.. **2022**, 10,	20
724	Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.. **2022**,	5
723	Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.. **2022**,	0
722	Synchronous/metachronous endometrial and colorectal malignancies in Taiwanese women: a population-based nationwide study.. **2022**, 1	
721	The Evolution of Ovarian Carcinoma Subclassification.. **2022**, 14,	5
720	Gynecological Cancers. **2022**, 357-410	

719	High-intermediate risk endometrial cancer: moving toward a molecularly based risk assessment profile.. **2022**, 27, 323	1
718	Immune Checkpoint Inhibitors (ICI) in Advanced and Recurrent Endometrial Cancer. **2022**, 20, 1	
717	Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer.. **2022**,	0
716	Highlighting the Multifaceted Role of Orai1 N-Terminal- and Loop Regions for Proper CRAC Channel Functions.. **2022**, 11,	0
715	Paclitaxel and Carboplatin for Uterine Carcinosarcoma: A Path to Inclusion.. **2022**, JCO2102667	1
714	KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas.. **2022**, 17, e0251286	
713	Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma.. **2022**,	1
712	A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.. **2022**,	4
711	Pervasive conditional selection of driver mutations and modular epistasis networks in cancer.	0
710	Endometrial hyperplasia as a risk factor of endometrial cancer.. **2022**, 1	5
709	Molecular Pathology of Endometrial Carcinoma on LBC Samples and Cell Blocks. **2022**, 217-224	
708	Follicular Helper T-Cell-Based Classification of Endometrial Cancer Promotes Precise Checkpoint Immunotherapy and Provides Prognostic Stratification.. **2021**, 12, 788959	0
707	Emerging Treatment Options for Advanced or Recurrent Endometrial Cancer.. **2022**, 13, 45-59	3
706	Emerging Roles of mA RNA Methylation Regulators in Gynecological Cancer.. **2022**, 12, 827956	0
705	Probing the mechanisms of two exonuclease domain mutators of DNA polymerase ?.. **2022**,	1
704	Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment.. **2022**, 14,	1
703	HMGA2: A Biomarker in Gynecologic Neoplasia.. **2022**, 2, 3-7	
702	Genomic landscape of advanced endometrial cancer analyzed by targeted next-generation sequencing and the cancer genome atlas (TCGA) dataset.. **2022**,	0

701	Cancer risk and genotype-phenotype correlation in Japanese patients with Cowden syndrome.. **2022**, 27, 639	0
700	Vaginal microbiome is associated with endometrial cancer grade and histology.	
699	Distinct Genomic Landscapes in Early-Onset and Late-Onset Endometrial Cancer.. **2022**, 6, e2100401	
698	Evaluating statistical approaches to define clonal origin of tumours using bulk DNA sequencing: context is everything.. **2022**, 23, 43	1
697	Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.. **2021**,	0
696	Pharmacological targeting of polyamine and hypusine biosynthesis reduces tumor activity of endometrial cancer.. **2022**, 1-28	1
695	Prediction of Clinical Outcome in Endometrial Carcinoma Based on a 3-lncRNA Signature.. **2021**, 9, 814456	1
694	Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.. **2022**,	1
693	Depth normalization of small RNA sequencing: using data and biology to select a suitable method.. **2022**,	
692	Oncogenic Events Dictate the Types and Locations of Gynecological Malignancies Originating from Mesothelial and MÜllerian-Derived Epithelial Cells.. **2022**, 14,	0
691	The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.. **2022**, 17, e0263585	1
690	MAX deficiency impairs human endometrial decidualization through down-regulating OSR2 in women with recurrent spontaneous abortion.. **2022**, 1	0
689	Clinicopathologic Evaluation and Molecular Profiling of Recurrent Stage IA Endometrial Endometrioid Carcinoma: A Case-control Study.. **2022**,	
688	HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology.. **2022**,	2
687	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.. **2022**, 185, 563-575.e11	11
686	Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.. **2022**,	0
685	Comprehensive Genomic Profiling for Therapeutic Decision and Identification of Gene Mutation in Uterine Endometrial Dedifferentiated Carcinoma.. **2022**, 15, 46-55	
684	Comparison of the IdyllaMSI assay with the PromegaMSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study.. **2022**, 1	0

683	Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models.. **2022**, 14,	5
682	Low grade endometrial endometrioid adenocarcinoma: A review and update with emphasis on morphologic variants, mimics, immunohistochemical and molecular features.. **2022**,	0
681	A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. **2021**,	6
680	Cancer gene mutation frequencies for the U.S. population. **2021**, 12, 5961	15
679	Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis.. **2021**,	1
678	The Pathogenesis of Endometriosis: Are Endometrial Stem/Progenitor Cells Involved?. **2022**, 193-216	1
677	Dostarlimab for the treatment of advanced endometrial cancer.. **2022**,	1
676	The Use of Targeted Agents in the Treatment of Gynecologic Cancers.. **2022**, 23, 15	0
675	Distinct Mechanisms of Mismatch Repair Deficiency Delineate Two Modes of Response to PD-1 Immunotherapy in Endometrial Carcinoma.	
674	Mouse model and human patient data reveal critical roles for Pten and p53 in suppressing POLE mutant tumor development.. **2022**, 4, zcac004	0
673	KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.. **2022**,	0
672	Major clinical research advances in gynecologic cancer in 2021.. **2022**, 33, e43	2
671	MicroRNA-152 Regulates Endometrial Serous Carcinoma Cell Motility by Suppressing Matrix Metalloproteinase 10 Expression.. **2022**, 256, 249-258	0
670	Early Breast Cancer Evolution by Autosomal Broad Copy Number Alterations.. **2022**, 2022, 9332922	0
669	POIBM: Batch correction of heterogeneous RNA-seq datasets through latent sample matching.. **2022**,	0
668	Relevance of Mutations in Endometrial Carcinomas.. **2022**, 12,	1
667	ARID1A maintains transcriptionally repressive H3.3 associated with CHD4-ZMYND8 chromatin interactions.	
666	The Many Faces of Serous Neoplasms and Related Lesions of the Female Pelvis: A Review.. **2022**, 29,	0

665	Biomolecular and Genetic Prognostic Factors That Can Facilitate Fertility-Sparing Treatment (FST) Decision Making in Early Stage Endometrial Cancer (ES-EC): A Systematic Review.. **2022**, 23,	3
664	Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer.. **2022**, 29, 1123-1135	1
663	Predicting Mutational Status of Driver and Suppressor Genes Directly from Histopathology With Deep Learning: A Systematic Study Across 23 Solid Tumor Types.. **2021**, 12, 806386	0
662	Progesterone Actions and Resistance in Gynecological Disorders.. **2022**, 11,	6
661	Neue Aspekte in Diagnostik und Therapie des Endometriumkarzinoms. **2022**, 55, 211-214	
660	Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation.. **2022**,	
659	Molecular features of endometrial metaplastic processes, the risk factors for cancer relapse and neoplastic transformation.	
658	Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high grade serous carcinoma.	
657	Immune checkpoint inhibitors for recurrent endometrial cancer.. **2022**,	1
656	Prognosis Stratification Tools in Early-Stage Endometrial Cancer: Could We Improve Their Accuracy?. **2022**, 14,	0
655	ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma.. **2022**,	0
654	Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit.. **2022**, 14,	0
653	TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.. **2022**,	2
652	Management of stage III and IVa uterine cancer.. **2022**, 32, 316-322	
651	Utility of p63 and PTEN Staining in Distinguishing Cervical Microglandular Hyperplasia from Endometrial Endometrioid Carcinoma with Microglandular/Mucinous Features.. **2022**,	
650	Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.. **2022**, 1	0
649	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients.. **2022**, 13, 1373	3
648	Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).. **2022**,	2

647	Reconsider the safety of laparoscopic surgery in endometrial cancer. **2022**, 2, 1-5	
646	Indications for Adjuvant Radiotherapy in Patients with pN0(i+) Adenocarcinoma of the Endometrium.. **2022**,	0
645	Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification.. **2022**,	0
644	Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma.. **2022**,	
643	Exosomes on Endometrial Cancer: A Biomarkers Treasure Trove?. **2022**, 14,	0
642	Rare Subtype of Endometrial Cancer: Undifferentiated/Dedifferentiated Endometrial Carcinoma, from Genetic Aspects to Clinical Practice.. **2022**, 23,	0
641	Combined modality including novel sensitizers in gynecological cancers.. **2022**, 32, 389-401	0
640	EZH2 and Endometrial Cancer Development: Insights from a Mouse Model.. **2022**, 11,	0
639	Chrysin attenuates estradiol-induced endometrial hyperplasia in rats via enhancing PPARγ activity.. **2022**, 1	
638	Improving the diagnosis of endometrial hyperplasia using computerized analysis and immunohistochemical biomarkers.	
637	Sentinel Lymph Node Biopsy in Surgical Staging for High-Risk Groups of Endometrial Carcinoma Patients.. **2022**, 19,	0
636	Aktuelle Diagnostik und Therapie des Endometriumkarzinoms. **2022**, 55, 197-210	
635	Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?. **2022**, 23,	2
634	Immunosuppressive tumor microenvironment in Uterine Serous Carcinoma via CCL7 signal with myeloid-derived suppressor cells.. **2022**,	0
633	Sera Protein Signatures of Endometrial Cancer Lymph Node Metastases.. **2022**, 23,	1
632	Pelvic Carcinosarcoma Showing a Diverse Histology and Hierarchical Gene Mutation with a Common Mutation to Endometrial Endometroid Carcinoma: A Case Report.. **2022**, 10668969221088880	
631	Differential Expression of Steroid Hormone Receptors and Ten Eleven Translocation Proteins in Endometrial Cancer Cells.. **2022**, 12, 763464	0
630	Vaginal brachytherapy management of stage I and II endometrial cancer.. **2022**, 32, 304-310	

629	Genomic Landscapes and Tumor Evolution in Metastatic Gynecological Cancers.		
628	Endometrioid Cancer Associated With Endometriosis: From the Seed and Soil Theory to Clinical Practice.. **2022**, 12, 859510		0
627	The role for vaginal cuff brachytherapy boost after external beam radiation therapy in endometrial cancer.. **2022**, 21, 177-185		
626	Testing for Lynch Syndrome in Endometrial Carcinoma: From Universal to Age-Selective Methylation Analysis.. **2022**, 14,		0
625	The clinicopathological characteristics, prognosis and immune microenvironment mapping in MSI-H/MMR-D endometrial carcinomas.. **2022**, 13, 12		0
624	The Two-Faced Role of Autophagy in Endometrial Cancer.. **2022**, 10, 839416		0
623	Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.. **2022**, 10,		2
622	SEOM-GEICO clinical guidelines on endometrial cancer (2021).. **2022**, 24, 625		1
621	Four-Year Disease-Free Remission in a Patient With POLE Mutation-Associated Colorectal Cancer Treated Using Anti-PD-1 Therapy.. **2022**, 20, 218-223		0
620	SWI/SNF Antagonism of PRC2 Mediates Estrogen-Induced Progesterone Receptor Expression.. **2022**, 11,		0
619	Diagnostic value of endometrial cytology and related technology.. **2022**,		2
618	Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases.. **2022**, 165, 376-384		2
617	Mismatch repair deficiency and clinical implications in prostate cancer.. **2022**,		1
616	Polymerase Epsilon-Associated Ultramutagenesis in Cancer.. **2022**, 14,		0
615	The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method.. **2022**,		1
614	Liquid Biopsy for Monitoring EC Patients: Towards Personalized Treatment.. **2022**, 14,		0
613	The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review.. **2022**, 11, 472-496		1
612	Anatomic position determines oncogenic specificity in melanoma.. *Nature*, **2022**,	50.4	3

611	Executive Summary of the Uterine Cancer Evidence Review Conference.. **2022**,	1
610	Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma.. **2022**,	1
609	Clinical Profile and Survival Outcome of Endometrial Cancer with p53 Mutation. 1	0
608	The Clinical Utility and Impact of Next Generation Sequencing in Gynecologic Cancers.. **2022**, 14,	0
607	Management of inoperable endometrial cancer.. **2022**,	0
606	Identification of molecular subtypes premised on the characteristics of immune infiltration of endometrial cancer.. **2022**, 10, 337	0
605	A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma.. **2022**, 40, 100974	1
604	Comprehensive Analysis of the Prognostic Signature of Mutation-Derived Genome Instability-Related lncRNAs for Patients With Endometrial Cancer.. **2022**, 10, 753957	1
603	Genomic landscape of endometrial carcinomas of no specific molecular profile.. **2022**,	0
602	Physiological Concentrations of Extract Do Not Affect Expression of Genes Involved in Estrogen Biosynthesis and Action in Endometrial and Ovarian Cell Lines.. **2022**, 12,	
601	MRI radiomics: A machine learning approach for the risk stratification of endometrial cancer patients.. **2022**, 149, 110226	3
600	Histopathologic and Genetic Features of Mismatch Repair-Deficient High-Grade Prostate Cancer.. **2022**,	0
599	Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal from the Italian Study Group.. **2022**, 12, 805613	2
598	Endometrial cancer.. **2022**, 399, 1412-1428	28
597	Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape.. **2022**,	0
596	PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance.. **2021**, 13, 9157-9165	0
595	Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma.. **2021**,	2
594	Molecular Pathology of Human Papilloma Virus-Negative Cervical Cancers.. **2021**, 13,	0

593	Endometrial cancer. **2021**, 7, 88	13
592	Autophagic Flux Unleashes GATA4-NF-B Axis to Promote Antioxidant Defense-Dependent Survival of Colorectal Cancer Cells under Chronic Acidosis.. **2021**, 2021, 8189485	0
591	A radiogenomics application for prognostic profiling of endometrial cancer. **2021**, 4, 1363	1
590	A Multiplex SNaPshot Assay is a Rapid and Cost-Effective Method for Detecting POLE Exonuclease Domain Mutations in Endometrial Carcinoma.. **2021**,	1
589	Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer.. **2021**, 12,	0
588	Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer. **2021**,	0
587	Adjuvant chemotherapy in patients with uterine carcinosarcoma: a review of clinical outcomes and considerations. **2021**, 9, 247-255	
586	Recurrent Endometrial Cancer: Local and Systemic Treatment Options.. **2021**, 13,	4
585	Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response.. **2021**, 12, 7297	1
584	Quantification of recurrence risk based on number of adverse prognostic factors in women with stage I uterine endometrioid carcinoma. **2021**, 22, 262-267	
583	Hematologic parameters as a predictor of myometrial and cervical invasion in endometrial cancer.. **2021**, 73, 770-775	
582	Contemporary Fertility-Sparing Management Options of Early Stage Endometrioid Endometrial Cancer in Young Nulliparous Patients.. **2021**, 11,	1
581	The Advance and Correlation of Mutation With the Fertility-Preservation Treatment of Endometrial Cancer in the Background of Molecular Classification Application.. **2021**, 27, 1609906	
580	Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel.. **2021**, 27, 1610013	3
579	Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis?. **2021**, 14,	
578	Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer.. **2021**, 12, 689076	5
577	Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.. **2021**, 17, e1009986	6
576	Classification Systems of Endometrial Cancer: A Comparative Study about Old and New.. **2021**, 12,	1

575	Comparative transcriptome analysis between patient and endometrial cancer cell lines to determine common signaling pathways and markers linked to cancer progression.. **2021**, 12, 2500-2513	0
574	Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.. **2021**,	2
573	Postoperative Radiotherapy for Endometrial Cancer in Elderly (≥80 Years) Patients: Oncologic Outcomes, Toxicity, and Validation of Prognostic Scores.. **2021**, 13,	0
572	Treatment of Carcinosarcoma of the Fallopian Tube Mimicking Ovarian Cancer: A Case Report and Genetic Analysis.. **2021**, 88, 574-578	
571	Pan-cancer analysis reveals molecular patterns associated with age. **2021**, 37, 110100	0
570	Attentive deep learning-based tumor-only somatic mutation classifier achieves high accuracy agnostic of tissue type and capture kit.	
569	Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue "Diagnosis and Management of Endometrial Cancer".. **2021**, 13,	0
568	Identification of as an Immune-Associated Gene in Endometrial Carcinoma and Associated with Macrophage Infiltration by Bioinformatic Analysis.. **2021**, 2021, 4372373	1
567	IgA-dominated humoral immune responses govern patients' outcome in endometrial cancer.. **2021**,	1
566	Conservative Surgery in Endometrial Cancer.. **2021**, 11,	3
565	Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in 27 Cases.. **2021**, 11, 732782	0
564	Changing treatments paradigms and role of immunotherapy in recurrent endometrial cancer.. **2022** , 34, 28-35	
563	Two-Way Development of the Genetic Model for Endometrial Tumorigenesis in Mice: Current and Future Perspectives.. **2021**, 12, 798628	0
562	Histopathologic diagnosis of endometrial precancers: Updates and future directions.. **2021**,	0
561	Urologic Cancer Molecular Biology.	
560	Cell-Type Heterogeneity in DNA Methylation Studies: Statistical Methods and Guidelines. **2022**, 67-96	
559	Endometrial Cancer and Precancer in Polycystic Ovary Syndrome. **2022**, 411-429	
558	Analysis of lncRNA sequences: FAM3D-AS1, LINC01230, LINC01315 and LINC01468 in endometrial cancer.. **2022**, 22, 343	0

557	Endometrial Cancer Management in Young Women.. **2022**, 14,	0
556	Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy. **2022**, 12, 655	0
555	Panel Informativity Optimizer (PIO): an R package to improve cancer NGS panel informativity.. **2022** ,	
554	How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.. **2022**, 12, 844801	1
553	PIM1 is a Poor Prognostic Factor for and Potential Therapeutic Target in Serous Carcinoma of the Endometrium.. **2022**,	0
552	Tumor genetics and individualized therapy.	
551	Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review.. **2022**, 10, 860985	3
550	Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients.. **2022**, 8, 52	
549	SETD2 haploinsufficiency enhances germinal center-associated AICDA somatic hypermutation to drive B cell lymphomagenesis.. **2022**,	1
548	L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma.. **2022**,	0
547	Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.. **2022**,	0
546	Survival outcomes in endometrial cancer patients according to diabetes: a systematic review and meta-analysis.. **2022**, 22, 427	1
545	Image_1.PDF. **2018**,	
544	Image_2.PDF. **2018**,	
543	Image_3.PDF. **2018**,	
542	Image_4.PDF. **2018**,	
541	Table_1.XLSX. **2018**,	
540	Table_2.XLSX. **2018**,	

539 Table_3.XLSX. **2018**,

538 Table_4.XLSX. **2018**,

537 Table_5.XLSX. **2018**,

536 Table_6.XLSX. **2018**,

535 Image_1.TIF. **2020**,

534 Table_1.DOCX. **2020**,

533 Data_Sheet_1.PDF. **2020**,

532 Image_1.TIF. **2019**,

531 Table_1.xlsx. **2019**,

530 Data_Sheet_1.PDF. **2020**,

529 Table_1.XLSX. **2020**,

528 Data_Sheet_1.pdf. **2019**,

527 Table_1.xlsx. **2019**,

526 Table_2.xls. **2019**,

525 Table_3.docx. **2019**,

524 DataSheet_1.xlsx. **2020**,

523 DataSheet_2.docx. **2020**,

522 Image_1.jpeg. **2020**,

521 Image_2.jpeg. **2020**,

520 Image_3.jpeg. **2020**,

519 Image_4.jpeg. **2020**,

518 Data_Sheet_1.PDF. **2018**,

517 Table_1.docx. **2020**,

516 Data_Sheet_1.docx. **2020**,

515 Table_1.doc. **2020**,

514 Data_Sheet_1.xls. **2018**,

513 Image_1.tif. **2018**,

512 Image_2.tif. **2018**,

511 Beyond T Cells: IgA Incites Immune Recognition in Endometrial Cancer.. **2022**, 82, 766-768 0

510 Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma.. **2022**, 17, e0264014 0

509 Prognostic factors in clear cell carcinoma of endometrium: analysis of 55 cases.. **2022**, 92, e2021362

508 Papillary mucinous metaplasia: a distinct precursor of mucinous adenocarcinoma of the endometrium.. **2022**, 15, 83-87

507 Clinical Interpretation of Immunohistochemistry in Gynaecological Cancers. **2022**, 173-191

506 DNA Methylation Imputation Across Platforms.. **2022**, 2432, 137-151

505 Hormonal Treatment in Gynaecological Malignancies. **2022**, 139-146

504 The Role of CTNNB1 in Endometrial Cancer.. **2022**, 2022, 1442441 0

503	Hypermethylated and in Cytological Specimens as Screening Biomarkers for Endometrial Cancer.. **2022**, 12, 714663	0
502	Vibrational Biospectroscopy: An Alternative Approach to Endometrial Cancer Diagnosis and Screening.. **2022**, 23,	1
501	A 13-Gene Signature Based on Estrogen Response Pathway for Predicting Survival and Immune Responses of Patients With UCEC.. **2022**, 9, 833910	0
500	Current and Emerging Prognostic Biomarkers in Endometrial Cancer.. **2022**, 12, 890908	1
499	Biomarkers Associated with Lymph Nodal Metastasis in Endometrioid Endometrial Carcinoma.. **2022**, 14,	
498	Molecular profiles of endometrial cancer tumors among Black patients.. **2022**,	1
497	Replicative Instability Drives Cancer Progression.	
496	Updates in Adjuvant Therapy for High-Risk and Locally Advanced Endometrial Cancer. **2022**, 2, 25-33	1
495	Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.. **2022**, 8, 60	1
494	Interdisciplinary approach to the management of patients with uterine cancer progression. **2022**, 18, 87-96	
493	Sentinel Lymph Node Sampling in Endometrial Cancers. **2022**, 2, 107-118	
492	Improving the Diagnosis of Endometrial Hyperplasia Using Computerized Analysis and Immunohistochemical Biomarkers. **2022**, 4,	0
491	Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.. **2022**,	2
490	Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.. **2022**, 2022, 2547029	1
489	Developing a novel DNA methylation risk score for survival and identification of prognostic gene mutations in endometrial cancer: a study based on TCGA data.. **2022**,	
488	The Landscape of Personalized Medicine in Gynecologic Cancer. **2022**, 2, 99-105	
487	Impact of Type 2 Diabetes Mellitus on Endometrial Cancer Survival: A Prospective Database Analysis. **2022**, 12,	0
486	Clinicopathologic and genomic characteristics of mucinous gastric adenocarcinoma.. **2022**,	0

485	High incidence of PI3K pathway gene mutations in South Indian cervical cancers.. **2022**, 264-265, 100-108	
484	Endometrioid endometrial carcinoma of no-specific-molecular-profile with multiple bone metastases and muscle involvement: Case report and review of the literature.. **2022**, 17, 2346-2352	0
483	The role of progesterone receptor membrane component (PGRMC) in the endometrium.. **2022**, 184, 109040	0
482	Molecular Progression of Breast Cancer and Personalized Medicine in Terms of Clinical Trials. **2022**, 367-401	
481	Single-cell sequencing reveals the heterogeneity and intratumoral crosstalk in human endometrial cancer.. **2022**, e13249	1
480	Mapping Human Reproduction with Single-Cell Genomics.. **2022**,	0
479	Expression of periostin according to endometrial cancer grade. **2022**, 24,	0
478	Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somatic mutation on recurrence-free survival.. **2022**,	0
477	Research Progress of Wnt Signaling in Endometrial Cancer Stem Cancer and EMT. **2022**, 12, 4143-4148	
476	The vaginal microbiome is associated with endometrial cancer grade and histology.	0
475	Comprehensive Analysis and Experimental Validation of a Novel Estrogen/Progesterone-Related Prognostic Signature for Endometrial Cancer. **2022**, 12, 914	0
474	Management of Metastatic Endometrial Cancer: Physicians Choices Beyond the First Line. A MITO Survey. 12,	0
473	Network Control Models With Personalized Genomics Data for Understanding Tumor Heterogeneity in Cancer. 12,	
472	The Prognostic Effect of HER2 Gene Amplification in High-Grade Endometrial Carcinomas and its Correlation with Protein Overexpression. 106689692211025	
471	Endometrial Cancer Following Levonorgestrel-Releasing Intrauterine System Insertion in Young Women with Atypical Hyperplasia: Two Case Reports and Literature Review.	0
470	Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. **2022**,	1
469	CTNNB1-mutated High-grade Endometrioid Carcinoma With Extensive Squamous and Shadow Cell Differentiation Can Mimic Pilomatrix Carcinoma. **20**, Publish Ahead of Print,	
468	Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer. **2022**, 10, e004338	1

467	Clinicopathologic significance of DNA mismatch repair protein status in endometrial cancer. **2022**, 61, 415-421	0
466	Molecular Classification in Patients With Endometrial Cancer After Fertility-Preserving Treatment: Application of ProMisE Classifier and Combination of Prognostic Evidence. 12,	1
465	Whole-Exome Sequencing Reveals Clinical Potential of Circulating Tumor DNA from Peritoneal Fluid and Plasma in Endometrial Cancer. **2022**, 14, 2506	1
464	Should Endometrial Cancer Treatment Be Centralized?. **2022**, 11, 768	0
463	Potential competing risk of death in older high-risk endometrial carcinoma patients: Results from a multicentric retrospective cohort. **2022**,	
462	Open Surgery including Lymphadenectomy without Adjuvant Therapy for Uterine-Confined Intermediate- and High-Risk Endometrioid Endometrial Carcinoma. **2022**, 29, 3728-3737	0
461	Molecular classification of endometrial carcinoma: a clinically oriented review. jclinpath-2022-208345	0
460	Diagnosis of endometrium hyperplasia and screening of endometrial intraepithelial neoplasia in histopathological images using a global-to-local multi-scale convolutional neural network. **2022**, 221, 106906	1
459	Molecular classification in endometrial cancer: Opportunities for precision oncology in a changing landscape.	1
458	Genomic Validation of Endometrial Cancer Patient-Derived Xenograft Models as a Preclinical Tool. **2022**, 23, 6266	1
457	PPP2R1A Regulates Migration Persistence through the WAVE Shell Complex.	0
456	TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.	1
455	Bone Metastases of Endometrial Carcinoma Treated by Surgery: A Report on 13 Patients and a Review of the Medical Literature. **2022**, 19, 6823	0
454	Molecular classification of endometrial carcinoma: protocol for a cohort study (Preprint).	
453	Novel Therapies in Gynecologic Cancer. **2022**, 1-17	1
452	Overexpression of LPCAT1 enhances endometrial cancer stemness and metastasis by changing lipid components and activating TGF-β-Smad2/3 signaling pathway. **2022**,	0
451	Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma.	0
450	FOXA2 suppresses endometrial carcinogenesis and epithelial-mesenchymal transition by regulating enhancer activity. **2022**, 132,	0

449	Analysis of vanishing endometrial cancer by pathological types.	
448	Transient, DNA-free in vivo CRISPR/Cas9 genome edition for flexible modelling of endometrial carcinogenesis.	
447	Blood group antigens SLeX, SLeA, and LeY as prognostic markers in endometrial cancer.	1
446	Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer. **2022**, 14, 2842	0
445	The Double Engines and Single Checkpoint Theory of Endometriosis. **2022**, 10, 1403	0
444	Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. **2022**,	5
443	The prognosis of endometrial cancers stratified with conventional risk factors and modified molecular classification.	
442	Radiomics and artificial intelligence in malignant uterine body cancers: Protocol for a systematic review. **2022**, 17, e0267727	1
441	Paired box 8 facilitates the c-MYC related cell cycle progress in TP53-mutation uterine corpus endometrial carcinoma through interaction with DDX5. **2022**, 8,	
440	Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma. **2022**, 13,	0
439	A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer. ijgc-2022-003480	2
438	Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer.	0
437	Genomic determinants of early recurrences in low-stage low-grade endometrioid endometrial carcinoma.	0
436	ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer. **2022**,	0
435	Operative Therapie des Endometriumkarzinoms und mögliche Entwicklungen. **2022**, 16, 233-245	
434	Endometrial Cancer. **2022**, 15, 277-299	
433	Editorial for "Amide Proton Transfer-Weighted Imaging Combined With Intravoxel Incoherent Motion for Evaluating Microsatellite Instability in Endometrial Cancer."	
432	A hierarchical spike-and-slab model for pan-cancer survival using pan-omic data. **2022**, 23,	

431	Evaluating multiple next-generation sequencing derived tumor features to accurately predict DNA mismatch repair status.	
430	Replication Stress Defines Distinct Molecular Subtypes Across Cancers. **2022**, 2, 503-517	0
429	Comprehensive immunohistochemical analysis of N6-methyladenosine (m6A) writers, erasers, and readers in endometrial cancer.	1
428	Colon cancer organoids using monoclonal organoids established in four different lesions of one cancer patient reveal tumor heterogeneity and different real-time responsiveness to anti-cancer drugs. **2022**, 152, 113260	0
427	MicroRNA 182, 183, 200a, and 200b exhibit strong correlations but no involvement in PTEN protein regulation in uterine endometrial carcinoma. **2022**, 236, 153986	
426	Durable complete remission after Pembrolizumab in pretreated advanced endometrial cancer: A case report. **2022**, 7, 100172	
425	Gynecological Cancer and Breast Cancer. **2022**, 163-200	
424	Interpretable Deep Learning Predicts the Molecular Endometrial Cancer Classification from H&E Images: A Combined Analysis of the Portec Randomized Clinical Trials.	0
423	Gynecological Cancers in Lynch Syndrome: A Comparison of the Histological Features with Sporadic Cases of the General Population. **2022**, 11, 3689	0
422	Biomarker characterization in endometrial cancer in Italy: first survey data analysis. **2022**, 114, 189-198	1
421	Clinicopathologic association and prognostic impact of microcystic, elongated and fragmented pattern invasion, combined with tumor budding in endometrioid endometrial cancer.	0
420	Prognostic Ability of Enhancer RNAs in Metastasis of Non-Small Cell Lung Cancer. **2022**, 27, 4108	0
419	A Novel Defined Endoplasmic Reticulum Stress-Related lncRNA Signature for Prognosis Prediction and Immune Therapy in Glioma. 12,	0
418	BHLHE22 Expression Is Associated with a Proinflammatory Immune Microenvironment and Confers a Favorable Prognosis in Endometrial Cancer. **2022**, 23, 7158	0
417	An Integrated Approach for the Early Detection of Endometrial and Ovarian Cancers (Screenwide Study): Rationale, Study Design and Pilot Study. **2022**, 12, 1074	
416	Facts and hopes in immunotherapy of endometrial cancer.	1
415	Mesonephric-Like Adenocarcinoma of Uterine Corpus: A Clinicopathological and Targeted Genomic Profiling Study in a Single Institution. 12,	0
414	Incorporating Molecular Diagnostics into Treatment Paradigms for Endometrial Cancer.	0

413	The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer. **2022**, 12, 1737	0
412	Multi-omics analysis to screen potential therapeutic biomarkers for anti-cancer compounds. **2022**, e09616	
411	Integrated bioinformatics data analysis reveals a risk signature and PKD1 induced progression in endometrial cancer patients with postmenopausal status.	
410	Age-associated differences in the cancer molecular landscape. **2022**,	0
409	Research Progress of DNA Methylation in Endometrial Cancer. **2022**, 12, 938	1
408	Evaluation of a Patient With Non-Myoinvasive Uterine Serous Carcinoma Confined to a Polyp and Positive Peritoneal Washings With Somatic ARHGAP35 and KRAS Mutations. **2022**,	
407	Construction and validation of a prognostic model based on 11 lymph node metastasis-related genes for overall survival in endometrial cancer.	0
406	Impact of the new molecular classification of endometrial cancer: A French cohort study. **2022**,	1
405	CYLD expression in endometrial carcinoma and correlation with clinicohistopathological parameters. **2022**, 61, 596-600	1
404	Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort. **2022**, 13,	0
403	Relationship between ATOH1 and tumor microenvironment in colon adenocarcinoma patients with different microsatellite instability status. **2022**, 22,	
402	Ferroptosis: Opportunities and Challenges in Treating Endometrial Cancer. 9,	
401	Significance of TP53 Mutational Status-Associated Signature in the Progression and Prognosis of Endometrial Carcinoma. **2022**, 2022, 1-18	0
400	Endometrial polyps are non-neoplastic but harbor epithelial mutations in endometrial cancer drivers at low allelic frequencies.	0
399	Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials. **2022**,	0
398	Enhanced polymerase activity permits efficient synthesis by cancer-associated DNA polymerase ? variants at low dNTP levels.	
397	Morules but Not Squamous Differentiation are a Reliable Indicator of CTNNB1 (β-catenin) Mutations in Endometrial Carcinoma and Precancers. Publish Ahead of Print,	0
396	Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma. **2022**, 2022, 1-20	0

395	Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities. **2022**, 11, 3912	1
394	Novel Endometrial Cancer Models Using Sensitive Metastasis Tracing for CXCR4-Targeted Therapy in Advanced Disease. **2022**, 10, 1680	1
393	Microsatellite instability and sex differences in resectable gastric cancer A pooled analysis of three European cohorts. **2022**, 173, 95-104	0
392	Recommendations for extracellular vesicle miRNA biomarker research in the endometrial cancer context. **2022**, 23, 101478	1
391	Integration of androgen hormones in endometrial cancer biology. **2022**,	1
390	Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles.	0
389	To Identify Adenomatous Polyposis Coli Gene Mutation as a Predictive Marker of Endometrial Cancer Immunotherapy. 10,	0
388	An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer. **2022**, 29, 5209-5212	
387	Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation. **2022**, 10, e004487	0
386	Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerations. **2022**,	
385	Clinical utility of pathology data: endometrial and tubo-ovarian carcinomas. **2022**, 75, 529-536	
384	Somatic mutation analysis of Mesonephric-Like adenocarcinoma and associated putative precursor Lesions: Insight into pathogenesis and potential molecular treatment targets. **2022**, 42, 101049	
383	Prognostication of early-onset endometrioid endometrial cancer based on genome-wide DNA methylation profiles. 33,	
382	L1CAM Expression in Microcystic, Elongated, and Fragmented (MELF) Glands Predicts Lymph Node Involvement in Endometrial Carcinoma. **2022**, 14, 3635	0
381	Endometrial Carcinoma: Molecular Cytogenetics and Transcriptomic Profile. **2022**, 14, 3536	0
380	Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma.	0
379	Genetic variation as a long-distance modulator of RAD21 expression in humans. **2022**, 12,	
378	The Associations between Metalloestrogens, GSTP1, and SLC11A2 Polymorphism and the Risk of Endometrial Cancer. **2022**, 14, 3079	0

377	Detection of Microsatellite Instability in Colonoscopic Biopsies and Postal Urine Samples from Lynch Syndrome Cancer Patients Using a Multiplex PCR Assay. **2022**, 14, 3838	0
376	High-sensitivity mutation analysis of cell-free DNA for disease monitoring in endometrial cancer.	0
375	Cancer de l'endomètre de stade localisé: la perspective d'une désescalade thérapeutique guidée par la classification moléculaire. **2022**,	
374	Glucose transporters: Important regulators of endometrial cancer therapy sensitivity. 12,	
373	Molecular classification grade 3 endometrial endometrioid carcinoma using a next-generation sequencing-based gene panel. 12,	
372	The top 100 most cited papers on endometrial carcinoma: A bibliometric analysis. 12,	1
371	African Ancestry is Associated with Aggressive Endometrial Cancer. **2022**,	
370	Recent progress in the use of pharmacotherapy for endometrial cancer. 1-12	1
369	Importance of the endometrial immune environment in endometrial cancer and associated therapies. 12,	0
368	Endometrial Cancer in Aspect of Forkhead Box Protein Contribution. **2022**, 19, 10403	0
367	Improved preoperative risk stratification in endometrial carcinoma patients: external validation of the ENDORISK Bayesian network model in a large population-based case series.	0
366	Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States. 1-18	
365	Towards less invasive molecular diagnostics for endometrial cancer: massively parallel sequencing of endometrial lavage specimens in women attending for an office hysteroscopy.	0
364	Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors. **2022**, 12, 1903	
363	Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab. ijgc-2022-003492	0
362	One-Stop Molecular Classification of Endometrial Carcinoma using Comprehensive Next-Generation Sequencing.	
361	Predicting the Prognostic Value of POLI Expression in Different Cancers via a Machine Learning Approach. **2022**, 23, 8571	0
360	Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study. **2022**, 14, 4070	0

359	Clinical and Biological Activity of Chemo-immunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium.	
358	Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers. **2022**, 23, 8726	0
357	Predicting recurrence and metastasis risk of endometrial carcinoma via prognostic signatures identified from multi-omics data. 12,	
356	Mouse lemur transcriptomic atlas elucidates primate genes, physiology, disease, and evolution.	
355	Reassessment of intensive surveillance practices adopted for endometrial cancer survivors. **2022**, 22,	0
354	Characterization of a novel estrogen- and progesterone-responsive endometrial cancer cell line: HCI-EC-23.	
353	Update on MRI in Evaluation and Treatment of Endometrial Cancer.	0
352	Pervasive conditional selection of driver mutations and modular epistasis networks in cancer. **2022**, 40, 111272	0
351	Feasibility and clinical applicability of genomic profiling based on cervical smear samples in patients with endometrial cancer. 12,	0
350	Mortality patterns of synchronous uterine and ovarian cancers: a SEER registry analysis.	
349	Improving the Management of Endometrial Cancer Patients through the Use of Liquid Biopsy Analyses: A Case Report. **2022**, 23, 8539	
348	Association between adrenal-restrictive HSD3B1 inheritance and hormone independent subtypes of endometrial and breast cancer.	1
347	LncRNA-LA16c-313D11.11,A Signature to Predict Endometrial Carcinoma Patients with a Better Survival.	
346	Less is more in endometrial cancer (SLN, conservative treatment, radical hysterectomy, molecular classification). **2022**, 34, 511-517	
345	Identification of cuproptosis-related subtypes, establishment of a prognostic model and tumor immune landscape in endometrial carcinoma. **2022**, 149, 105988	0
344	Novel approaches for treatment of endometrial carcinoma. **2022**, 46, 100895	1
343	Uterine serous carcinoma. **2023**, 197-212	
342	ASPM, CDC20, DLGAP5, BUB1B, CDCA8, and NCAPG May Serve as Diagnostic and Prognostic Biomarkers in Endometrial Carcinoma. **2022**, 2022, 1-18	0

341	Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer. 13,	0
340	Therapeutic Benefit of Systematic Lymphadenectomy in Node-Negative Uterine-Confined Endometrioid Endometrial Carcinoma: Omission of Adjuvant Therapy. **2022**, 14, 4516	0
339	Molecular Classification of Endometrial Cancer of Chinese Population.	0
338	MCluster-VAEs: An end-to-end variational deep learning-based clustering method for subtype discovery using multi-omics data. **2022**, 150, 106085	1
337	Research progress of neoantigens in gynecologic cancers. **2022**, 112, 109236	0
336	Epithelial Tumors and Precursors, Type 1. **2022**, 1-15	0
335	Construction of Gene Network Based on Inter-tumor Heterogeneity for Tumor Type Identification. **2022**, 345-355	0
334	Incorporating Intratumoral Heterogeneity into Weakly-Supervised Deep Learning Models via Variance Pooling. **2022**, 387-397	0
333	PLK3 amplification and tumor immune microenvironment of metastatic tumors are linked to adjuvant treatment outcomes in uterine serous cancer. **2022**, 4,	0
332	Cancer cell histone density links global histone acetylation, mitochondrial proteome and histone acetylase inhibitor sensitivity. **2022**, 5,	1
331	Prognostic Significance of Size, Location, and Number of Lymph Node Metastases in Endometrial Carcinoma. Publish Ahead of Print,	0
330	Detection of BRCA1 Pathogenic Variant in a 24-Year-Old Endometrial Cancer Patient: Risks of Several Hereditary Tumor Syndromes Assessed Using Germline Multigene Panel Testing. **2022**, 15, 792-797	0
329	Improved survival with combination chemotherapy and external beam radiation therapy in uterine carcinosarcoma. ijgc-2022-003717	0
328	Pembrolizumab as a single agent for patients with MSI-H advanced endometrial carcinoma. 1-9	0
327	Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after IFN-from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer	1
326	Enrollment of Individuals From Racial and Ethnic Minority Groups in Gynecologic Cancer Precision Oncology Trials. **2022**, 140, 654-661	0
325	Investigation of Transcriptome Patterns in Endometrial Cancers from Obese and Lean Women. **2022**, 23, 11471	0
324	Current Approaches to the Management of Patients with Endometrial Cancer. **2022**, 14, 4500	1

323	A population-based risk scoring system to individualize adjuvant treatment for stage IIIC endometrial cancer patients after surgery. **2022**,	0
322	Association of immunohistochemical profiles with histotypes in endometrial carcinomas. **2022**, 61, 823-829	0
321	A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.	3
320	LncRNA THOR promotes endometrial cancer progression through the AKT and ERK signaling pathways. **2022**, 39,	0
319	Validity of a two-antibody testing algorithm for mismatch repair deficiency testing in cancer; a systematic literature review and meta-analysis.	0
318	The Best of Both Worlds: Combining the Molecular and Traditional (Histotype/Grade) Endometrial Cancer Classification. **2022**, 27, 179-186	0
317	Mesonephric-Like Adenocarcinoma of the Endometrium: Review of the Literature and Practical Diagnostic Recommendations. **2022**, 27, 198-207	0
316	Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women. **2022**, 58, 1256	0
315	Strategies for modelling endometrial diseases.	0
314	Translational experimental research in gynaecological oncology. 1-2	0
313	Proteomic and functional characterization of intra-tumor heterogeneity in human endometrial cancer. **2022**, 3, 100738	1
312	TP53 mutations in endometrial cancer contribute to clinically-relevant radiation resistance and highlight the potential for biomarker-driven radiosensitization strategies.	0
311	Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.	0
310	Progress in surgical oncology: Gynecology perspective. **2022**, 126, 902-905	0
309	Immunohistochemical Markers and TILs Evaluation for Endometrial Carcinoma. **2022**, 11, 5678	0
308	The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma. **2022**,	0
307	Interpretation of the role of germline and somatic non-coding mutations in cancer: expression and chromatin conformation informed analysis. **2022**, 14,	0
306	ARID1A-dependent maintenance of H3.3 is required for repressive CHD4-ZMYND8 chromatin interactions at super-enhancers. **2022**, 20,	0

305	Cancer-associated gene analysis of cervical cytology samples and liquid-based cytology significantly improve endometrial cancer diagnosis sensitivity. **2022**, 24,	0
304	Mechanisms of mutant β-catenin in endometrial cancer progression. 12,	0
303	Counterpoint: Integration of Molecular Subtype and Histotype/Grade Into One Classification System for Endometrial Carcinoma. **2022**, 27, 187-197	0
302	BAT26 Only Microsatellite Instability with High Tumor Mutation Burden—A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression. **2022**, 23, 10730	0
301	Comparison of the mutational profiles of neuroendocrine breast tumours, invasive ductal carcinomas and pancreatic neuroendocrine carcinomas. **2022**, 11,	0
300	Claudin-9 is a novel prognostic biomarker for endometrial cancer. **2022**, 61,	0
299	The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.	0
298	HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy. **2022**,	0
297	CRABP2—A novel biomarker for high-risk endometrial cancer. **2022**,	0
296	Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. **2022**, 3, 1026-1038	4
295	Beyond Serous: Treatment Options for Rare Endometrial Cancers.	0
294	22nd meeting of the European Society of Gynaecological Oncology (ESGO 2021) report. ijgc-2022-003593	0
293	Endometrial carcinomas with dyshesive, eosinophilic, and vacuolated (histiocyte-like) tumor cells: a reactive-like phenotype associated with aggressive behavior.	0
292	Survival nomogram for endometrial cancer with lung metastasis: A SEER database´analysis. 12,	0
291	Reassessment of low- and intermediate-risk endometrial cancer reports by gynecological pathologists increases risk classification without impacting outcome. **2022**, 278, 172-176	1
290	Recent advances of β-catenin small molecule inhibitors for cancer therapy: Current development and future perspectives. **2022**, 243, 114789	1
289	Differential Intracellular Protein Distribution in Cancer and Normal Cells—Beta-Catenin and CapG in Gynecologic Malignancies. **2022**, 14, 4788	0
288	ARID1A, BRG1, and INI1 deficiency in undifferentiated and dedifferentiated endometrial carcinoma: a clinicopathologic, immunohistochemical, and next-generation sequencing analysis of a case series from a single institution. **2022**,	0

287	Applications and Safety of Sentinel Lymph Node Biopsy in Endometrial Cancer. **2022**, 11, 6462	1
286	Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset.	0
285	Development of a 4-miRNA prognostic signature for endometrial cancer. **2022**, 101, e30974	0
284	Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive Outcomes. **2022**, 14, 5187	1
283	Cancer Genomics and Evolution. 1-30	0
282	Endometrial cancer: molecular classification and future treatments. **2022**, 1, e000152	0
281	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. **2022**, 15,	1
280	Replicative Instability Drives Cancer Progression. **2022**, 12, 1570	1
279	Radiation Therapy for Endometrial Cancer: An ASTRO Clinical Practice Guideline. **2022**,	0
278	TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives. **2022**, 23, 11684	2
277	Data Set for the Reporting of Endometrial Cancer: Recommendations From the International Collaboration on Cancer Reporting (ICCR). **2022**, 41, S90-S118	0
276	Single-cell transcriptomic analysis highlights origin and pathological process of human endometrioid endometrial carcinoma. **2022**, 13,	0
275	The effect of progestin therapy in advanced and recurrent endometrial cancer: a systematic review and meta-analysis.	0
274	Identification and Validation of Hub Genes in Uterine Corpus Endometrioid Carcinoma.	0
273	Tumor-derived ARHGAP35 mutations enhance the G13-Rho signaling axis in human endometrial cancer.	0
272	Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular Classification. **2022**,	1
271	Advances in Chemotherapy and Targeted Therapies in Endometrial Cancer. **2022**, 14, 5020	0
270	Prognostic model for the exemption of adjuvant chemotherapy in stage IIIC endometrial cancer patients. 13,	0

269	STUDY OF IMMUNOHISTOCHEMICAL EXPRESSION OF BETA-CATENIN IN ENDOMETRIAL BIOPSY SPECIMENS AMONG PATIENTS OF ABNORMAL UTERINE BLEEDING IN A TERTIARY CARE HOSPITAL. **2022**, 54-57	0
268	Identification and verification of the prognostic value of CUL7 in colon adenocarcinoma. 13,	0
267	Mining of clinical and prognosis related genes in the tumor microenvironment of endometrial cancer.	0
266	The E3 Ligases in Cervical Cancer and Endometrial Cancer. **2022**, 14, 5354	0
265	Atypical Macropinocytosis Contributes to Malignant Progression: A Review of Recent Evidence in Endometrioid Endometrial Cancer Cells. **2022**, 14, 5056	0
264	Development and validation of a nomogram involving immunohistochemical markers for prediction of recurrence in early low-risk endometrial cancer. 039361552211322	0
263	Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification.	0
262	Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR). **2022**, 41, S119-S142	0
261	Endometrial Cancer. 1-12	0
260	RNA m6A methylation regulators in endometrial cancer (Review). **2022**, 61,	0
259	Biomarkers discovery for endometrial cancer: A graph convolutional sample network method. **2022** , 150, 106200	0
258	Iris metastasis from endometrial carcinoma: a challenging diagnosis and individualized eye-sparing treatment. **2022**, 101098	0
257	Multi-regional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Tumors from Latinos.	0
256	Advanced and recurrent endometrial cancer: State of the art and future perspectives. **2022**, 180, 103851	0
255	Multisite gynecologic endometrioid adenocarcinomas: Can mutation profiling be used to distinguish synchronous primary cancers from metastases?. **2022**, 44, 101076	0
254	Does the presence of single compared to multiple endometrial polyps alter the risk of cancer in post-menopausal women?. **2022**, 279, 118-121	0
253	Molecular hallmarks of cancer. **2023**, 489-505.e5	0
252	Endometrial hyperplasia, estrogen therapy, and the prevention of endometrial cancer. **2023**, 104-124.e5	0

251	Adenocarcinoma of the uterine corpus and sarcomas of the uterus. **2023**, 125-174.e30	0
250	Incidence and survival rates of primary uterine carcinosarcoma in Korea: a National Cancer Registry study. 34,	0
249	Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon?. **2023**, 168, 1-7	0
248	Targeted therapy and molecular genetics. **2023**, 464-488.e11	0
247	Elucidation of genomic origin of synchronous endometrial and ovarian cancer (SEO) by genomic and microsatellite analysis. 34,	0
246	Molecular testing for endometrial cancer: An SGO clinical practice statement. **2023**, 168, 48-55	0
245	JAK1 inactivation promotes proliferation and migration of endometrial cancer cells via upregulating the hypoxia-inducible factor signaling pathway. **2022**, 20,	0
244	Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma. **2022**, 14, 5429	2
243	Recurrence and Survival Rates of Patients Who Undergo Minimally Invasive Surgery for Endometrial Carcinoma with Different Prognostic Risk Groups. **2023**, 36, 1-10	0
242	Application of NGS molecular classification in the diagnosis of endometrial carcinoma: A supplement to traditional pathological diagnosis.	0
241	APOBEC3A /B deletion polymorphism and endometrial cancer risk.	0
240	Evaluating multiple next-generation sequencing derived tumor features to accurately predict DNA mismatch repair status. **2022**,	0
239	Molecular monitoring in endometrial cancer ready for prime time?.	0
238	Landmark Series on Disparities: Uterine Cancer and Strategies for Mitigation.	0
237	The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients. **2022**, 22,	0
236	Multiplexed genome editing by in vivo electroporation of Cas9 ribonucleoproteins effectively induces endometrial carcinoma in mice.	0
235	Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma. **2022**, 11, 3563	0
234	Construction of Oxidative Stress-Related Genes Risk Model Predicts the Prognosis of Uterine Corpus Endometrial Cancer Patients. **2022**, 14, 5572	0

233	Generation and Integrated Analysis of Advanced Patient-Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer. 2204211	0
232	HE4 Tissue Expression as A Putative Prognostic Marker in Low-Risk/Low-Grade Endometrioid Endometrial Cancer: A Review. **2022**, 29, 8540-8555	0
231	A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case report.	0
230	Excavation of Molecular Subtypes of Endometrial Cancer Based on DNA Methylation. **2022**, 13, 2106	0
229	Endometrial Hyperplasia. **2022**, Publish Ahead of Print,	0
228	Comprehensive Analysis of PHGDH for Predicting Prognosis and Immunotherapy Response in Patients with Endometrial Carcinoma.	0
227	The role of toll-like receptors (TLRs) and their therapeutic applications in endometrial cancer.	0
226	Dostarlimab For Recurrent Mismatch Repair Deficient Endometrial Cancer: A Cost-Effectiveness Study.	1
225	Preoperative Tumor Texture Analysis on MRI for High-Risk Disease Prediction in Endometrial Cancer: A Hypothesis-Generating Study. **2022**, 12, 1854	1
224	Diagnostic accuracy of mutational analysis along the Müllerian tract to detect ovarian cancer. ijgc-2022-003911	0
223	Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line. **2022**, 12,	0
222	Decreased expression of miR-23b is associated with poor survival of endometrial cancer patients. **2022**, 12,	0
221	Targeting the PI3K Pathway in Gynecologic Malignancies.	0
220	Endocrine disruption of early uterine differentiation causes adenocarcinoma mediated by Wnt/β-catenin- and PI3K/AKT signaling.	0
219	A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma. **2022**, 2022, 1-43	0
218	Role of Tumor Suppressor PTEN and Its Regulation in Malignant Transformation of Endometrium. **2022**, 87, 1310-1326	0
217	Identification of PRIM2 as a new prognostic and immune-related marker in cancer based on a comprehensive pan-cancer analysis.	0
216	Histopathological and molecular findings in 98 cases of endometrial carcinoma: MMR, p53 and next generation sequencing. **2023**, 241, 154275	0

215	Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer. 34,	0
214	Racial and ethnic differences in type II endometrial cancer mortality outcomes: The contribution of sociodemographic, clinicopathologic, and treatment factors. **2023**, 168, 119-126	0
213	Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study. **2023**, 169, 64-69	0
212	The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma. **2023**, 169, 27-33	0
211	Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma. **2023**, 169, 78-84	0
210	MIG-6 Is Critical for Progesterone Responsiveness in Human Complex Atypical Hyperplasia and Early-Stage Endometrial Cancer. **2022**, 23, 14596	0
209	Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations. **2022**,	0
208	A novel systemic inflammation response index (SIRI) for predicting postoperative survival of patients with endometrial cancer.	0
207	Endometrial cancer: Part I. Basic concept. **2022**, 61, 951-959	1
206	The roles and clinical applications of interleukins in endometrial carcinoma. 12,	0
205	Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer.	0
204	The Somatic Mutation Landscape of UDP-Glycosyltransferase (UGT) Genes in Human Cancers. **2022**, 14, 5708	0
203	Targeted Therapies in the Treatment of Uterine Serous Carcinoma. **2022**, 23, 1804-1817	0
202	Effect of integrin β7 on cell proliferation, invasion, apoptosis and the PI3K/AKT pathway, and its association with clinicopathological features in endometrial cancer. **2022**, 25,	0
201	Contemporary Use of Hormonal Therapy in Endometrial Cancer: a Literature Review. **2022**, 23, 1818-1828	1
200	Adjuvant Therapy in Node-Positive Endometrial Cancer: A Focus on Chemotherapy. **2022**, 24, 1677-1683	0
199	Molecular pathology and prognosis of endometrial cancer. **2022**, 61, 921-922	0
198	Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study. 13,	0

197	Integration of Molecular Data in the Prognostic Stratification and Management of Endometrial Carcinoma. **2022**, 12, 2083	0
196	Malignant transformation of endometrial hyperplastic processes: immunohistochemical features. **2022**, 18, 89-99	0
195	Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma. 13,	0
194	ECPPF (E2F1, CCNA2, POLE, PPP2R1A, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer. **2022**, 17, e0278408	0
193	Cross-omics integration shows cortex-wide synaptic dysfunction at later stages of Alzheimer disease.	0
192	Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts. **2022**,	0
191	Antibody reliability influences observed mRNA-protein correlations in tumour samples.	0
190	miRNA-576-5p promotes endometrial cancer cell growth and metastasis by targeting ZBTB4.	0
189	Oxidative stress-induced FAK activation contributes to uterine serous carcinoma aggressiveness.	0
188	CRAC and SK Channels: Their Molecular Mechanisms Associated with Cancer Cell Development. **2023**, 15, 101	0
187	Massively parallel sequencing of endometrial lavage specimens for the detection of cancer-associated mutations in atypical and non-atypical endometrial hyperplasia. 9,	0
186	Tumor cell plasticity in endometrioid carcinoma is regulated by neuronal membrane glycoprotein M6-b. **2022**, 25,	0
185	Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma. **2022**, 14, 6210	0
184	Mass spectrometry imaging in gynecological cancers: the best is yet to come. **2022**, 22,	0
183	STK4 protein expression pattern follows different trends in endometrioid and serous endometrial adenocarcinoma upon tumor progression. **2022**, 12,	0
182	Endometrial hyperplasia with loss of APC in a novel population of Lyz2-expressing mouse endometrial epithelial cells.	0
181	Correlation of PD-L1 immunohistochemical expression with microsatellite instability and p53 status in endometrial carcinoma. **2022**, 16, 100172	0
180	A comprehensive analysis focusing on cuproptosis to investigate its clinical and biological relevance in uterine corpus endometrial carcinoma and its potential in indicating prognosis. 9,	0

179	Protein biomarkers in cervicovaginal lavages for detection of endometrial cancer. **2022**, 10,	0
178	Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative. ijgc-2022-004160	0
177	Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value.	0
176	Integration of Genomic and Clinical Retrospective Data to Predict Endometrioid Endometrial Cancer Recurrence. **2022**, 23, 16014	0
175	Relevance of Molecular Profiling in Patients With Low-Grade Endometrial Cancer. **2022**, 5, e2247372	0
174	Multimodal Learning for Multi-Omics: A Survey.	0
173	Use of clinicopathological factors to predict prognosis of fertility-sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia. **2022**, 25,	1
172	Pr□dispositions h□□ditaires au cancer de l□endom□□re1. **2022**,	0
171	Prediction of high-risk factors for ovarian metastasis in patients with endometrial cancer: A large-sample retrospective case□control study.	0
170	Corded and hyalinized endometrioid endometrial carcinoma with high-grade features: a clinicopathological and TCGA-based molecular analysis.	0
169	ARID1A-deficient cells promote endometrial carcinoma progression and dissemination by reprograming tumor microenvironment.	0
168	Association between ABO blood type and type I endometrial cancer: a retrospective study. **2023**, 43,	0
167	Fluorescence in situ hybridization test for detection of endometrial carcinoma cells by non-invasive vaginal swab.	0
166	Endometrial Cancer. **2022**, 247-278	0
165	Serum protein N-glycome patterns reveal alterations associated with endometrial cancer and its phenotypes of differentiation.	0
164	Oncotherapeutic Strategies in Early Onset Colorectal Cancer. **2023**, 15, 552	1
163	Ovarian, Uterine, and Vulvovaginal Cancers. **2023**,	0
162	Immunologic Signatures across Molecular Subtypes and Potential Biomarkers for Sub-Stratification in Endometrial Cancer. **2023**, 24, 1791	0

161	Metabolism-associated molecular classification of uterine corpus endometrial carcinoma. 14,	0
160	Identification of tumour antigens and immune subtypes in the development of an anti-cancer vaccine for endometrial carcinoma.	0
159	DeteX: A highly accurate software for detecting SNV and InDel in single and paired NGS data in cancer research. 13,	0
158	Incorporating Molecular Classification When Stratifying the Survival Risk of Patients with High-Grade Endometrial Carcinomas. **2023**, 12, 530	0
157	The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer. 12,	0
156	Differential DNA methylation associated with multiple sclerosis and disease modifying treatments in an underrepresented minority population. 13,	0
155	Structural basis for transcription factor ZBTB7A recognition of DNA and effects of ZBTB7A somatic mutations that occur in human acute myeloid leukemia. **2023**, 102885	0
154	SADLN: Self-attention based deep learning network of integrating multi-omics data for cancer subtype recognition. 13,	0
153	The Impact of Racial Disparities on Outcome in Patients With Stage IIIC Endometrial Carcinoma. Publish Ahead of Print,	0
152	Invasiveness of endometrial cancer cell lines is potentiated by estradiol and blocked by a traditional medicine Guizhi Fuling at clinically relevant doses. 12,	0
151	A Hypoxia Molecular Signature-Based Prognostic Model for Endometrial Cancer Patients. **2023**, 24, 1675	0
150	Gynecologic imaging. **2023**, 313-331	0
149	What role does adjuvant therapy play in the management of endometrial cancer?. **2023**, 24, 7-10	0
148	ARID1A Regulates Progesterone Receptor Expression in Early Endometrial Endometrioid Carcinoma Pathogenesis. **2023**, 100045	0
147	Fast, accurate, and racially unbiased pan-cancer tumor-only variant calling with tabular machine learning. **2023**, 7,	0
146	Fast and reliable Sanger POLE sequencing protocol in FFPE tissues of endometrial cancer. **2023**, 154315	0
145	Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT). 34,	0
144	Identification and characterization of metabolic subtypes of endometrial cancer using systems-level approach.	0

143	Improved Progression-Free Survival Associated with Tumor-Infiltrating Lymphocytes in High-Grade Endometrial Cancer. **2023**, 12, 603	0
142	Menopausal Status Contributes to Overall Survival in Endometrial Cancer Patients. **2023**, 15, 451	0
141	Can mismatch repair status be added to sentinel lymph node mapping algorithm in endometrioid endometrial cancer?. **2023**, 169, 131-136	0
140	Identification of 2,4,5-trisubstituted-2,4-dihydro-3H-1,2,4-triazol-3-one-based small molecules as selective BRD9 binders. **2023**, 247, 115018	0
139	Analysis of endometrial carcinoma TCGA reveals differences in DNA methylation in tumors from Black and White women. **2023**, 170, 1-10	0
138	Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). **2023**, 15, 254	0
137	Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin Interactions with Its Nuclear Partners. **2023**, 66, 1-31	1
136	The current status of immunotherapy in the treatment of primary advanced and recurrent endometrial cancer. **2023**, 35, 34-42	1
135	Endometrial carcinosarcoma. ijgc-2022-004073	1
134	Biomarkers of tumor-reactive CD4+and CD8+TILs associate with improved prognosis in endometrial cancer.. **2022**, 10, e005443	0
133	Noninvasive detection of microsatellite instability in patients with endometrial cancer.	0
132	The diverse morphology and immunophenotype of ovarian endometrioid carcinomas. **2023**,	0
131	Zielgerichtete Therapien beim rezidivierten Endometriumkarzinom´2: Moderne Ansätze.	0
130	Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.	0
129	PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy. ijgc-2022-003990	0
128	Immunotherapy for Gynecologic Cancer. **2023**, 1-19	0
127	Shared sex hormone metabolism-related gene prognostic index between breast and endometrial cancers. 14,	0
126	The continuing evolution of endometrial carcinoma molecular classification: Risk stratification within the No Specific Molecular Profile (NSMP) subtype. **2023**,	1

125	Exploitation of a shared genetic signature between obesity and endometrioid endometrial cancer. 10,	0
124	Adjuvante Therapie beim Endometriumkarzinom.	0
123	Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome. **2023**, 13,	0
122	Simulated annealing for balancing covariates.	0
121	Molekularpathologie in der Gynäkoonkologie Beschreibung einer Revolution.	0
120	CD133 as Biomarker and Therapeutic Target in Gynecologic Malignancies. **2023**,	0
119	Anti-tumor effect of Wasabi component, 6-(methylsulfinyl) hexyl isothiocyanate, against endometrial carcinoma cells. **2023**, 14,	0
118	Advanced endometrial cancer: New medical treatment options on the horizon. **2023**, 102, 128-129	0
117	Risk stratification and molecular heterogeneity of endometrial cancer and expression profile of TIM-3: A retrospective cohort study. **2023**, 170, 210-220	0
116	Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death. **2023**, 36, 100085	1
115	Molekulare Klassifikation des Endometriumkarzinoms ein kurzer Überblick.	0
114	Machine learning-based neddylation landscape indicates different prognosis and immune microenvironment in endometrial cancer. 13,	0
113	Diagnostic Performance of Immunohistochemistry Compared to Molecular Techniques for Microsatellite Instability and p53 Mutation Detection in Endometrial Cancer. **2023**, 24, 4866	0
112	An Innovative Drug Repurposing Approach to Restrain Endometrial Cancer Metastatization. **2023**, 12, 794	0
111	Treatment options for molecular subtypes of endometrial cancer in 2023. Publish Ahead of Print,	0
110	Genetic modifiers of APOBEC-induced mutagenesis.	0
109	ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing. **2023**, 171, 59-66	0
108	Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review. **2023**, 115, 102531	0

107	HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis. **2023**, 172, 98-105	0
106	Landscape of chromatin remodeling gene alterations in endometrial carcinoma. **2023**, 172, 54-64	0
105	Treatment of Endometrial Cancer. **2023**, 3, 11-19	0
104	Sentinel lymph node biopsy in endometrial cancer: The new norm - A multicentre, international experience. **2023**, 48, 101922	0
103	Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification. **2023**, 186, 98-112	0
102	Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy. **2023**, 15, 2288	0
101	Recent Advances in Gynaecological Oncology. **2022**, 475-494	0
100	The Diagnostic Role of FGF 21 in Endometrial Cancer and Other Pathologies of the Uterine Corpus. **2023**, 13, 399	0
99	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer. **2023**, 8, 100774	0
98	Estrogen/Progesterone Receptor Loss, CTNNB1 and KRAS Mutations Are Associated With Local Recurrence or Distant Metastasis in Low-Grade Endometrial Endometrioid Carcinoma. **2023**, 31, 181-188	0
97	Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): Its therapeutic potential and selective inhibition. **2023**, 230, 123428	0
96	Cytopathological features associated with POLE mutation in endometrial cancer. **2023**, 34, 211-218	0
95	Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol. Publish Ahead of Print,	0
94	Nuclear ‡Catenin Expression in the Context of Abnormal p53 Expression Indicates a Nonserous Histotype in Endometrial Carcinoma. Publish Ahead of Print,	0
93	Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas. Publish Ahead of Print,	0
92	MSIMEP: Predicting microsatellite instability from microarray DNA methylation tumor profiles. **2023**, 26, 106127	0
91	Update of sentinel lymph node mapping assessment in endometrial cancer. **2023**, 3, 1-6	0
90	Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies TCGA-like Prognostic Subgroups. **2023**, 100123	0

89	The Co-Expression of Estrogen Receptors ER□ER□and GPER in Endometrial Cancer. **2023**, 24, 3009	0
88	Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer. **2023**, 170, 282-289	0
87	Comprehensive analysis of germline drivers in endometrial cancer.	0
86	Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: a retrospective single-center experience. **2023**, 33, 514-520	0
85	C□cer de endometrio: diagn□tico, estudio preterap□tico, tratamiento y seguimiento. **2023**, 59, 1-16	0
84	Immunoth□apies valid□s en oncogyn□ologie. **2023**, 110, 395-401	0
83	Transient and DNA-free in vivo CRISPR/Cas9 genome editing for flexible modeling of endometrial carcinogenesis.	0
82	Dostarlimab: From preclinical investigation to drug approval and future directions. **2023**, 19,	0
81	A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case report. **2023**, 18,	0
80	The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Endometrial Carcinoma (2023). **2023**, 12, 1480	0
79	Hysterectomy alone vs. hysterectomy plus sentinel node mapping in endometrial cancer: Perioperative and long-term results from a propensity-score based study. **2023**,	1
78	Development of adverse outcome pathways relevant for the identification of substances having endocrine disruption properties Uterine adenocarcinoma as adverse outcome. **2023**, 21,	1
77	Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition..	0
76	Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives. **2023**, 11, 571	4
75	Molecular Profiling of Endometrial Cancer From TCGA to Clinical Practice. **2023**, 21, 210-216	1
74	Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer. **2023**, 21, 217-226	0
73	Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial. **2023**, 24, 286-296	0
72	Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype. **2023**, 171, 15-22	0

71	Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer. **2023**, 128, 1582-1591	0
70	The etiology of clonal mosaicism in human aging and disease. **2023**, 4, 3-20	0
69	Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma. **2023**, 16,	0
68	A compilation of bioinformatic approaches to identify novel downstream targets for the detection and prophylaxis of cancer. **2023**, 75-113	0
67	Pathology of the Uterine Corpus. **2023**, 1-18	0
66	Therapie des primären Endometriumkarzinoms auf der Grundlage molekularpathologischer Befunde. **2023**, 56, 176-183	0
65	HER2 Amplification in p53-Mutated Endometrial Carcinomas. **2023**, 15, 1435	0
64	Molecular correlates of invasion pattern in HPV-associated endocervical adenocarcinoma: emergence of two distinct risk-stratified tiers.	0
63	Molekulare Klassifikation beim Endometriumkarzinom. **2023**, 56, 164-175	0
62	Immunotherapy in Urological, Gynecological and Gastrointestinal Cancers: Current Landscape. **2023**, 112, 149-155	1
61	Endometrial Carcinomas With Subclonal Loss of Mismatch Repair Proteins. **2023**, 47, 589-598	0
60	ImmuneScore of eight-gene signature predicts prognosis and survival in patients with endometrial cancer. 13,	0
59	Deciphering comprehensive features of tumor microenvironment controlled by chromatin regulators to predict prognosis and guide therapies in uterine corpus endometrial carcinoma. 14,	0
58	Molecular typing guiding treatment and prognosis of endometrial cancer. **2023**, 3, 7-17	0
57	Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients.	0
56	Mapping single-cell transcriptomes of endometrium reveals potential biomarkers in cancer.	0
55	Estrogen receptors as potential therapeutic target in endometrial cancer. **2023**, 43, 19-26	0
54	Prognosis and Characterization of Microenvironment in Cervical Cancer Influenced by Fatty Acid Metabolism-Related Genes. **2023**, 2023, 1-34	0

53	FAM193A is a positive regulator of p53 activity. **2023**, 42, 112230	0
52	Characteristics of molecular classification in 52 endometrial cancer and atypical hyperplasia patients receiving fertility-sparing treatment. **2023**, 3, 38-43	0
51	Novel Insights into Molecular Mechanisms of Endometrial Diseases. **2023**, 13, 499	0
50	A case of solitary lymph node recurrence 9´years after initial treatment for advanced premenopausal endometrioid endometrial cancer; clinical usefulness of hormonal replacement therapy.	0
49	Identification and Characterization of Metabolic Subtypes of Endometrial Cancer Using a Systems-Level Approach. **2023**, 13, 409	0
48	The impact of lymphovascular space invasion on survival in early stage low-grade endometrioid endometrial cancer. **2023**, 28,	0
47	The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?. **2023**, 1-32	0
46	Clinical characteristics and prognostic characterization of endometrial carcinoma: a comparative analysis of molecular typing protocols. **2023**, 23,	0
45	Update in the molecular classification of endometrial carcinoma. **2023**, 33, 333-342	0
44	Factor affecting lymph node metastasis in uterine papillary serous carcinomas: a retrospective analysis. **2022**, 42, 3725-3730	0
43	Statistical Methods for Integrative Clustering of Multi-omics Data. **2023**, 73-93	0
42	Type II endometrial cancer: Incidence, overall and disease-free survival in Martinique. **2023**, 18, e0278757	0
41	PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia. 34,	0
40	Immunotherapy in endometrial cancer. **2023**, 33, 351-357	0
39	Biomarker-driven therapy in endometrial cancer. **2023**, 33, 343-350	0
38	Malignant Diseases of the Uterus. **2023**, 189-198	0
37	Do Not Forget about Hormonal Therapy for Recurrent Endometrial Cancer: A Review of Options, Updates, and New Combinations. **2023**, 15, 1799	0
36	An integrated approach of network pharmacology, molecular docking, and experimental verification uncovers kaempferol as the effective modulator of HSD17B1 for treatment of endometrial cancer. **2023**, 21,	0

35	HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy. **2023**, 47, 580-588	0
34	β-catenin, Pax2, and Pten Panel Identifies Precancers Among Histologically Subdiagnostic Endometrial Lesions. **2023**, 47, 618-629	0
33	PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: A systematic review and meta-analysis. **2023**, 18, e0283203	0
32	Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma. **2023**, 23, 361-368	0
31	Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma. 10,	0
30	p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. **2023**, 9, 208-222	0
29	The Role of WNT Pathway Mutations in Cancer Development and an Overview of Therapeutic Options. **2023**, 12, 990	0
28	Undifferentiated/dedifferentiated endometrial carcinoma; the reappearance of an old friend with insights into the new data.	0
27	Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma. **2023**, 14,	0
26	Endometrial hyperplasia and progesterone resistance: a complex relationship. **2023**, 27, 65-70	0
25	Survival outcomes and the prognostic significance of clinicopathological features in patients with endometrial clear cell carcinoma: a 35-year single-center retrospective study. **2023**, 21,	0
24	Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.	0
23	Imaging of Endometrial Cancer. **2023**,	0
22	Immunotherapy in gynaecological oncology: standard in endometrial and cervical cancer. **2023**, 56, 245-252	0
21	Improving Endometrial cancer assessment by combining the new techniqUe of GENomic profiling with surgical Extra uterIne disEase assessment (EUGENIE). ijgc-2023-004289	0
20	Determination of the Cancer Genome Atlas (TCGA) Endometrial Cancer Molecular Subtypes Using the Variant Interpretation and Clinical Decision Support Software MH Guide. **2023**, 15, 2053	0
19	Mapping the landscape of sentinel lymph nodes in endometrial cancer: let us continue in the right direction. ijgc-2023-004472	0
18	Vangl2 suppresses NF-κB signaling and ameliorates sepsis by targeting p65 for NDP52-mediated autophagic degradation.	0

17	Predictive approach to the management of women with endometrial hyperplasia without atypia. **2023**, 8-13	0
16	Endometrial cancer diagnostic and prognostic algorithms based on proteomics, metabolomics, and clinical data: a systematic review. 13,	0
15	Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy inCTNNB1-mutated endometrial cancer.	0
14	Endometrial safety of low-dose vaginal estrogens. Publish Ahead of Print,	0
13	Epigenetic MMR defect identifies a risk group not accounted for through traditional risk stratification algorithms in endometrial cancer. 13,	0
12	Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. **2023**,	0
11	Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. **2023**, 11, 1073	0
10	LncRNAs signatures associated with cuproptosis predict the prognosis of endometrial cancer. 14,	0
9	The Role of Genetic Mutations in Mitochondrial-Driven Cancer Growth in Selected Tumors: Breast and Gynecological Malignancies. **2023**, 13, 996	0
8	Elevated enhancer-oncogene contacts and higher oncogene expression levels by recurrent CTCF inactivating mutations in acute T´cell leukemia. **2023**, 42, 112373	0
7	Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine Cancer. **2023**, 6, e238437	0
6	Survival rate and chronic diseases of TCGA cancer and KoGES normal samples by clustering for DNA methylation.	0
5	Pure and mixed clear cell carcinoma of the endometrium: A molecular and immunohistochemical analysis study.	0
4	Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?. **2023**, 12, 3014	0
3	Therapeutic approaches in patients with bone metastasis due to endometrial carcinoma A systematic review. **2023**, 41, 100485	0
2	Commentary: novel observations and detailed molecular characterisation of mixed tumours and mesonephric-like carcinosarcomas by Mirkovic et´al . (2023). **2023**, 82, 974-977	0
1	Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1 , an ancillary of JCOG0910.	0